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Avian Paramyxovirus (APMV) serotype 3 is one of the nine serotypes of APMV 
that infect a variety of avian species around the world. In chickens and turkeys, APMV-3 
causes respiratory illness and drop in egg production. To understand the molecular 
characteristics of APMV-3, the complete genome sequences of prototype strain 
Netherlands and strain Wisconsin were determined. The genome length of APMV-3 
strain Netherlands is 16,272 and for strain Wisconsin is 16,181 nucleotides (nt). Each 
genome consists of six non-overlapping genes in the order 3’N-P/V/W-M-F-HN-
L5’ similar to most of APMVs. Comparison of the APMV-3 strain Wisconsin nt and the 
aggregate predicted amino acid (aa) sequences with those of APMV-3 strain Netherlands 
revealed 67 and 78%, identity, respectively.  The phylogenetic and serological analyses 
of APMV-3 strains Netherlands and Wisconsin indicated the existence of two subgroups 
  
within the same serotype. Both the strains were found to be avirulent for chickens by 
mean death time and intracerebral pathogenicity test. 
To further study the molecular biology and pathogenesis of APMV-3, a reverse 
genetics system for strain Netherlands was established in which infectious recombinant 
APMV-3 was recovered from a cloned APMV-3 antigenomic cDNA. The recovered 
recombinant virus showed in vitro growth characteristics and in vivo pathogenicity 
similar to parental virus. A recombinant APMV-3 expressing enhanced green fluorescent 
protein was also recovered, suggesting its potential use as a vaccine vector. Furthermore, 
generation and characterization of recombinant APMV-3 expressing Newcastle disease 
virus (NDV) F and HN proteins demonstrated that the F protein plays a major role in 
protection against virulent NDV challenge. Overall, the study conducted here has several 
downstream applications. The complete genome sequence of APMV-3 is useful in 
designing diagnostic reagents and in epidemiological studies. The reverse genetics 
system for APMV-3 would be of considerable utility for introducing defined mutations 
into the genome of this virus and developing a vaccine vector for animal and human 
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Avian Paramyxovirus serotype 3 (APMV-3) belongs to the genus Avulavirus within 
the subfamily Paramyxovirinae in the family Paramyxoviridae. This virus family is large 
and diverse. Its members have been isolated from many species of avian, terrestrial, and 
aquatic animals around the world (Lamb and Parks, 2007). Paramyxoviruses are 
pleomorphic, enveloped and have a non-segmented, negative-sense RNA genome. 
During influenza virus surveillance programs, avian paramyxoviruses were also isolated 
and were classified into nine serotypes based on hemagglutination inhibition (HI) and 
neuraminidase inhibition (NI) tests (Alexander, 2003a). The cross-HI and –NI tests 
suggested organizing APMV isolates into two broad subgroups;  the first subgroup 
consisting of APMV-2 and -6 and the second subgroup consisting of APMV-1, -3, -4, -7, 
-8 and -9, while little was known about APMV-5 (Lipkind and Shihmanter, 1986). 
Among these serotypes, Newcastle disease virus (NDV) belonging to APMV-1, is an 
economically important poultry pathogen and hence, the most well characterized virus 
within this genus. In contrast, little is known about the pathogenesis of other avian 
paramyxoviruses. 
APMV-3 was first isolated from turkeys in Ontario in 1967 and later in Wisconsin in 




turkeys in different parts of the world, including England (Macpherson et al., 1983), 
France (Andral and Toquin, 1984) and Germany (Zeydanli et al., 1988). The APMV-3 
strain parakeet/Netherlands/449/75, isolated from parakeets in the Netherlands, is the 
prototype for the entire serotype (Alexander and Chettle, 1978). APMV-3 was also 
isolated from non-domesticated species such as Psittaciformes and Passeriformes 
(Alexander, 1980). APMV-3 infection has been associated with encephalitis and high 
mortality in caged birds, and with respiratory disease in turkeys (Tumova et al., 1979b). 
The virus causes acute pancreatitis and CNS symptoms in psittacine and Passeriformes 
birds (Beck et al., 2003). APMV-3 also infects chickens at an early age, with evidence of 
stunting growth that may be more marked in broiler chicken breeds (Alexander and 
Collins, 1982). In terms of pathogenicity in chickens, APMV-3 probably is second in 
importance only to NDV in chickens. 
The genome of APMV-3 has six genes arranged in tandem in the order of 3’ -N-P-M-
F-HN-L- 5’ (Kumar et al., 2008). There are conserved sequences present at the beginning 
and end of each gene, known as gene start (GS) and gene end (GE), respectively. The GS 
is recognized as a transcription initiation signal and the GE is recognized as a 
transcription termination signal by the viral RNA polymerase. Between each gene, non-
coding sequences of variable lengths called intergenic sequences (IGS) are present, which 
are shown in NDV to regulate the transcription efficiency of downstream genes (Yan and 
Samal, 2008). In addition, the genome of APMV-3 contains a 55 nt long viral promoter 
known as leader at its 3’ end and a 707 nt long viral antigenome promoter known as 
trailer at its 5’ end (Kumar et al., 2008). The leader and trailer regions serve as cis-acting 




2007). APMV-3 genome encodes three internal proteins, nucleocapsid protein (N), a 
phosphoprotein (P) and a large polymerase protein (L), and three surface glycoproteins, 
fusion protein (F), hemagglutinin-neuraminidase (HN) protein and matrix protein M.  
The N protein is the most abundant protein in infected cells and in virus particles. N 
is an RNA binding protein that coats the full-length genomic (-) sense and anti-genomic 
(+) sense RNAs to protect them from nuclease digestion and form biologically active 
templates (Lamb and Parks, 2007). Most members of subfamily Paramyxovirinae show 
RNA editing mechanism, wherein a specific motif within the P gene called RNA editing 
site directs non-templated addition of one or more G nucleotides to P transcripts by viral 
polymerase stuttering. This yields mRNA subpopulations with frame shifts causing 
alternate internal ORFs. Two non-structural proteins, V and W, are produced by 
insertions of one and two G residues, respectively. The V protein has a highly conserved 
cysteine motif and has interferon antagonist activity in NDV (Huang et al., 2003).  The M 
is a hydrophobic protein and it is located on the inner face of the virion envelope. In 
addition, the M protein plays an important role in the assembly of the virion by 
interacting with the nucleocapsid, the lipid bilayer and the cytoplasmic region of the HN 
protein. 
The outer surface glycoproteins, F and HN, mediate viral penetration and attachment, 
respectively. The HN protein is responsible for attachment of the virion to sialic acid-
containing cell surface receptors. In addition, HN has neuraminidase activity (NA) that 
cleaves sialic acid form sugar side chains, thereby, releasing progeny virions from the 
surface of infected cells (Lamb and Parks, 2007). The F protein is synthesized as an 




enzyme(s) into biologically active F1 and F2 subunits connected by a disulphide bond 
(Scheid and Choppin, 1974). The avirulent NDV strains have a monobasic amino acid 
residue at the F protein cleavage site and a leucine at the F1 N terminus, while virulent 
NDV strains have multiple basic amino acids at the F protein cleavage site and a 
phenylalanine at the F1 N terminus (Nagai et al., 1976). The F protein cleavage site of 
APMV-3 has three basic amino acids and a leucine residue at F1 N terminus and is 
analogous with the avirulent cleavage site of NDV (Kumar et al., 2008). The neutralizing 
antibody responses to NDV are directed against both the surface glycoproteins F and HN. 
Although, antibodies against either F or HN protein provide protection against ND 
(Heckert et al., 1996), it is still not clear, which surface glycoprotein is the major 
protective antigen. 
Pathogenesis and molecular characteristics of APMV-3 have rarely been studied; 
only M gene sequence was previously accessible in GenBank (Shihmanter et al., 2005). 
The complete genome sequences of none of the strains of APMV-3 were available. 
Therefore, in this study, the complete genome sequences of two strains of APMV-3 were 
determined and compared with those of other paramyxoviruses to understand its biology 
at the molecular level. The knowledge of complete genome sequence is essential for 
genetic manipulation of these viruses. The most successful system for genetic 
manipulation of negative-sense RNA viruses is a plasmid based reverse genetics system. 
In this approach, four plasmids – one encoding the viral anti-genome and the others 
encoding the viral polymerase complex (N, P and L proteins), all under the control of T7 
promoter are cotransfected in permissive cells expressing T7 RNA polymerase or in cells 




negative-sense RNA viruses have been recovered using this system (Schnell et al., 1994; 
Collins et al., 1995; Garcin et al., 1995; Lawson et al., 1995; Radecke et al., 1995; Baron 
and Barrett, 1997; He et al., 1997; Hoffman and Banerjee, 1997; Buchholz et al., 1999; 
Peeters et al., 1999; Yunus et al., 1999; Krishnamurthy et al., 2000; Govindarajan et al., 
2006). There are many downstream applications of reverse genetics technology such as 
development of vaccines and vaccine vectors and use as a tool to study the molecular 
biology of viruses. In this study, a reverse genetics system for APMV-3 was established 
which was then used as a vector to determine the individual contributions of the NDV F 
and HN proteins in protection and immunity against NDV in chickens.  
 
1.3 Research Objectives 
 
1. Determination of complete genome sequence of APMV- 3 prototype strain 
Netherlands. 
 
2. Determination of complete genome sequence of APMV- 3 strain Wisconsin and 
comparison with that of prototype strain Netherlands. 
 
3. Pathogenicity of APMV-3 strains Netherlands and Wisconsin in chickens and 
turkeys. 
 
4. Establishment of a reverse genetics system for APMV-3 and recovery of 






5. Evaluation of the Newcastle disease virus F and HN proteins in protective 
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2.2 Classification 
 
The family Paramyxoviridae includes many species of viruses isolated from 
avian, terrestrial and aquatic animals isolated worldwide (Lamb and Parks, 2007; Nylund 
et al., 2008).  Members of this family are characterized by pleomorphic enveloped 
particles that contain a single-stranded, negative sense RNA genome (Lamb and Parks, 
2007). The family is divided into two subfamilies, Paramyxovirinae and Pneumovirinae. 
Subfamily Paramyxovirinae is further divided into five genera: Rubulavirus (including 
mumps virus, human parainfluenza viruses [HPIV] 2 and 4, simian virus type 5 [SV5] 
and Tioman virus [TiV]), Respirovirus (including Sendai virus [SeV] and HPIV-1 and 3), 
Henipavirus (comprising Hendra virus [HeV] and Nipah virus [NiV]), Morbillivirus 
(including measles [MeV] and canine distemper [CDV] viruses), and Avulavirus 
(comprising avian paramyxovirus [APMV] serotypes 1 to 9). Subfamily Pneumovirinae 
is divided into two genera: Pneumovirus (comprising human respiratory syncytial virus 
[HRSV] and its animal counterparts including bovine respiratory syncytial virus 
[BRSV]), and Metapneumovirus (comprising human metapneumovirus [HMPV] and 
avian metapneumovirus [AMPV]) (Mayo, 2002b; Mayo, 2002a). 
2.3 Virion 
 
Examination of partially-purified virus under an electron microscope showed that 




size ranging from 150-250 nm. The viral envelope is derived from the host cell 
membrane. The outer surface of the envelope consists of two glycoproteins, namely 
fusion (F) and hemagglutination neuraminidase (HN) proteins. The HN protein mediates 
attachment by binding to sialic acid receptor, has neuraminidase activity, and plays a role 
in fusion promotion where as F protein directs the membrane fusion. Matrix protein (M) 
lies below the envelope and is shown to play a major role in virus assembly and budding 
of NDV (Fig. 2.1). The viral envelope encloses the ribonucleocapsid core that is formed 
by nucleoprotein (N), the phosphoprotein (P) and large polymerase (L) protein bound 
with viral genomic RNA. This viral RNA genome is single stranded, non-segmented and 
with negative polarity.  
 
Fig. 2.1. Schematic diagram of an avian paramyxovirus type-3. The lipid bilayer derived from host cell 
membrane is shown as envelope. The viral matrix protein is shown as a black concentric circle beneath the 




inside the viral envelope. The inside of virion is made up of negative-strand RNA encapsidated with 
nucleocapsid protein (N) and associated with the phosphoprotein (P) and the large polymerase protein (L).  
 
2.4 Genome organization 
 
The genome of APMV-3 strain Netherlands consists of 16,272 nt (GenBank 
accession number EU403085). The genome organization of APMV-3 is very similar to 
that of other members of family Paramyxoviridae. The 3’ leader sequence of APMV-3 
consists of 55 nt while the length of the 5’ trailer sequence is 707 nt. They flank the six 
genes 3’-N-P-M-F-HN-L-5’ that encodes for six open reading frames (ORF) 
corresponding to respective putative proteins. Each gene is flanked by conserved 
transcriptional control sequences, known as the gene start (GS) and gene end (GE) that 
are followed by 5’ and 3’ untranslated regions (UTR), respectively (Fig. 2.2). The GS 
sequence of APMV-3 strain Netherlands is 3’UCCUCGCCUU and is conserved exactly 
among the six genes. The GE signal is slightly less conserved: the consensus gene-end 
sequence is 3’AAUUA(U)6. Non-coding intergenic sequences (IGS) are located between 
each gene boundary and ranges in length from 31 to 63 nt. 
 




The single-stranded, negative-sense genome RNA has leader sequence at 3’ end and a trailer sequence at 5’ 
end. The N, P, M, F, HN and L genes are arranged in tandem. Each gene is flanked by conserved GS and 
GE sequences and has untranslated sequences (UTR) at 3’ and 5’ regions of the ORF between each gene 
boundary.  
 
2.5 Viral proteins 
 
The genome of APMV-3 consists of six genes N, P, M, F, HN and L encoding 
eight proteins: N, P, V, W, M, F, HN and L (Kumar et al., 2008). The two proteins, V and 
W, are generated by stuttering of the viral RNA polymerase, known as RNA editing, 
wherein non-templated G residue(s) get inserted into P gene (Steward et al., 1993). The 
genomic structure and proteins of APMV-3 are known to be similar to those of APMV-1 
and other paramyxoviruses; hence, the knowledge about the APMV-3 proteins is derived 
from studies done with other members of the family Paramyxoviridae (Lamb and Parks, 
2007). 
2.5.1 Nucleocapsid and its associated proteins 
 
The nucleocapsid protein (N):  It is the most abundant protein in infected cells and in 
virus particles. N is an RNA binding protein that coats the full-length genomic (-) sense 
and anti-genomic (+) sense RNAs to protect them from nuclease digestion and to form 
biologically active templates. It is able to self-assemble to form herringbone-like 
structures, which morphologically resemble the authentic nucleocapsid structures (Kho et 
al., 2003). The N protein forms nucleocapsids only when it is available in a soluble 
complex with the P protein. The association of the N and P proteins prevents non-specific 




genome leader and antigenome trailer sequences. It has been shown that the first 25 
amino acids of N-terminus of NDV N protein is involved in forming soluble complex 
with the P protein (Kho et al., 2004). The N protein interacts with P and L proteins during 
transcription and replication and with M protein during virus assembly. 
P, V and W proteins: The P protein produced from unedited P mRNA is acidic and 
heavily phosphorylated at specific serine and threonine residues (Steward et al., 1993). 
The P protein along with N and L forms viral polymerase complex.  It prevents 
nonspecific assembly or self aggregation of N protein. The P protein also acts as a 
chaperone to prevent uncontrolled encapsidation of non-viral RNA by the N protein. The 
complex of P with unassembled N monomer is believed to regulate the switch from 
transcription to replication. The non-structural V and W proteins are produced by 
cotranscriptional insertions of one or two G residues, respectively, at the editing site of 
the P gene ORF (Steward et al., 1993). The V protein has anti-interferon-alpha activity in 
NDV, while the function of W protein is still unknown (Huang et al., 2003). 
L protein: The L protein is the largest structural protein but the least abundant protein in 
infected cells or in virions. It is the major component of the viral RNA dependent RNA 
polymerase (Tordo et al., 1988). The L protein possess all the enzymatic activities 
necessary for synthesis of viral mRNAs and genomic RNA replication, including 
nucleotide polymerization, mRNA capping and polyadenylation of mRNAs. 






2.5.2 Matrix protein 
 
The M protein is the most abundant protein in the virion. It functions as the 
central organizer of viral morphogenesis and has been found to interact with the 
cytoplasmic tails of the integral membrane proteins, the lipid bilayer and the 
nucleocapsid. The self-association of M protein and its affinity to interact with the 
nucleocapsid might be the driving force for forming a budding virus particle (Peeples, 
1991). In addition, the M protein may also play a role in transport of viral components to 
the plasma membrane (Takimoto and Portner, 2004).      
 
2.5.3 Envelope glycoproteins 
 
APMV-3 envelope has two integral membrane glycoproteins namely, the fusion 
(F) glycoprotein that mediates pH-independent fusion of the viral envelope with the 
plasma membrane of the host cell and the hemagglutinin-neuraminidase (HN) 
glycoprotein that aides in the attachment of the virus to host cell membrane. 
The hemagglutinin-neuraminidase (HN) protein 
The HN protein is a multifunctional protein. It is a type II integral membrane protein and 
is responsible for attachment of the virion to sialic acid-containing cell surface receptors. 
In addition, HN has neuraminidase activity (NA) that cleaves sialic acid from the surface 
of the infected cells, thereby, releasing progeny virions (Lamb and Parks, 2007). The HN 
protein also interacts with the F protein for fusion promotion activity (Morrison et al., 




terminal globular head that help in attachment. In addition, globular head also has NA 
activities and all known antibody binding sites (Mirza et al., 1993). 
The Fusion (F) protein: The F glycoprotein mediates entry of the virus into the host cell 
by fusion of the viral envelope to the plasma membrane in a pH independent manner. It is 
a type I integral membrane protein and is synthesized as an inactive precursor (F0), which 
is then cleaved in the trans-Golgi membranes to F2 and F1 subunits derived from the 
amino terminal and carboxyl terminal domains, respectively. The F1 and F2 subunits 
remain covalently linked to each other by disulfide bonds (Morrison, 2003). the F protein 
is a trimer consisting of a globular head held distal from the viral membrane by stalk and 
neck regions (Chen et al., 2001). 
2.6 Stages of APMV-3 replication 
 







Fig. 2.3. Stages of replication in a avian paramyxovirus. Schematic diagram of different stages of 
replication in a paramyxovirus. 
 
The initial step of APMV-3 infection is the attachment of the virus to sialic acid 
containing receptors at the host cell surface that is mediated by HN protein. The next step 
is fusion of viral envelope with the host cell plasma membrane, which is mediated by F 
protein and subsequently the release of the viral nucleocapsid into the host cell 
cytoplasm. In the cytoplasm of the host cell, the viral genome is transcribed into mRNAs 
and translated to viral proteins. The viral RNA-dependent RNA polymerase (RDRP) 
complex enters the 3’ end of viral genome promoter, i.e. leader, and synthesizes short (+) 
strand leader RNA followed by re-initiation of N gene mRNA synthesis from N gene 
start sequence. The transcription in most cases terminates at the GE sequence, but some 
of RDRP continues to transcribe the downstream genes (Fig. 2.4). The sequential start 
and stop mechanism results in a gradient mRNA production with higher concentration of 














Fig. 2.4. Schematic diagram of RNA replication and transcription in avian paramyxoviruses. 
Schematic diagram showing transcription and replication of a paramyxovirus. Genome and antigenome are 
shown encapsidated by nucleocapsid protein subunits (small spheres). The vertical lines indicate the gene 
junctions. The polymerase complex (P-L complex) transcribes the genome to yield capped and poly A-
tailed mRNAs. When sufficient amount of viral nucleocapsid protein levels are achieved, the viral 
polymerase switches from its transcription mode to replicative mode to produce antigenome, which serves 
as the template for the synthesis of the progeny viral genome.  
 
The proteins N, P, and L are required for nucleocapsid assembly. The positive-
sense nucleocapsid “antigenome” is then used as template for synthesis of progeny 
genomic RNAs. 
The N protein subunits encapsidate the viral genomic RNA and form a helical 
ribonucleoprotein (RNP) structure. Subsequently, the P and L proteins loosely bind to the 
RNP forming transcriptase complex (Kingsbury, 1972). The membrane glycoproteins (F 




maturation before getting transported to the cell surface following post translational 
modifications, such as modification of carbohydrate chains of HN protein and cleavage 
of F protein (Feller et al., 1969).  The M protein has a major role in bringing the 
assembled RNP core to the appropriate place at the plasma membrane (Peeples, 1991). 
The cytoplasmic tails of F and HN glycoproteins interact with M protein, which in turn, 
associates with the nucleocapsid thus helping the process of budding of the mature 
virions. 
2.7 Epidemiology of APMV-3 infections 
 
APMV-3 has been isolated from wild and domesticated birds in different parts of 
the world (Tumova et al., 1979b; Alexander, 1980; Macpherson et al., 1983; Andral and 
Toquin, 1984; Zeydanli et al., 1988; Alexander, 2003a). The APMV-3 strain 
parakeet/Netherlands/449/75, isolated from parakeets in the Netherlands, is the prototype 
for the entire serotype (Alexander and Chettle, 1978). Recently, APMV-3 was isolated 
from ostrich, indicating a wide host range for the virus (Kaleta et al., 2010). The virus has 
been isolated from diseased turkeys associated with coughing, nasal discharge and 
swelling of the infra-orbital sinus (Redmann et al., 1991). APMV-3 has been associated 
with encephalitis and high mortality in caged birds (Tumova et al., 1979b). The virus 
causes acute pancreatitis and central nervous system (CNS) symptoms in Psittacine and 
Passerine birds (Beck et al., 2003). APMV-3 also infects chickens at an early age, with 
evidence of stunting growth that may be more marked in broiler chicken breeds 
(Alexander and Collins, 1982). In terms of pathogenicity to domestic poultry birds, 





2.8 Reverse genetics 
 
Reverse genetics is a method by which infectious viruses can be generated 
entirely from cloned DNA and provides a method for introducing desired changes into 
the viral genome.  Reverse genetics is a useful method for identifying the functions of 
viral genes. Development of reverse genetics methods for negative-strand RNA viruses 
has led not only to study the structure and function of viral genes and their proteins, but 
also to engineer live vaccines and vaccine vectors. Most of the systems for recovery of 
negative-strand RNA viruses are based on co-transfection of a plasmid expressing full-
length antigenomic RNA with three other support plasmids encoding viral N, P and L 
proteins all under the control of bacteriophage T7 RNA polymerase promoter. The T7 
RNA polymerase was provided by either a recombinant vaccinia virus expressing the T7 
gene or a cell line constitutively expressing the T7 polymerase.  
Many viruses, such as rabies virus (Schnell et al., 1994), vesicular stomatitis virus 
(Lawson et al., 1995), simian virus 5 (He et al., 1997), human respiratory syncytial virus 
(Collins et al., 1995), sendai virus (Garcin et al., 1995), rinderpest virus (Baron and 
Barrett, 1997), parainfluenza virus (Hoffman and Banerjee, 1997), measles virus 
(Radecke et al., 1995), and Nipah virus (Yoneda et al., 2006) were successfully recovered 
using this approach. This system has also been used for recovery of different pathotypes 
of NDV strains: (1) lentogenic strains LaSota (Peeters et al., 1999; Romer-Oberdorfer et 
al., 1999; Huang et al., 2001) and B1 (Nakaya et al., 2001); (2) mesogenic strains 
Beaudette C (Krishnamurthy et al., 2000)and Anhinga (Estevez et al., 2007); and (3) 




(Paldurai et al., 2010). The reverse genetics system has been used to study the molecular 
































The complete genome sequence was determined for prototype 
parakeet/Netherlands/449/75 strain of avian paramyxovirus (APMV) serotype 3. The 
genome is 16,272 nucleotides (nt) in length, consisting of six non-overlapping genes in 
the order of 3’-N-P/V/W-M-F-HN-L-5’, with intergenic regions of 31-63 nt. APMV-3 
genome follows the “rule of six” and is the largest among the avian paramyxoviruses 
reported to date, with a trailer region of 707 nt, the longest in the family 
Paramyxoviridae. The cleavage site of F protein, A-R-P-R-G-RL, does not conform to 
the preferred cleavage site of the ubiquitous cellular protease furin. Therefore, exogenous 
protease was needed for replication in vitro. Alignment and phylogenetic analysis of the 
predicted amino acid sequences of strain Netherlands proteins with the cognate proteins 
of viruses of all of the five genera of family Paramyxoviridae showed that APMV-3 
strain Netherlands is more closely related to APMV-1 than APMV-6. 
3.3 Introduction 
 
The family Paramyxoviridae includes viruses of many species of avian, terrestrial 
and aquatic animals isolated worldwide (Lamb and Parks, 2007; Nylund et al., 2008). 
Members of this family are characterized by pleomorphic enveloped particles that contain 




divided into two subfamilies, Paramyxovirinae and Pneumovirinae. Subfamily 
Paramyxovirinae is further divided into five genera: Rubulavirus (including mumps 
virus, human parainfluenza viruses [HPIV] 2 and 4, simian virus type 5 [SV5] and 
Tioman virus [TiV]), Respirovirus (including Sendai virus [SeV] and HPIV-1 and 3), 
Henipavirus (comprising Hendra virus [HeV] and Nipah virus [NiV]), Morbillivirus 
(including measles [MeV] and canine distemper [CDV] viruses), and Avulavirus 
(comprising avian paramyxovirus [APMV] serotypes 1 to 9). Subfamily Pneumovirinae 
is divided into two genera: Pneumovirus (comprising human respiratory syncytial virus 
[HRSV] and its animal counterparts including bovine respiratory syncytial virus 
[BRSV]), and Metapneumovirus (comprising human metapneumovirus [HMPV] and 
avian metapneumovirus [AMPV]) (Rima et al., 1995; Mayo and Pringle, 1998; Pringle, 
1998; Lamb et al., 2005).  
The genomes of members of family Paramyxoviridae range in length from 15-19 
kb and contain six to ten genes in a linear array (Lamb and Parks, 2007). Transcription 
begins at a single promoter at the 3’ leader end and the genes are copied into individual 
mRNAs by a start-stop-restart mechanism guided by conserved gene-start and gene-end 
transcription signals that border the individual genes (Lamb and Parks, 2007). Genome 
replication involves the synthesis of a complete positive-sense copy of the genome that is 
called the antigenome and serves as a template for producing progeny genomes. All 
members of family Paramyxoviridae encode a nucleocapsid protein (N), a 
phosphoprotein (P), a matrix protein (M), a fusion protein (F), an attachment protein 
called the hemagglutinin (H) or haemagglutinin-neuraminidase (HN) or glycoprotein (G), 




Many paramyxoviruses encode additional proteins that play important roles in 
viral morphogenesis, RNA synthesis, and pathogenesis (Lamb and Parks, 2007). For 
example, most members of subfamily Paramyxovirinae encode additional proteins from 
the P gene by RNA editing. This involves the introduction of one or more G residues into 
a subset of the P transcripts by polymerase stuttering at a specific editing sequence motif. 
This shifts the reading frame to access alternative ORFs in one or both of the alternative 
frames, resulting in the expression of proteins in which the upstream domain is P-derived 
and the downstream domain is derived from the alternative frame. In one such protein, 
called V, the downstream domain contains a cysteine-rich motif that is highly conserved 
across the subfamily. The V protein has been implicated in the regulation of viral RNA 
synthesis (Horikami et al., 1996; Lin et al., 2005) and in counteracting host antiviral 
responses (Goodbourn et al., 2000). All members of subfamily Paramyxovirinae follow 
the “rule of six”, whereby efficient RNA replication depends on the genome length being 
an even multiple of six (Calain and Roux, 1993; Samal and Collins, 1996; Kolakofsky et 
al., 1998).  
The APMVs have been classified into nine different serotypes based on 
haemagglutination inhibition (HI) and neuraminidase inhibition (NI) assays (Alexander 
and Collins, 1984). Newcastle disease virus (NDV) belongs to serotype 1. It is the most 
extensively-characterized APMV and is a major pathogen of poultry worldwide 
(Alexander, 1980). APMV-2 has been isolated from chickens, turkeys and wild birds, and 
is responsible for causing decreases in egg production and fertility in turkeys (Lipkind et 
al., 1979; Tumova et al., 1979a). The pathogenicity of APMV 4-9 is generally unknown 




turkey in 1968 in Wisconsin. Since then, many APMV-3 strains have been isolated from 
turkeys in different parts of the world including Canada, the United States (Tumova et al., 
1979a) and England (Macpherson et al., 1983). The APMV-3 strain 
parakeet/Netherlands/449/75, isolated from parakeets in the Netherlands, is the prototype 
for the entire serotype (Alexander and Chettle, 1978). APMV-3 was also isolated from 
non-domesticated species such as Psittaciformes and Passeriformes (Alexander, 1980). 
APMV-3 has been associated with encephalitis and high mortality in caged birds, and 
with respiratory disease in turkeys (Tumova et al., 1979a). The virus causes acute 
pancreatitis and CNS symptoms in psittacine and Passeriformes birds (Beck et al., 2003). 
APMV-3 also infects chickens at an early age, with evidence of stunting growth that may 
be more marked in broiler chicken breeds (Alexander and Collins, 1982). In terms of 
pathogenicity, APMV-3 probably is second in importance only to NDV. 
An understanding of the molecular and pathological characteristics of APMV-3 is 
of general interest and is important for developing vaccines against this virus. Here, I 
report the first complete genome sequence of APMV-3 strain 
parakeet/Netherlands/449/75. The genome was found to be the longest among the 
APMVs and has the longest trailer region in family Paramyxoviridae. APMV-3 strain 
Netherlands would be predicted to be avirulent based on its F protein cleavage site and its 
observed requirement for exogenous protease for replication in vitro.  
3.4 Materials and Methods 
3.4.1 Virus and cells 
 
APMV-3 strain parakeet/Netherlands/449/75 was obtained from the National 




embryonated chicken eggs and the chicken embryo fibroblast DF1 cells were used to 
propagate APMV-3 strain Netherlands. Hemagglutination (HA) titers of virus stocks 
were determined using 0.5% chicken RBC at room temperature. The ability of the virus 
to replicate in cell culture was examined in nine different established cell lines, each 
representing a different species of origin: DF1, chicken embryo fibroblast; QT35, Quail 
fibrosarcoma; MDBK, Madin Darby Bovine Kidney; MDCK, Madin Darby Canine 
Kidney; Vero, African green monkey kidney; HEp2, Human Epidermoid carcinoma; 
PK15, Pig Kidney; CEF, Chicken Embryo Fibroblast; and BHK21, Baby Hamster 
Kidney. All the cells, except DF1 cells, were grown in Eagle’s minimum essential media 
(MEM) with 10% fetal calf serum (FCS), while DF1 cells were grown in Dulbecco’s 
MEM containing 10% FCS. All the cells were grown in a 37°C incubator with 5% CO2. 
Cell monolayers were infected with a 10-3 dilution of 29 HA units of egg-grown APMV-3 
strain Netherlands and, after 1 hr of adsorption, the viral inoculum was replaced with 
maintenance media containing 2% FCS. The growth of virus in each cell type was 
observed with and without the presence of 10% allantoic fluid, or 1-5 μg/ml of acetyl 
trypsin/ml (Gibco), or 1-5 μg/ml of α-chymotrypsin/ml (Sigma), each of which provided 
a source of protease for cleavage of the F protein if necessary. The cells were observed 
daily for cytopathic effects (CPE) and HA titers were recorded every 24 h until the fifth 
day post-infection. The virus titer in each cell type was quantified by plaque assay in DF 
1 cells as previously described (Krishnamurthy et al., 2000). The cells were overlaid with 
DMEM containing 2% FCS and 0.9% methylcellulose that were further supplemented 
with 10% allantoic fluid as a source of proteases. The plaques were visualized by staining 




3.4.2 Virus RNA isolation and sequence analysis 
 
Total RNA from virus-infected DF1 cells was isolated using TRIZOL reagent, 
following the manufacturer’s instructions (Invitrogen, USA). Viral RNA also was 
isolated from allantoic fluid collected from virus-infected eggs, using RNeasy kit 
according to the manufacturer’s instruction (QIAGEN, USA). 
Most of the APMV-3 genome, except the 3’ and 5’ termini, was copied and 
amplified into cDNA using (i) gene-specific primers designed from the known APMV-3 
M gene sequence, and (ii) consensus primers designed by using published Rubulavirus, 
Respirovirus and Morbillivirus genome sequences (Table 3.1). All primers were 
synthesized by a commercial provider (IDT, USA). N 787 forward and N 1022 reverse 
consensus primers were used to amplify a 235 base pair (bp) fragment that served as one 
starting point for downstream genome walking (Chang et al., 2001). The primer designed 
from the available M gene sequence (GenBank Accession number AY137207) was used 
in conjunction with a consensus sequence designed for the F gene, F 350 reverse, to 
amplify a 800-bp product and F 842 reverse, to amplify a 1500-bp product that were used 
as a second starting point for downstream genome walking. The HN and L genes were 
amplified by using gene-start forward (GS forward) primers and consensus reverse 
primer (Table 3.1). Initial 500 nt in HN gene was amplified by consensus GS forward and 
consensus HN550 reverse primer (Table 3.1), further downstream was amplified by HN 
gene-specific forward primer (HN428F correspond to 7047-7068 in antigenome 
sequence) and consensus HN1568 reverse primer. Furthermore, upstream of L gene was 
amplified by gene-specific HN forward primer (HN960F correspond to 7579-7603 in 




downstream of L gene was amplified by L gene-specific forward and consensus L reverse 

















Position in gene Primer sequences
 
Table 3.1. Different primers used to amplify APMV-3 genome based on consensus sequences. The primer 
name represents an individual gene, position from gene-start and forward or reverse from left to right, 
different unconventional codes represent a mixture of nucleotides ( N=A/T/C/G, R= A/G, K= G/T, Y=C/T, 
S=G/C, W=A/T, D= A/G/T and M=A/C). Sequences used for alignment were taken from published NCBI 
Genbank NC_003043 for APMV-6, NC_002617 for NDV, NC_003443 for HPIV-2, NC_006430 for SV5, 
NC_004074 for Tioman virus, NC_001552 for Sendai virus, NC_001796 for HPIV-3, AY988601 for 
Nipah virus, NC_001906 for Hendra virus NC_001498 for Measles virus, NC_001921 for Canine 
distemper virus and NC_007454 for J virus. 
 
The sequence of the 3’ terminus was determined from cDNA prepared by rapid 
amplification of cDNA ends (RACE) (Troutt et al., 1992; Li et al., 2005). Genomic RNA 
obtained from partial purified virus was ligated to adopter1 (5’ 
GGTTTTGCGGTAAAGGTGGAAGAGAAG 3’), using T4 RNA ligase according to the 




transcribed, using adopter2 (5’ CCAAAACGCCATTTCCACCTTCTCTTC 3’) primer 
according to the manufacturer’s instructions (Invitrogen). PCR was carried out with 
adopter 2 and a gene-specific reverse primer (complementary to nucleotides 450 to 472 in 
the antigenome sequence), using recombinant Taq polymerase (Invitrogen). 
The sequence of the 5’ end of the genome was determined from cDNA obtained 
by 5’ RACE (Invitrogen). Briefly, the downstream end of the L gene and adjoining trailer 
region were reverse-transcribed using a gene-specific forward primer L6760F 
representing nucleotides 15411-15433 in the antigenome sequence. The resulting cDNAs 
were column-purified and tailed with dCTP or, in a parallel reaction, with dGTP, using 
terminal deoxynucleotide tranferase (TdT, Invitrogen). The cDNAs were then amplified 
in separate reactions, using an L gene-specific forward primer L7308F representing 
nucleotides 15959-15981 in the antigenome sequence, and an anchored G primer 
(provided in the kit) in the case of product tailed with dC, or with oligo dC in the case of 
product tailed with dG.  
PCR-amplified products and plasmid DNAs were sequenced by using BigDye 
terminator v 3.1 matrix standard kit (Applied Biosystem) and 3130xl genetic analyzer 
data collection software v3.0 (Applied Biosystem). All sequencing was done in a 3130xl 
genetic analyzer or 3100 Avant genetic analyzer, using the manufacturer’s instructions. 
The entire genome was sequenced at least three times, and at least once from uncloned 
PCR product, to ensure a consensus sequence.  
3.4.3 Sequence and phylogenetic tree analysis 
 
 Sequence similarity searches were conducted using the basic length alignment 




DNA pair-wise alignment was done using MagAlign (clustalW) in a Lasergene6 software 
package. To construct phylogenetic trees and determine divergence among different 
genus, amino acid sequences were aligned using clustalW multiple alignment algorithm. 
Modified data sets were generated by bootstrapping samples using a Seqboot program, 
and modified data were analyzed by Protodist and Fitch program (Phylip 3.67).  
3.4.4 Database accession numbers 
 
The complete genome sequence of APMV-3 strain Netherlands has been 
submitted in GenBank under accession number EU403085. Different sequences from 
GenBank were used for designing primers and comparing the APMV-3 genome. These 
include NC_003043 for APMV-6, NC_002617 for NDV, NC_003443 for hPIV2, 
NC_006430 for SV5, NC_004074 for Tioman virus, NC_001552 for Sendai virus, 
NC_001796 for hPIV3, NC_003461 for hPIV1, AY988601 for Nipah virus, NC_001906 
for Hendra virus NC_001498 for Measles virus, NC_001921 for Canine distemper virus 
and NC_007454 for J virus. 
3.5 Results 
3.5.1 In vitro growth characteristics of APMV-3 strain Netherlands 
 
 APMV-3 strain Netherlands produced a titer of 28-210 HA units in nine-day-old 
embryonated SPF chickens eggs four days post inoculation. It was necessary to include 
10% allantoic fluid for replication of the virus in cell culture, indicating a requirement of 
external proteases for efficient cleavage of the F protein. Eight out of nine cell lines were 
found to support growth of APMV-3, as determined by observable CPE and HA activity 




necessary to include 10% allantoic fluid for replication of the virus in cell culture, 
indicating a requirement of external proteases for efficient cleavage of the F protein. The 
virus failed to grow in MDCK cells even after three serial passages. The virus grew most 
efficiently in MDBK cells, followed by chicken embryo fibroblast, BHK21 and Vero 
cells. The peak HA titers of the different cell lines tested were: MDBK, 27; BHK21, 26; 
CEF, 26; Vero, 25; PK15, 23; DF1, 23; QT35, 22; and HEp2, 22.  Viral CPE involved 
rounding, detachment and syncytia formation. APMV-3 was able to produce distinct 
plaques under methylcellulose overlay in DF1 cells in the presence of 10% allantoic 
fluid. The growth of APMV-3 in different cell lines was evident after the addition of 
allantoic fluid which was not substituted by the addition of either trypsin or chymotyrpsin 
in the medium. 
Examination of partially-purified virus under an electron microscope showed that 
the particles were enveloped, pleomorphic but mostly spherical in shape, with a size 
ranging from 150-250 nm (data not shown).  
3.5.2 Determination of the complete genome sequence of APMV-3 strain 
Netherlands 
 
The genome of APMV-3 strain Netherlands consists of 16,272 nt (GenBank 
accession number EU403085). The genome organization is very similar to those of other 
members of family Paramyxoviridae. The genome encodes for six open reading frames 
(ORF) corresponding to putative proteins N, P, M, F, HN and L, from the 3’ to 5’ end of 
the genome. In addition, there is evidence of a cysteine-rich V ORF in the P coding 
region. 84.1% of the genome codes for protein, which is less than the average coding 




The length, position and characteristics of the six genes and their intergenic sequences 




start Total length  5’UTR    ORF    3’UTR
Intergenic
Sequence









































mRNA characteristics (nt) Deduced protein characteristics 
50         1374         182
42         1161         175
42 747         590
42           378         960    
89 1191         198 
101 1632         189 
43 1734         197


















Table 3.2. Genomic features and protein characteristics of APMV-3 strain Netherlands. The table shows 
hexamer phasing position along with individual genes, coding and non-coding,  and intergenic sequences 
































Gene            Gene-start            Gene-end              Intergenic sequence
 
Table 3.3. Gene-start, gene-end and intergenic sequences of APMV-3 strain Netherlands. The underline 





The 3’ leader sequence of APMV-3 consists of 55 nt, a length that is conserved 
among almost all the members of subfamily Paramyxovirinae (Krishnamurthy and 
Samal, 1998). The similarity of APMV-3 leader sequence to that of NDV and APMV-6 






























Fig. 3.1. Alignment of the (a) 3’ leader and N gene start sequence. Dots indicate identity with the 
assignment in APMV-3 (Top line). (b) 5’ trailer regions of APMV-3 strain Netherlands with other avian 
paramyxoviruses and Rubulaviruses. (c) Complementary of 3’leader and 5’ trailer regions of APMV-3 
strain Netherlands. Abbreviations: NDV, Newcastle disease virus(APMV-1); SV5, Simian virus 5; APMV, 
Avian paramyxovirus; HPIV, Human parainfluenza virus; TiV, Tioman virus; SeV, Sendai virus; NiV, 
Nipah virus; HeV, Hendra virus; MeV, Measles virus; CDV, canine distemper virus. 
 
Surprisingly, the length of the APMV-3 5’ trailer sequence is 707 nt, which is the 
longest among the members of family Paramyxoviridae sequenced to date. Also, the 
nucleotide assignment at the third position from the 3’ leader (3’UGAU) and 5’ trailer 
(ACUA 5’) termini was different from those found in other APMVs and other members 
of subfamily Paramyxovirinae. Otherwise, the sequence of the genomic termini of 
APMV-3 strain Netherlands are closely related to those of APMV-1 and -6, but are 
different from those of the rubulaviruses, consistent with the classification of avian 
paramyxoviruses in the genus Avulavirus (Fig 3.1b). The sequences of the 3’leader and 
5’trailer termini showed a high degree of complementarity (87.5 percent complementarity 
for the first 16 nt), suggestive of conserved elements in the 3’ promoter regions of the 
genome and antigenome (Fig 3.1c). The gene-start sequence of APMV-3 strain 
Netherlands is 3’UCCUCGCCUU and is conserved exactly among the six genes (Table 
3.3). The  gene-end signal is slightly less well-conserved: the consensus gene-end 
sequence is 3’AAUUA(U)6, but among three of the six signals there is a total of four nt 
differences involving positions 2, 3, 4, and 6 ( Table 3.3). The intergenic sequences of 





The nucleocapsid (N) gene  
 The APMV-3 N gene is 1604 nt long and encodes an N protein of 457 amino 
acid. It contains a highly-conserved sequence motif, 322-FAPGNYSLLYSYAMG-336 
(F-X4-Y-X3-α-S- α-AMG, where X is any amino acid and α is any aromatic amino acid), 
that corresponds to a motif previously identified in the central region of the N protein of 
other members of Paramyxovirinae and which has been implicated in the self assembly 
of N with RNA or with other N monomers (Yu et al., 1998; Lamb and Parks, 2007). The 
APMV-3 N protein has 39-41% amino acid sequence identity with that of APMV-1, 
38.3% with APMV-6, 32-34% with Rubulavirus, 21-22% with Respirovirus, 26% with 
Henipavirus, 24% with Morbillivirus and 25.4% with J virus.   
The phosphoprotein (P) gene 
The APMV-3 P gene is 1378 nt long. The unedited version of the P mRNA 
encodes a P protein of 386 amino acids. The predicted P protein contains an abundance of 
phosphorylation sites, with 19 serine and 6 threonine residues identified as potential 
phosphorylation sites using NetPhos 2.0 software.  The APMV-3 P protein has 22.8% 
amino acid sequence identity with that of APMV-1, 19% with APMV-6, 18%-21% with 
Rubulavirus, 9-12% with Respirovirus, 13-15% with Henipavirus, 12% with 
Morbillivirus and 11.4% with J virus.   
The P gene contains a putative editing site, 5’- TTTTTAAAGGGGG (mRNA 
sense), at positions 362-374 in the P gene (positions 2076-2088 in the complete genome 
sequence), which showed a high degree of sequence identity with the editing sites in 
other members of subfamily Paramyxovirinae (Fig 3.2). The insertion of a single G 




amino acid V protein in which the N-terminal 112 amino acids were derived from P, and 
the downstream 136 amino acids include seven cysteine residues and one tryptophan 
residue that are highly conserved within Paramyxovirinae (Fig 3.3). Alternatively, the 
insertion of two G residues would shift the reading frame to access an internal ORF that 



















Fig. 3.2. RNA editing site in P gene of selected members of the family Paramyxoviridae. Sequences are 
shown in positive mRNA sense. Addition of one and two G residues into the stretch of G residues leads to 
formation of V and W proteins.  
APMV-3 184 TWCNPACSPVTAFPKQYKCACRQCPRFCDLCF 215
APMV-6 194 SWCNPSWSPIKAEPKQYPCFCGSFPPTCRLCA 225
NDV 194 SWCNPSCSPIRAEPRQYSCTCGSCPATCRLCA 225
HPIV-2 191 EWCNPRCAPVTASARKFTCTCGSCPSICGECE 222
SV5 188 EWCNPSCSPITAAARRFECTCHQCPVTCSECE 219
TiV 181 EWCNPICHPISQFTYRGTCRCGCCPDVCSLCE 212
NiV 425 EWCNPACSRITPLPRRQECQCGECPIECSHCC 456
HeV 423 EWCNPVCSRITPQPRKQECYCGECPTECSQCC 454
CDV 249 KWCNPICTQVNWGIIRAKCVCGECPPTCNECK 280
JVirus 253 EWCNPQCAPITVTPTQSRCTCGECPKVCARCI 284
 
Fig.3.3. Sequence alignment of C terminal end of V proteins of different members of subfamily 
Paramyxovirinae. Stars indicate conserved cysteine and tryptophan residues. Numbers in both side of 






The matrix protein (M) gene  
The M gene of APMV-3 is 1478 nt long and encodes a 396-amino-acid M 
protein. The protein is highly basic with an isoelectric point of 9.3, which may be 
important for ionic interaction with acidic N protein (Lamb and Parks, 2007). The 
bipartite cluster, which comprises clusters of basic amino acids—either ‘single cluster’, 
containing three to five basic amino acids, or ‘bipartite’ sequence, containing two 
interdependent clusters of such amino acids separated by an intervening sequence, is 
clearly seen in the positions 257-272, which was similar to that described previously 
(Coleman and Peeples, 1993). The M protein of APMV-3 contains a putative nuclear 
localization sequence (NLS) at position 371-383 aminoacids, which was previously 
found in the C terminal of NDV M protein (Coleman and Peeples, 1993; Shihmanter et 
al., 2005). .  The APMV-3 M protein has 26.3% amino acid sequence identity with that of 
APMV-1, 25.8% with APMV-6, 22%-24% with Rubulavirus, 15-18% with Respirovirus, 
13-14% with Henipavirus, 13-15% with Morbillivirus and 15.9% with J virus. 
 
The fusion protein (F) gene 
The APMV-3 F gene is 1922 nt long and encodes for a 543-amino-acid F protein. 
The protein is predicted to be a type I transmembrane protein, similar to the F proteins of 
other members of family Paramyxoviridae. It has a predicted signal anchor of residues 1-
19 and a predicted transmembrane anchor of residues 491-513. The putative cleavage site 
of the APMV-3 F protein is A-R-P-R-G-RL (corresponding to 101-107 amino-acid 




APMV-3 101 A-R-P-R-G-R-L 107
NDV (Virulent) 111 G-R-R-Q-K-R-F 117
NDV (Avirulent) 111 G-G-R-Q-G-R-L 117
APMV-6 113 P-A-P-E-P-R-L 119
APMV-2 93  D-K-P-A-S-R-F 99
NiV 104 L-V-G-D-V-R-L 110
SV5 97  T-R-R-R-R-R-F 103
HPIV-2 101 K-T-R-Q-K-R-F 107
SeV 111 D-V-P-Q-S-R-F 117
HPIV-3 104 N-P-R-T-K-R-F 110
CDV 219 G-R-R-Q-R-R-F 225
MeV 107 S-R-R-H-K-R-F 113
 
Fig. 3.4. Comparison of the F protein cleavage site of different members of family Paramyxoviridae. 
Number of polybasic residues (R= Arginine) in some of the strains shown represents virulent cleavage site. 
The number represents the amino acid sequence covering the cleavage site.  
 
The deduced amino acid sequence contains five putative N-linked glycosylation 
sites at positions 68 and 81 in the F2 subunit, and at positions 356, 435 and 485 in the F1 
subunit, predicted using EXPASY software. The amino-acid sequence of APMV-3 
contained heptad repeats located between position 105 to 189 similar to those of other 
fusion glycoproteins (Chambers et al., 1990). The F protein sequence of APMV-3 also 
contained an ALGVAT fusion peptide motif (amino acid positions 116-121 in F protein), 
which is conserved among other family members (Lamb and Parks, 2007).  The APMV-3 
F protein has 31.3% amino acid sequence identity with that of APMV-1, 30.6% with 
APMV-6, 29% with APMV-2, 24%-29% with Rubulavirus, 21-23% with Respirovirus, 






The hemagglutinin-neuraminaidase protein (HN) gene 
The HN gene is 1974 nt long and encodes a polypeptide of 577 amino acids. The 
HN protein is a type II integral membrane protein that spans the membrane once and has 
a predicted hydrophobic signal anchor domain spanning residues 27-46. Seven potential 
N-linked glycosylation sites were identified at positions 32, 57, 122, 312, 325, 383 and 
502, using the Expasy, NetNGlyc program. The HN protein contains a high amount of 
acidic amino acids with an isoelectric point (pI) of 7.83. The HN proteins of subfamily 
Paramyxovirinae and the HA proteins of influenza viruses contain a conserved sequence, 
N-R-K-S-K-S, which is thought to contribute to the sialic acid binding site (Varghese et 
al., 1983). The aminoacid sequence of APMV-3 HN protein contains a similar motif, N-
R-K-S-C-S (237-243 amino-acid position in HN protein). The APMV-3 HN protein has 
34% amino acid sequence identity with that of APMV-1, 31% with APMV-6, 31% with 
APMV-2, 40% with APMV-4, 18%-33% with Rubulavirus, 21-22% with Respirovirus, 
16-17% with Henipavirus, 10-11% with Morbillivirus and 23% with J virus.  
  
The large polymerase protein (L) gene 
The L gene is 6913 nt long and encodes for 2198 amino-acids L protein. 
Alignment of L gene sequence of APMV-3 with other members of Paramyxoviridae 
demonstrated six linear conserved domains, which have been described earlier for these 
family members and represent catalytic domains (Poch et al., 1989). The conserved 
QGDNQ sequence that is found within domain III involved in transcription activity 
(Schnell and Conzelmann, 1995) was also found in L protein of APMV-3 at amino-acid 




that of APMV-1, 36% with APMV-6, 32-34% with Rubulavirus, 25-26% with 
Respirovirus, 25% with Henipavirus, 25-26% with Morbillivirus and 24.7% with J virus.   
 
 
3.5.3 Phylogenetic analysis 
 
Phylogenetic trees were generated from amino acid sequence alignments of N, P, 
M, F, HN and L proteins of APMV-3 strain Netherlands with the cognate proteins of 
representative viruses of all five genera of family Paramyxoviridae (Fig 3.5). Based on 
N, P, M, F, HN and L protein phylogenic trees, APMV-3 was phylogenetically closely 
related to NDV. Phylogenic analysis of HN protein showed that APMV-3 was more 
closely related to that of APMV-4. All six trees clearly indicated the close genetic 






























































































































































































































Fig. 3.5. Phylogenic analysis of N, P, M, F, HN and L proteins of members of family Paramyxoviridae. 




                                                                   
3.6 Discussion 
 
The genome of APMV-3 is 16,272 nt long, which is larger than the other two 
APMV serotypes sequenced to date, APMV-1 (15,186 nt, 15,192 nt and 15,198 nt) 
(Krishnamurthy and Samal, 1998; Czegledi et al., 2006; Ujvari, 2006) and APMV-6 
(16,232 nt) (Chang et al., 2001). The APMV-3 genome length is also larger than the 
typical genome size (approximately 15,500 nt) of other members of family 
Paramyxoviridae, but is smaller than the 18,234 nt genome of Hendra virus (Wang et al., 
2000) and the 18,954 nt genome of J virus, the largest genome reported to date for 
Paramyxoviridae (Jack et al., 2005). The genome length of APMV-3 was consistent with 
the “rule of six” that is a characteristic of the subfamily Paramyxovirinae (Calain and 
Roux, 1993). The genome contains six genes (N, P, M, F, HN and L) that are also found 
in all members of the subfamily. The amino acid sequence relatedness of APMV-3 
proteins with the corresponding proteins of APMV-1 and APMV-6 clearly places this 
virus in the genus Avulavirus, consistent with the International Committee on Taxonomy 
of Viruses statement that amino acid sequence relationships are the main criteria for 
grouping viruses into genera within the family Paramyxoviridae (Lamb et al., 2005). 
APMV-3 has a 55 nt 3’ leader region, which is exactly conserved in length with all other 
known members of Paramyxoviridae (Lamb and Parks, 2007), and its sequence is 
generally conserved within subfamily Paramyxovirinae. For members of subfamily 
Paramyxovirinae, the first 12-13 nt genomic termini are genus-specific and are used in 
classification of new isolates. Unexpectedly, however, the third nucleotide of the leader 




will be of interest to determine whether this difference is consistent in other strains of 
APMV-3 and might also be found in some of the other serotypes. In most members of 
family Paramyxoviridae, the 5’ trailer region is 40-60 nt long (Shioda et al., 1986), 
although there are a few exceptions where the trailer region is somewhat longer: for 
example, 155 nt in RSV (Mink et al., 1991) and 159 nt in Mapuera virus (Wang et al., 
2007). The trailer region of APMV-3 is unusually long (707 nt), and is the longest trailer 
among members of family Paramyxoviridae sequenced to date. RNA secondary structure 
analysis using Genebee (www.genebee.msu.su/genebee.html) software provided 
suggestive evidence of secondary structure in this region (not shown), although it is not 
clear whether a structure could form with an RNA that is completely encapsidated. 
Further analysis of the 707 nt trailer region did not reveal any open reading frame, 
indicating that it is not a part of the L gene which was truncated at some point in the 
evolution. Whether this unusually long trailer region has any functional significance can 
ultimately be determined using reverse genetics techniques.  
The availability of the first sequence of a representative of APMV-3 described 
here, together with the recent description of complete sequence of representative of 
APMV-6 and the availability of complete genome sequences from APMV-1, provides the 
opportunity to assess the relatedness of these putative serotypes on a genome-wide basis. 
For example, APMV-3 Netherlands strain shares 41.7% and 42.2% nt sequence identity 
with representatives of APMV-1 and -6, respectively (a comparison made exclusive of 
the SH gene of APMV-6 and the long trailer of APMV-3). Amino acid sequence identity 
between APMV-3 versus -1 and -6 for the N protein was 39-41% and 38.3%, 




25.8% respectively; that involving F was 31.3% and 30.6%, respectively; that involving 
HN was 36% and 31%, respectively (and 41% with HN of APMV-4, the sole reported 
sequence for that serotype); and that involving L was 33% and 36%, respectively. These 
values, together with the phylogenic analysis shown in Fig 3.5, show that APMV-3 strain 
Netherlands is more closely related to APMV-1 than APMV-6. This is consistent with the 
results of cross HI and NI tests, which suggested that the nine putative serotypes 
segregated into two broad, larger groupings, the first containing APMV-2 and -6, and the 
second APMV-1, -3, -4, -7, -8, and -9 (Lipkind and Shihmanter, 1986). Furthermore, the 
pattern of sequence relatedness outlined above also indicates that the overall extent of 
divergence among the proposed APMV serotypes is comparable to that among the HPIV 
serotypes. For comparison, I note the genomes of HPIV-1 and HPIV-3, both of 
Respirovirus, have 60.3% nt identity, and their proteins share the following percent 
amino acid sequence identities: N, 62; P, 26;M, 63; F, 45; HN, 49%, L, 61 (Newman et 
al., 2002). HPIV-1 and HPIV-2, representing different genera (Respirovirus versus 
Rubulavirus, respectively), share 42.9% nt sequence identity and share the following 
percent amino acid sequence identities: N, 25; M, 20; F, 24; HN, 28 L, 31 (Newman et 
al., 2002). Thus, the APMVs appear to be somewhat more divergent than the HPIV-1 and 
HPIV-3 difference and somewhat less divergent than the HPIV-1 and HPIV-2 difference.  
This supports the idea that APMV-1 through- 9 are indeed true serotypes. This is offered 
with the caveat that it will be important to examine cross-reactivity and cross-protection 
following experimental primary infections of the various APMV serotypes. In addition, it 
will be important to determine complete sequences for representatives of each of the 




The F protein of members of Paramyxoviridae is responsible for virus penetration 
into a host cell and cell fusion. The putative F protein cleavage site of APMV-3 strain 
Netherlands (A-R-P-R-G-RL) does not conform to the preferred furin cleavage site (R-
X-R/K-RF), which is an important determinant of virulence for NDV and avian 
influenza viruses. In addition, the first residue of the F1 subunit is leucine, and thus, 
matches the assignment in avirulent strains of NDV as well as the single strain of APMV-
6 sequenced to date, but differs from virulent strains of NDV, which have phenylalanine 
at this position. The observation that the F protein of APMV-3 strain Netherlands has 
characteristics consistent with that of an avirulent NDV strain is consistent with its 
dependence of exogenous protease for replication in vitro. However, it is in sharp 
contrast to the observed virulence of APMV-3 in birds (Alexander and Collins, 1982). It 
will be interesting to study further the pathogenicity of this virus in chickens and turkeys. 
The analysis of additional strains of APMV-3, and the development of a reverse genetics 
system to study viral biology and pathogenesis, and to create live attenuated strains, will 













Complete genome sequence of avian paramyxovirus-3 strain Wisconsin: evidence 
for the existence of subgroups within the serotype. 
4.2 Abstract 
 
The complete consensus genome sequence was determined for avian 
paramyxovirus (APMV) serotype 3 strain Wisconsin. The genome is 16,182 nucleotides 
(nt) in length, consisting of six non-overlapping genes in the order of 3’-N-P/V/W-M-F-
HN-L-5’, with a 55-nt leader at its 3’ end and a 681-nt trailer at its 5’end. Comparison of 
the APMV-3 strain Wisconsin nt and the aggregate predicted amino acid (aa) sequences 
with those of APMV-3 strain Netherlands revealed 67 and 78%, identity, respectively. 
The nt and aa sequence identities between the two APMV-3 strains were lower than 
between the two antigenic subgroups of human respiratory syncytial virus (81 and 88% 
identity, respectively) and the two subgroups of human metapeumovirus (80 and 90% 
identity, respectively). Reciprocal cross-hemagglutination inhibition and cross-
neutralization assays using post infection sera from chickens indicated that strains 
Wisconsin and Netherlands are highly related antigenically, with only a 2- to 4-fold 
difference in antibody reactivity between the homologous and heterologous strains. 
Taken together, the results indicate that the two APMV-3 strains represent a single 
serotype with two subgroups that differ substantially based on nt and aa sequences, but 







The APMVs have been classified into nine different serotypes based on 
hemagglutination inhibition (HI) and neuraminidase inhibition (NI) assays (Alexander 
and Collins, 1984). Newcastle disease virus (NDV) composes serotype 1. Naturally-
occurring strains of NDV include highly virulent strains capable of causing devastating 
disease in poultry, as well as strains of moderate or low virulence. NDV is the most 
highly characterized virus among all APMV serotypes (Alexander, 1980). APMV-2 has 
been isolated from chickens, turkeys and wild birds, and is responsible for decreases in 
egg production and fertility in turkeys (Lipkind et al., 1979; Tumova et al., 1979a). The 
pathogenicity of APMV 4-9 is generally unknown except for a few isolated reports 
(Alexander, 1982; Warke et al., 2008). APMV-3 was first isolated from a turkey in 1968 
in Wisconsin. Since then, many APMV-3 strains have been isolated from turkeys in 
different parts of the world including Canada, the United States (Tumova et al., 1979a) 
and England (Macpherson et al., 1983). The APMV-3 strain 
parakeet/Netherlands/449/75, isolated from parakeets in the Netherlands, is considered 
the prototype for the entire serotype (Alexander and Chettle, 1978). APMV-3 has also 
been isolated from non-domesticated species such as Psittaciformes and Passeriformes 
(Alexander, 1980). APMV-3 has been associated with encephalitis and high mortality in 
caged birds, and with respiratory disease in turkeys (Tumova et al., 1979a). The virus 
causes acute pancreatitis and central nervous system symptoms in psittacine and 
Passeriformes birds (Beck et al., 2003). APMV-3 also infects chickens at an early age, 




(Alexander and Collins, 1982). In terms of pathogenicity, APMV-3 probably is second in 
importance only to NDV. 
As noted, APMV-3 strains have been isolated from a wide range of avian species 
and from different parts of the world. But very little is known about the genetic and 
antigenic relatedness among these strains. This information is important for 
epidemiological studies and for the development of vaccines against this virus. I recently 
described a complete consensus sequence of the APMV-3 prototype strain 
parakeet/Netherlands/449/75 (Kumar et al., 2008), but other strains remain to be 
characterized. As a first step towards understanding the genetic and serological 
relationship among APMV-3 strains, I now report the complete genome sequence of 
APMV-3 strain turkey/Wisconsin/68 and describe comparison with those of prototype 
strain parakeet/Netherlands/449/75 and other APMV serotypes. The genome of strain 
turkey/Wisconsin/68 is 16,182 nt long, which is smaller than that of strain 
parakeet/Netherlands/449/75 by 90 nt. There is 67 % nt and 78% amino acid (aa) 
sequence identity between the two strains. The cleavage site of F protein of strain 
turkey/Wisconsin/68 contains a monobasic residue, compared to a dibasic residue in 
strain parakeet/Netherlands/449/75. Antigenic and sequence analysis suggested that the 
two strains represent a single serotype with two genetic subgroups. 
 
4.4 Materials and Methods 
4.4.1 Virus and cells 
 
APMV-3 strain turkey/Wisconsin/68 was obtained from the National Veterinary 




embryonated chicken eggs and the chicken embryo fibroblast DF1 cell line were used to 
propagate APMV-3 strain Wisconsin. Hemagglutination (HA) titers of virus stocks were 
determined using 0.5% chicken RBC at room temperature. The ability of the virus to 
replicate in cell culture was examined in nine different established cell lines, each 
representing a different species of origin: DF1; MDBK, Madin Darby Bovine Kidney; 
MDCK, Madin Darby Canine Kidney; Vero, African green monkey kidney; HEp2, 
Human Epidermoid carcinoma; PK15, Pig Kidney, all the cell lines were obtained from 
the American Type Culture Collection (ATCC, Manassas, VA). All cells, except DF1 
cells, were grown in Eagle’s minimum essential media (MEM) with 10% fetal calf serum 
(FCS), while DF1 cells were grown in Dulbecco’s MEM containing 10% FCS. All cells 
were grown in a 37°C incubator with 5% CO2. Cell monolayers were infected with a 10
-3 
dilution of 29 HA units of egg-grown APMV-3 strain Wisconsin and, after 1 h of 
adsorption, the viral inoculum was replaced with maintenance medium containing 2% 
FCS. The growth of virus in each cell type was observed with and without the presence 
of 10% allantoic fluid, or 1-5 μg/ml of acetyl trypsin/ml (Gibco), or 1-5 μg/ml of α-
chymotrypsin/ml (Sigma), each of which provided a source of protease for the cleavage 
of F protein if necessary. The cells were observed daily for cytopathic effects (CPE) and 
HA titers were recorded every 24 h until the fifth day post-infection. The virus titer in 
each cell type was quantified by plaque assay in DF 1 cells as previously described 
(Krishnamurthy et al., 2000). The cells were overlaid with DMEM containing 2% FCS 
and 0.9% methylcellulose that were further supplemented with 10% allantoic fluid as a 
source of proteases. The plaques were visualized by staining with 1% crystal violet after 




4.4.2 Serological analysis  
 
Antisera against APMV-3 strains turkey/Wisconsin/68 and 
parakeet/Netherlands/449/75 were prepared at separate times to avoid cross infections. 
Briefly, groups of six two-week old SPF chicken were inoculated with infective allantoic 
fluid (29 HA units) of each virus through intranasal (IN) and intraocular (IO) routes. Two 
weeks after inoculation the birds were bled and sera were collected. The sera were heat-
inactivated at 560C for 30 minutes and stored at -200C. The antibody level of serum 
samples collected from chicken immunized with APMV-3 strains were evaluated by HI 
assay with chicken erythrocyte as previously described (Alexander, 1988). Cross 
reactivity of immunized chicken sera were determined by HI assay against the 
heterologous APMV-3 strains and other APMV serotypes. The ability of chicken sera to 
cross neutralize heterologous APMV-3 strains  was determined by plaque reduction 
neutralization (PRN) assay in DF-1 cells and virus neutralization (VN) assay in 
embryonated chicken eggs using standard procedures (Alexander, 1995; Alexander, 
2003b). 
4.4.3 Virus RNA isolation and sequence analysis 
 
Total RNA from virus-infected DF1 cells was isolated using TRIZOL reagent, 
following the manufacturer’s instructions (Invitrogen, USA). Viral RNA was also 
isolated from allantoic fluid collected from virus-infected eggs, using RNeasy kit 
according to the manufacturer’s instruction (QIAGEN, USA). 
Most of the APMV-3 genome, excepting the 3’ and 5’ termini, was copied and 
amplified into cDNAs using (i) primers designed from the published APMV-3 




using published Avulavirus, Rubulavirus, Respirovirus, Morbillivirus, and Henipavirus 
genome sequences (Table 4.1). In addition, as APMV-3 Wisconsin sequence became 
available, it was used to design additional primers. N787 forward and N1022 reverse 
consensus primers were used to amplify a 235 base pair (bp) fragment that served as one 
starting point for downstream genome walking (Chang et al., 2001). A primer designed 
from the available APMV-3 Netherlands P gene sequence (GenBank Accession number 
EU403085) (P 780 forward) was used in conjunction with (i) a consensus sequence 
designed for the M gene, M350 reverse, to amplify a 800-bp product, and (ii) a second 
consensus sequence, M1066 reverse, to amplify a 1500-bp product that were used as a 
second starting point for downstream genome walking. The upstream 850 nt in the HN 
gene were amplified using the consensus GS forward (GE forward) primer and consensus 
HN840 reverse primer (Table 4.1). An overlapping region containing the rest of the HN 
gene was amplified using the consensus forward primer HN490 forward and the 
consensus gene-end reverse (GE reverse) primer. The upstream end of the L gene was 
amplified using the consensus primer HN1492 forward primer and consensus L669 
reverse primer (Table 4.1). Downstream regions of L gene were amplified by L gene-
specific forward and consensus L reverse primers listed in Table 4.1. 
The sequence of the 3’ terminus was determined from cDNA prepared by rapid 
amplification of cDNA ends (RACE) (Troutt et al., 1992; Li et al., 2005; Kumar et al., 
2008) as described previously (Kumar et al., 2008). The sequence of the 5’ end of the 
genome was determined from cDNA obtained by 5’ RACE (Invitrogen) as described 




To investigate RNA editing of the P gene, DF1 cells were infected with APMV-3 
strain Wisconsin at a MOI of 0.1 PFU per cell. mRNAs were isolated from total RNA 
using an oligo-dT column (Oligotex mRNA mini kit, QIAGEN). RT was performed 
using a gene-specific reverse primer, P551 reverse (Table 4.1). A 414-bp cDNA fragment 
spanning the putative editing site in the P gene of APMV-3 strain Wisconsin was 
amplified using gene-specific primers P137 forward and P551 reverse (identified 
according to their position in the complete antigenome sequence). The PCR-amplified 
products were cloned and individual clones were sequenced spanning the putative P gene 
RNA editing site. 
PCR-amplified products and plasmid DNAs were sequenced by using the BigDye 
terminator v 3.1 matrix standard kit (Applied Biosystems) and 3130xl genetic analyzer 
data collection software v3.0 (Applied Biosystems). The entire genome was sequenced at 
























L5377reverse 5’GTATATWTWGTMRCTTCTAATG3’  
Table 4.1. Primers used to amplify APMV-3 genome based on consensus sequences from Avulavirus, 
Rubulavirus, Respirovirus, Morbillivirus, and Henipavrus genome sequences. The primer name indicates 
the gene name, position from the gene-start, and the forward or reverse direction of priming. N=A/T/C/G, 
R= A/G, K= G/T, Y=C/T, S=G/C, W=A/T, D= A/G/T and M=A/C. Sequences used for alignment are 
noted in the Materials and Methods. 
 
4.4.4 Sequence and phylogenetic tree analysis 
 
 Sequence similarity searches were conducted using the basic length alignment 
search tool (BLAST) from the National Center for Biotechnology Information (NCBI). 
DNA pair-wise alignment was done using MegAlign (clustalW) in a Lasergene 8 
software package. Prediction of phosphorylation sites, signal sequences and glycosylation 
sites in the complete genome sequence was determined by using NetPhos 2.0 software, 
SignalP 3.0 server and NetNGlyc program respectively (all from ExPASy Proteomics 




aa sequences were aligned using clustalW multiple alignment algorithm. In addition, boot 
strap values were calculated for maximum parsimony using PHYLIP software. 
4.4.5 Database accession numbers 
 
The complete genome sequence of APMV-3 strain Wisconsin has been submitted 
in GenBank under accession number EU782025. Different sequences from GenBank 
were used for designing primers and comparing the APMV-3 genome. These include 
NC_002617 for NDV, EU338414 for APMV-2, EU403085 for APMV-3 Netherlands, 
FJ177514 for APMV-4, NC_003043 for APMV-6, FJ215863 for APMV-8, EU910942 
for APMV-9, NC_003443 for hPIV2, NC_006430 for SV5, NC_004074 for TiV, 
NC_001552 for SeV, NC_001796 for hPIV3, NC_003461 for hPIV1, AY988601 for 
NiV, NC_001906 for HeV, NC_001498 for MeV, NC_001921 for CDV, NC_006383 for 
Peste des petits ruminants virus (PPRV), NC_006296 for RPV. 
4.5 Results 
4.5.1 In vitro growth characteristics of APMV-3 strain Wisconsin 
 
 APMV-3 strain Wisconsin produced a titer of 29-210 HA units per ml of allantoic 
fluid in 9-day-old embryonated SPF chickens eggs four days post inoculation. It was 
necessary to include 10% allantoic fluid for replication of the virus in cell culture, 
indicating a requirement of external proteases for efficient cleavage of the F protein. The 
virus grew most efficiently in DF1, with the next most efficient growth being in MDBK 
cells. Viral CPE involved rounding, detachment and syncytia formation. The growth 
kinetics and plaque morphology in DF-1 cells were similar for APMV-3 strains 





4.5.2 Antigenic relationship between APMV-3 strains Wisconsin and Netherlands 
 
The antigenic relationship between APMV-3 strains Wisconsin and Netherlands 
was evaluated by reciprocal HI tests using strain specific convalescent sera raised by a 
single infection of chickens by the IN/IO route. Each of the antisera exhibited a four-fold 
difference in HI titer between the homologous and heterologous strains (Table 4.2A). As 
expected, the two APMV-3 strains were serologically distinct from representatives of the 
other APMV serotypes, although there was a low level of cross-reaction with APMV-8 
(Table 4.2A).  
The ability of antisera to neutralize homologous and heterologous APMV-3 
strains was assessed by PRN test in cell culture and by VN test in embryonated eggs. The 
results showed that both the antisera cross neutralized the heterologous strain, but the 
neutralization titers were two-fold higher against the homologous strain than with the 
heterologous strain (Table 4.2B). These reactions indicated existence of a low level of 










HI titer are expressed as the reciprocal of the highest dilution of antisera inhibit 4HA units of the virus. Viruses used as antigen were NDV-
LaSota, APMV-2/Ck/Yucaipa/56, APMV-3/PKT/Netherlands/449/75, APMV-3/Turkey/Wisconsin/68, APMV-4/DK/HK/D3/75, APMV-




















APMV-3 (Wisconsin)APMV-3 (Netherlands) serum
APMV-3(Netherlands)
APMV-3 (Wisconsin)APMV-3 (Wisconsin) serum
VirusAntiserum
a The APMV-3 serum neutralizing titer against each strain was determined and is expressed as the reciprocal log2.




Table 4.2. Antigenic analysis of APMV-3 strains Wisconsin and Netherlands using antisera from chickens 
infected with the individual strains. (A) Homologous and heterologous hemaggutination-inhibition titers. 
(B) Homologous and heterologous neutralization titers based on plaque reduction assays in cell monolayers 
and serum neutralization assays in embryonated eggs. 
 
4.5.3 Determination of the complete genome sequence of APMV-3 strain Wisconsin 
 
I determined the sequence of the entire genome of APMV-3 Wisconsin. A 
number of the initial cDNAs in this analysis were prepared using primers derived from 
consensus sequences identified by sequence alignment of multiple members of the 
Avulavirus, Rubulavirus, Respirovirus, Morbillivirus, and Henipavrus genera (Table 4.1). 
A few primers were also designed based on the published APMV-3 Netherlands 
sequence. Every nt in the complete sequence was confirmed in uncloned cDNA, 
indicating that it is a consensus sequence. 
The genome of APMV-3 strain Wisconsin consists of 16,182 nt. Its genome 




genome codes for six open reading frames (ORF) corresponding to putative proteins N, 
P, M, F, HN and L, from the 3’ to 5’ end of the genome (Fig. 4.1A). In addition, there is 
evidence of a cysteine-rich V ORF in the P coding region. 84% of the genome codes for 
protein, which is less than the average coding percentage (92%) of other members of 
subfamily Paramyxovirinae (Miller et al., 2003). Comparison of complete genome 
sequence of APMV-3 strain Wisconsin with that of strain Netherlands showed minor 
changes in the length of the P, M, F, HN, and L genes as well as the trailer region, 
whereas the lengths of the N gene and leader region were the same in each strain (Fig. 
4.1A and 4.1B). 
(A) 
N P M F HN L
APMV -3 strain Wisconsin, 16,182 nucleotide
APMV-3 strain Netherlands, 16,272 nucleotide
Gene length ( nt)    1604            1389         1418              1966        1987                             6835
Gene length ( nt)     1604            1378         1478              1922       1974                             6913
55 50 63 37 36 61 681
55 55 63 31 34 59 707
protein length(aa )   457              390           375                538       577                              2198
protein length(aa )   457              386           396                543       577                               2198








APMV-3 strain Wisconsin leader
APMV-3 strain Netherlands leader
APMV-3 strain Netherlands trailer (distal 100 nucleotide)







Fig. 4.1. Structure of the APMV-3 genome. (A) Gene maps of APMV-3 strains Wisconsin and 
Netherlands. Individual genes are indicated by boxes, with gene lengths given in nt together with the 
predicted amino acid length of the unmodified protein. The nt lengths of the extragenic 3’ leader, 5’ trailer, 
and intergenic regions are underlined. (B) Alignment of the sequences (genome-sense) of the leader region 
(i) or the downstream end of the trailer region (ii) of APMV-3 strains Wisconsin and Netherlands. Shading 
denotes identity between the strains.  
 
The 3’ leader sequence of APMV-3 strain Wisconsin consists of 55 nt, a length 
that is conserved among almost all the members of subfamily Paramyxovirinae 
(Krishnamurthy and Samal, 1998). The nt sequences of the leader region of the 
Wisconsin and Netherlands strains differed at 16 out of 55 positions, with the 3’-terminal 
12 nt being identical between the two strains (Fig. 4.1B). The length of the 5’ trailer 
region of APMV-3 strain Wisconsin is 681 nt, which is 26 nt shorter than that of APMV-
3 strain Netherlands. The sequences of the 3’ leader and 5’ trailer termini of strain 
Wisconsin showed a high degree of complementarity, with only a single mismatch in the 
terminal 16 positions (94% complementarity), suggestive of conserved elements in the 3’ 




APMV-3 strain Wisconsin showed 59% identity (aggregate of the complete 3’ leader and 
5’ trailer sequence) with that of strain Netherlands. 
The boundaries of the individual genes were putatively identified based on the 
presence of conserved putative gene-start and gene-end transcription signals. The 
sequence of the APMV-3 strain Wisconsin putative gene-start signal is 
3’UCCU/CCGCCUU and is highly conserved among the six genes (Table 4.3). The  
gene-end signal is slightly less well-conserved: the consensus gene-end sequence is 
3’AAU/AUA/U(U)6, but among four of the six signals there is a total of four nt 
differences involving positions 3 and 5 ( Table 4.3). The intergenic sequences of APMV-
3 Wisconsin range in length from 37 to 63 nt. The lengths of the intergenic sequences are 
similar to those in strain Netherlands, although the length is exactly the same only for the 




























 Table 4.3. Putative gene-start, gene-end and intergenic sequences of APMV-3 strain Wisconsin (sequences 





The nucleoprotein (N) gene 
 The N gene of APMV-3 strain Wisconsin is 1604 nt long and encodes an N 
protein of 457 amino acids. The predicted N protein contains a highly-conserved 
sequence motif, 322-FAPGNYALLYSYAMG-336 (F-X4-Y-X3-α-S- α-AMG, where X 
is any aa and α is any aromatic aa), that corresponds to a motif previously identified in 
the central region of the N protein of other members of Paramyxovirinae and which has 
been implicated in the self assembly of N with RNA or with other N monomers (Yu et 
al., 1998; Lamb and Parks, 2007). The APMV-3 strain Wisconsin N protein has 88.6% aa 


















Table 4.4. Amino acid identity between APMV-3 strain Wisconsin versus strain Netherlands and 
representatives of the other APMV serotypes. Individual values show the percent identity of N, P, M, F, 
HN and L proteins among different members of genus Avulavirus. The identity was determined by 







The phosphoprotein (P) gene 
The P gene of APMV-3 strain Wisconsin is 1389 nt long. The unedited version of 
the P mRNA encodes a P protein of 390 amino acids. The predicted P protein contains an 
abundance of phosphorylation sites, with 29 serine, 9 threonine and 1 tyrosine residues 
identified as potential phosphorylation sites using NetPhos 2.0 software.  The APMV-3 
strain Wisconsin P protein has 59.1% aa sequence identity with that of strain Netherlands 
(Table 4.4). 
 The P gene contains a putative editing site, 5’- TTTTTAAAGGGGG (mRNA 
sense), at positions 374-386 in the P gene (positions 2083-2095 in the complete 
antigenome sequence), which has a high degree of sequence identity with the editing sites 
in other members of subfamily Paramyxovirinae. The insertion of a single G residue 
(mRNA sense) at the editing site would shift the reading frame to encode a 252-aa V 
protein in which the N-terminal 115 amino acids are derived from P, and the downstream 
137 amino acids include seven cysteine residues and one tryptophan residue that are 
highly conserved within the subfamily Paramyxovirinae (Fig. 4.2). Alternatively, the 
insertion of two G residues would shift the reading frame to access an internal ORF that 
is open for only 12 additional amino acids, yielding a 127-aa W protein. Sequence 
analysis of cloned cDNAs of mRNAs isolated from infected cell culture showed mRNA 
with incorporation of one and two G residues at the predicted RNA editing site (Fig. 4.3). 
The APMV-3 strain Wisconsin V and W proteins have 63% and 55% aa sequence 




APMV-3(Net) 184 TWCNPACSPVTAFPKQYKCACRQCPRFCDLCF 215
APMV-3(Wis) 188 TWCNPACSPVTALPKQYRCACRQCPKFCDLCF 219
APMV-1 194 SWCNPSCSPIRAEPRQYSCTCGSCPATCRLCA 225
APMV-2 198 SWCNPVCSPIRSEPRREKCTCGTCPESCILCR 229
APMV-4 190 EWCNPGCTAVRIEPTRLDCVCGHCPTICSLCM 221
APMV-6 194 SWCNPSWSPIKAEPKQYPCFCGSFPPTCRLCA 225
APMV-7 195 SWCNPTCAPIRPYPTVERCRCGNCPKFCPGCQ 226
APMV-8 204 EWCNPGCTAVRIEPTRLDCVCGHCPTICSLCM 235
APMV-9 218 SWCNPVCSPVTYEPREFTCSCGSCPTECRLCA 249
 
Fig. 4.2. Sequence alignment of C terminal end of the V proteins of different members of genus Avulavirus. 









Fig. 4.3. Sequence analysis of the P gene editing site in cDNAs made from polyadenylated intracellular 
mRNA. This shows sequencing electropherograms across the editing site region  of transcripts that were 
unedited (5G, encoding the P protein), or contained the insertion of one (5G+G, encoding the V protein) or 
two (5G+2G, encoding the W protein) G residues. The sequence is mRNA-sense. 
 
The matrix (M) protein gene  
The M gene of APMV-3 strain Wisconsin is 1418 nt long and encodes a 375-aa 




important for ionic interaction with the acidic N protein (Lamb and Parks, 2007). The 
bipartite cluster, which comprises clusters of basic amino acids either ‘single cluster’, 
containing three to five basic amino acids, or ‘bipartite’ sequence, containing two 
interdependent clusters of such amino acids separated by an intervening sequence is 
clearly seen in the positions 257-272 (257 KQRRRTPSEITQKVRR 272), which was 
different in two aa at position 267 and 272 with strain Netherlands (Kumar et al., 2008). 
The APMV-3 strain M protein has 93.3% aa sequence identity with that of strain 
Netherlands (Table 4.4). 
The fusion (F) protein gene 
The F gene of APMV-3 strain Wisconsin is 1966 nt long and codes for a 538-aa F 
protein. The protein is predicted to be a type I transmembrane protein, similar to the F 
proteins of other members of family Paramyxoviridae. The N-terminus of the F protein 
contains a predicted signal sequence that would mediate translocation of the nascent 
protein into the lumen of the endoplasmic reticulum and is predicted by the SignalP 3.0 
server to be cleaved between residues 22 and 23 (SQS↓AN). The predicted C-terminal 
transmembrane domain (residues 484–506) would anchor the protein in the host cell 
membrane leaving a short cytoplasmic tail of 32 amino acids. The predicted cleavage-
activation site of the APMV-3 F protein is R-P-S-G-RL (corresponding to 95-102 
amino-acid position), which differed at two amino acids with the cleavage site of strain 
Netherlands (Fig. 4.4). The APMV-3 stain Wisconsin F protein has 70.1% aa sequence 




APMV-3(Wisconsin) 96  P-R-P-S-G-R-L 102
APMV-3(Netherlands) 101 A-R-P-R-G-R-L 107
APMV-1(Virulent) 111 G-R-R-Q-K-R-F 117
APMV-1(Avirulent) 111 G-G-R-Q-G-R-L 117
APMV-2 93  D-K-P-A-S-R-F 99
APMV-4 115 V-D-I-Q-P-R-F 121
APMV-6 113 P-A-P-E-P-R-L 119
APMV-7 101 T-L-P-S-S-R-F 107
APMV-8 98  T-Y-P-Q-T-R-L 104
APMV-9 105 I-R-E-G-R-I-F 111
 
Fig. 4.4. Comparison of the F protein cleavage sites of different members of genus Avulavirus. Basic 
residues (R= arginine, K= lysine) are underlined and in bold. Numbers indicate the amino acid position. 
 
The hemagglutinin-neuraminidase (HN) protein gene 
The HN gene of APMV-3 strain Wisconsin is 1987 nt long and encodes a 
polypeptide of 577 amino acids. The Paramyxovirinae HN protein is a type II integral 
membrane protein that spans the membrane once: the predicted HN protein of APMV-3 
Wisconsin has a predicted hydrophobic signal anchor domain spanning residues 23-45. 
Five potential N-linked glycosylation sites were identified at positions 122, 155, 312, 325 
and 342, using the Expasy, NetNGlyc program. The HN protein contains a high amount 
of acidic amino acids with an isoelectric point (pI) of 6.3. The HN proteins of subfamily 
Paramyxovirinae and the HA proteins of influenza viruses contain a conserved sequence, 
N-R-K-S-K-S, which is thought to contribute to the sialic acid binding site (Varghese et 
al., 1983). The aa sequence of the APMV-3 HN protein contains a similar motif, N-R-K-
S-C-S (positions 237-242, difference underlined). The APMV-3 strain Wisconsin HN 





The large polymerase protein (L) gene 
The L gene of APMV-3 strain Wisconsin is 6835 nt long and codes for a 2198-aa 
L protein. Alignment of the L protein aa sequence of APMV-3 Wisconsin with other 
members of Paramyxoviridae demonstrated six linear conserved domains, which have 
been described earlier for these family members and represent catalytic domains (Poch et 
al., 1989). The conserved QGDNQ sequence that is found within domain III involved in 
transcription activity (Schnell and Conzelmann, 1995) was also found in the L protein of 
APMV-3 at aa positions 744-748. The APMV-3 strain Wisconsin L protein has 83% aa 
sequence identity with that of strain Netherlands (Table 4.4). 
 
4.5.4 Phylogenetic analysis 
 
Phylogenetic trees were generated from alignments of the complete nt sequence 
of the genome of APMV-3 strain Wisconsin with the sequences of representative viruses 
of the other serotypes of APMV excluding only APMV-5, which remains to be 
sequenced (Fig. 4.5). The resulting phylogenic tree indicates that APMV-3 strains 
Wisconsin and Netherlands cluster together on a branch that is distinct from those of the 























Fig. 4.5. Phylogenetic tree depicting evolutionary relationships between the members of the family 
Paramyxoviridae based on complete genome nt sequences.  
4.6 Discussion 
 
Avian paramyxoviruses are classified into nine serotypes based on their 
serological relationships in HI and NI tests. Of these serotypes, a great deal of 
information is available on antigenic and genetic relationships among APMV-1 (NDV) 
strains isolated from different parts of the world (Alexander, 1988). Additionally, I and 
others have recently published complete genome sequences for representative strains of 
APMV-2, -3, -4, -6, -7, -8, and -9 (Chang et al., 2001; Kumar et al., 2008; Nayak et al., 
2008; Subbiah et al., 2008; Paldurai et al., 2009; Samuel et al., 2009; Xiao et al., 2009). 
However, very little is known about the antigenic and genetic relationships among strains 
within APMV-2 through -9 (Alexander, 2003b). In this study I compared APMV-3 strain 
Wisconsin, a virus isolated from a turkey in Wisconsin, and the prototype APMV-3 strain 
Netherlands, isolated from parakeets in the Netherlands. These two strains differ in their 
virulence for chickens (unpublished data). APMV-3 strain Wisconsin is avirulent for 
chickens, whereas APMV-3 strain Netherlands is moderately virulent for chickens 
leading to paralysis and death occasionally. Therefore, it was of my interest to know the 
extent of antigenic and genetic variation between these two strains. This information 
might have implications for studies in pathogenesis and epidemiology and for the 
development of vaccines.  
To evaluate the antigenic relationship between the two APMV-3 strains, I raised 
chicken antiserum against each virus separately by respiratory infection, mimicking a 




repeated antigenic exposure, I (i) limited the immunization to a single infection, and (ii) 
collected the serum samples at an early time point (14 days post infection). The antigenic 
relatedness between strains Wisconsin and Netherlands was examined by using reciprocal 
cross- HI and cross neutralization assays based on primary infection sera from chickens. 
The two APMV-3 strains were found to have a close antigenic relationship in each assay. 
The differences in homologous and heterologus HI titers between the two strains were 4- 
fold higher against the homologous virus versus the heterologous virus, indicating a 
minor antigenic difference. The difference in homologous and heterologous virus 
neutralization titers between the two strains was 2-fold higher for the homologous virus 
versus the heterologous virus, similar to the results of the HI tests. These results indicate 
that the two APMV-3 strains are somewhat more closely related antigenically than the 
two antigenic subgroups of human respiratory syncytial virus (HRSV). The two 
serogroups of HRSV exhibit a 3- to 4- fold reciprocal difference in neutralization by 
polyclonal convalescent serum for homologous versus heterologous strains (Johnson et 
al., 1987a; Johnson et al., 1987b; Biacchesi et al., 2003). The results suggested that the 
two APMV-3 strains certainly represent a single serotype, but do not unambiguously 
represent two antigenic subgroups. In this regard, it will be of interest to evaluate 
additional strains. 
In order to analyze the genetic relationship between the two APMV-3 strains, I 
determined the complete genome sequence of strain Wisconsin and compared it with the 
sequence of strain Netherlands that I reported earlier (Kumar et al., 2008). The genome 
lengths differ slightly: strain Wisconsin was 16,182 nt compared to 16,272 nt for strain 




genome terminal sequences and gene start and stop sequences. The two genomes shared 
67% nt identity, compared to 80% nt identity between the two subgroups of human 
metapneumovirus (HMPV) (Biacchesi et al., 2003) and 81% nt identity between the two 
subgroups of HRSV (Johnson et al., 1987a). This divergence was the greatest in regions 
that did not encode protein or constitute cis-acting RNA signals: for example,  the 
intergenic regions between the two APMV-3 strains were 48% identical, similar to the 
value of 48% identity between two HPMV subgroups and 42% identity between two 
HRSV subgroups (Biacchesi et al., 2003). When compared with the other serotypes of 
APMV, the genome of APMV-3 Wisconsin had a nt sequence identity of 43%, 44%, 
47%, 43%, 44%, 44%, and 44% versus APMV-1, -2, -4, -6, -7, -8, and -9, respectively. 
Thus, the divergence of nt sequence between the two APMV-3 strains was substantially 
more than between the subgroups of HRSV or HMPV, but was substantially less than the 
divergence between APMV serotypes. 
Comparison of nt sequence relatedness of ORFs between the two APMV-3 strains 
showed 72 to 75% nt identity except for P, F, and HN genes which were more divergent 
(66.2, 66.7 and 65.7 % nt identity respectively). This pattern is similar to those of the two 
subgroups of HMPV and HRSV, in which the genes of internal virion proteins are highly 
conserved, while the genes of outer surface proteins are more divergent (Johnson et al., 
1987b; Biacchesi et al., 2003). The most notable exception in the pattern was observed 
for the P gene of APMV-3 strains. The P gene of the two subgroups of HMPV and HRSV 
are highly conserved (81 and 85% nt identity respectively), while the P genes are more 




The total proteome of the two APMV-3 strains shared 78% aa sequence identity 
compared to 90% aa sequence identity between the HMPV subgroups and 88% aa 
sequence identity between the HRSV subgroups (Biacchesi et al., 2003). In comparison, 
the APMV-3 proteome had an aa sequence identity of 31%, 31%, 38%, 30%, 33%, 31%, 
and 31% when compared to APMV-1, -2, -4, -6, -7, -8, and -9, respectively. Thus, the aa 
sequence divergence between the two APMV-3 strains was substantially more than 
between the subgroups of HRSV or HMPV, but was substantially less than the 
divergence between APMV serotypes. 
The aa sequence identity between the cognate proteins of the two APMV-3 strains 
varied from 59% for P protein to 93% for M protein (Table 4.4). The envelope proteins 
(F and HN) were more divergent between the two APMV-3 strains (Table 4.4). It was 
surprising to find that the F protein of two APMV-3 strains exhibited more divergence 
(70% identity) than the F protein of the HMPV subgroups (95% identity) and the HRSV 
subgroups (89% identity) (Biacchesi et al., 2003). The HN protein of the two APMV-3 
strains had 73% identity, which was higher than between the G proteins of the two 
HMPV subgroups (55% identity) and the two HRSV subgroups (37% identity). In 
comparison, the APMV-3 F protein has 31%, 29%, 33%, 30%, 31%, 30%, and 28% 
when compared to the F protein of APMV-1, -2, -4, -6, -7, -8, and -9, respectively, and 
the APMV-3 HN protein has 35%, 31%, 40%, 30%, 36%, 32%, and 37% when compared 
to APMV-1, -2, -4, -6, -7, -8, and -9, respectively (Table 4.4).  The P, V and W proteins 
were more divergence between the two APMV-3 strains (59, 63 and 55% aa identity, 
respectively) compared to the P proteins of HMPV subgroups (85% aa identity) and 




divergence in P, V and W proteins is responsible for the difference in the pathogenicity of 
APMV-3 strains needs further studies.  
In conclusion, the complete genome sequence was determined for APMV-3 strain 
Wisconsin. Comparison of the nt and predicted aa sequences of strains Wisconsin and 
Netherlands showed that the divergence between the two strains was substantially greater 
overall than between the two HMPV and HRSV subgroups. This indicated that the two 
APMV-3 strains represent two distinct genetic subgroups. Given the rather substantial 
differences in the aa sequences between the APMV-3 strains, it was somewhat surprising 
that the extent of antigenic difference was modest. This is particularly evident when 
compared with the HRSV subgroups, where there was substantially greater aa sequence 
identity overall and yet greater antigenic difference. One factor may be that, while one of 
the HRSV neutralization antigens (F) was more highly conserved than for the APMV-3 
strains, the other HRSV neutralization antigen (G) was much more divergent than its 
APMV-3 counterpart (HN) (Johnson et al., 1987a). Additional antigenic and genetic 
analysis involving additional APMV-3 strains is needed to further define the antigenic 


















5.1 Title  
Experimental avian paramyxovirus serotype-3 infection in chickens and turkeys 
5.2 Abstract 
APMVs are divided into nine serotypes. NDV (APMV-1) is the most extensively 
characterized; while relatively little information is available for the other APMV 
serotypes. In the present study, I examined the pathogenicity of two divergent strains of 
APMV-3, Netherlands and Wisconsin, in (i) 9-day-old embryonated chicken eggs, (ii) 1-
day-old specific pathogen free (SPF) chicks and turkeys, and (iii) 2-week-old SPF 
chickens and turkeys. The mean death time in 9-day-old embryonated chicken eggs was 
112 h for APMV-3 strain Netherlands and >168 h for strain Wisconsin. The intracerebral 
pathogenicity index in 1-day-old chicks for strain Netherlands was 0.39 and for strain 
Wisconsin was zero. Thus, both strains are lentogenic. Both the strains replicated well in 
brain tissue when inoculated intracerebrally in 1-day-old SPF chicks, but without causing 
death. Mild respiratory disease signs were observed in 1-day-old chickens and turkeys 
when inoculated through oculonasal route with either strain. There were no overt signs of 
illness in 2-weeks-old chickens and turkeys by either strain, although all the birds 
seroconverted after infection. The viruses were isolated predominantly from brain, lungs, 
spleens, trachea, pancreas and kidney. Immunohistochemistry studies also showed the 
presence of large amount of viral antigens in both epithelial and sub-epithelial lining of 
respiratory and alimentary tracts. The result suggests systemic spread of APMV-3 even 
though the viral fusion glycoprotein does not contain the canonical furin proteases 
cleavage site. Furthermore, there was little or no disease despite systemic viral spread and 







Members of the family Paramyxoviridae are pleomorphic enveloped particles that 
contain a single-stranded, non-segmented RNA genome of 13-19 kilobases (Lamb and 
Parks, 2007). All paramyxoviruses that have been isolated to date from avian species are 
placed in the genus Avulavirus except for avian metapneumoviruses that are placed in the 
genus Metapneumovirus due to antigenic and genomic organization differences. The 
avian paramyxoviruses (APMVs) that comprise genus Avulavirus have been divided into 
nine different serotypes (APMV-1 through -9) based on haemagglutination inhibition 
(HI) and neuraminidase inhibition (NI) assays (Alexander and Collins, 1984). APMV-1 
comprises all strains of NDV and is the most completely characterized serotype due to 
the severity of disease caused by virulent NDV strains in chickens (Alexander, 1980). 
The complete genome sequences and the molecular determinants of virulence have been 
determined for representative NDV strains (Krishnamurthy and Samal, 1998; de Leeuw 
and Peeters, 1999; Huang et al., 2004b; Panda et al., 2004; Rout and Samal, 2008). As a 
first step in characterizing the other APMV serotypes, complete genome sequences of 
one or more representatives of APMV serotypes 2 to 9 were recently determined, 
expanding our knowledge about these viruses (Chang et al., 2001; Kumar et al., 2008; 
Nayak et al., 2008; Subbiah et al., 2008; Paldurai et al., 2009; Samuel et al., 2009; Xiao 
et al., 2009). 
NDV causes respiratory, neurological or enteric disease in birds. Among poultry, 
chickens are the most susceptible while geese and ducks are the least susceptible 




moderately virulent (mesogenic), and highly virulent (velogenic) pathotypes based on 
pathogenicity in chickens. In contrast very little is known on pathogenicity of APMV-2 to 
-9 in chickens and turkeys. APMV-2 has been shown to cause mild disease and drop in 
egg production in chickens and turkeys (Warke et al., 2008). APMV-6 and -7 have been 
associated with respiratory disease in turkeys (Shortridge et al., 1980; Saif et al., 1997). 
APMV-4, -8 and -9 have been isolated from different species of birds but the clinical 
signs of the disease in those birds were not apparent (Alexander et al., 1983; Gough and 
Alexander, 1984; Stallknecht et al., 1991; Maldonado et al., 1995; Capua et al., 2004). 
Recently, experimental infection of 1-day-old chicks with APMV-2, -4 and -6 showed 
viral infection in gastrointestinal tract, respiratory tract and pancreas (Warke et al., 2008). 
APMV-3 has been isolated from wild and domesticated birds in different parts of 
the world (Tumova et al., 1979b; Alexander, 1980; Macpherson et al., 1983; Alexander, 
2003a). Recently, APMV-3 was isolated from ostrich, indicating a wide host range for 
the virus (Kaleta et al.). The virus has been isolated from diseased turkeys associated with 
coughing, nasal discharge and swelling of the infra-orbital sinus (Redmann et al., 1991). 
APMV-3 has been associated with encephalitis and high mortality in caged birds 
(Tumova et al., 1979a). The virus causes acute pancreatitis and central nervous system 
(CNS) symptoms in Psittacine and Passerine birds (Beck et al., 2003). APMV-3 also 
infects chickens at an early age, with evidence of stunting growth that may be more 
marked in broiler chicken breeds (Alexander and Collins, 1982). In terms of 
pathogenicity to domestic poultry birds, APMV-3 probably is second in importance to 
NDV. The exact economic impact of APMV-3 infection in poultry industry is not known. 




studied. There is a high degree of amino acid sequence variation between APMV-3 and 
APMV-1 (NDV), but by the HI test there is cross reaction between APMV-3 and APMV-
1 serum samples, which often leads to misdiagnosis of APMV-3 as APMV-1.  
Currently, it is not known whether there is any variation in pathogenicity among 
APMV-3 strains in domestic poultry birds. The purpose of this study was to evaluate the 
pathogenicity of APMV-3 strains Netherlands and Wisconsin in chickens and turkeys. 
Both of these strains were completely sequenced recently (Kumar et al., 2008; Kumar et 
al., 2010b). APMV-3 strain Wisconsin was first isolated from a turkey in 1968 in 
Wisconsin (Tumova et al., 1979b). APMV-3 strain Netherlands was isolated from a 
parakeet in 1975 in the Netherlands and is the prototype for the entire serotype 
(Alexander and Chettle, 1978). Initially, these two viruses were considered as two 
different strains of APMV-3 based on cross HI test using monoclonal antibodies 
(Anderson et al., 1987; Anderson and Russell, 1988). Recently, reciprocal cross HI and 
cross neutralization assays using post infection serum from chicken indicated that these 
two strains are antigenically distinct, although the difference was modest (Kumar et al., 
2010b). However, complete genome sequence analysis revealed substantial genome-wide 
nucleotide and amino acid sequence differences that are consistent with the two strains 
representing distinct antigenic subgroups (Kumar et al., 2008; Kumar et al., 2010b). In 
the present study, I studied infection of APMV-3 strains Wisconsin and Netherlands in 9-
day-old embryonated chicken eggs, 1-day-old chicks and turkeys, and 2-week-old 
chickens and turkeys in order to investigate their tropism and pathogenicity.  Birds were 
infected by the oculonasal route and the viral tropism and replication efficiency were 




target organs. In addition, a separate group of 1-day old chicks were infected 
intracerebrally to evaluate the potential of these viruses to replicate in neural cells.  
 
5.4 Materials and Methods 
5.4.1 Viruses and cells 
 
APMV-3 strains parakeet/Netherlands/449/75 and turkey/Wisconsin/68 (obtained 
from National Veterinary Service Laboratory, Ames, Iowa, USA) and the NDV 
mesogenic strain Beaudette C (BC) and lentogenic strain LaSota were propagated in 
nine-day-old specific pathogen free (SPF) embryonated chicken eggs via allantoic route 
of inoculation. Work with NDV-BC was performed in our Bio Safety Level (BSL) -3 
animal facility. The allantoic fluids from infected embryonated eggs were collected 96 h 
post-inoculation and virus titer was determined by hemagglutination (HA) assay with 
0.5% chicken RBC. The virus titer in infected tissue samples was determined by the 
tissue culture infective dose (TCID50) (Reed and Muench, 1938) method and by plaque 
assay in chicken embryo fibroblast (DF-1) cells (ATCC, Manassas, VA). DF1 cells were 
maintained in Dulbecco’s minimum essential medium (DMEM) with 10% fetal bovine 
serum (FBS) at 37°C with 5% CO2 (Kumar et al., 2008). For the plaque assay, DF1 cell 
monolayers in 12 well plates were infected with different dilutions of tissue homogenates. 
The tissue homogenates were allowed to adsorb for 1 h at 370C, washed with PBS, and 
then overlaid with 1ml DMEM containing 0.8% (wt/vol) methylcellulose. The virus 
plaques in the DF1 cell monolayer were visualized 96 h post infection after staining with 




5.4.2 Pathogenicity index tests  
The pathogenicity of the APMV-3 strains Netherlands and Wisconsin was 
determined by two standard pathogenicity tests.  These included the mean death time 
(MDT) in 9-day-old embryonated SPF chicken eggs and the intracerebral pathogenicity 
index (ICPI) in 1-day-old SPF chicks (Alexander, 2009).  
MDT value was determined following the standard procedure (Alexander, 1998). 
Briefly, a series of 10-fold (10−6 to 10−12) dilutions of fresh infective allantoic fluid in 
sterile phosphate-buffered saline (PBS) were made and 0.1 ml of each dilution was 
inoculated into the allantoic cavities of five 9-day-old embryonated SPF chicken eggs, 
which were then incubated at 37°C. Each egg was examined three times daily for 7 days, 
and the times of embryo deaths were recorded. The minimum lethal dose is the highest 
virus dilution that caused death of all the embryos. MDT is the mean time in hours for the 
minimum lethal dose to kill all inoculated embryos. The MDT has been used to 
characterize the NDV pathotypes as follows: velogenic (less than 60 h), mesogenic (60 to 
90 h), and lentogenic (more than 90 h) (Alexander, 1980).  
For determining ICPI value, 0.05 ml of 1:10 dilution of fresh infective allantoic 
fluid (28 HA units) of each virus was inoculated into groups of ten 1-day-old SPF chicks 
via the intracerebral route. The birds were observed for clinical symptoms and mortality 
every 8 h for a period of 8 days. At each observation, the birds were scored as follows: 0, 
healthy; 1, sick; and 2, dead. The ICPI is the mean score for all of the birds in the group 
over the 8-day period. Highly virulent NDV (velogenic) viruses give values approaching 





5.4.3 Replication and viral growth kinetics in brain tissue of 1-day-old chicks 
To determine the ability of APMV-3 strains Netherlands and Wisconsin to 
replicate in chicken brain tissue, groups of fifteen 1-day-old SPF chicks were inoculated 
with a dose of 0.05 ml of a 1:10 dilution of 28 HA units of fresh infected allantoic fluid 
via the intracerebral route. NDV strain BC and LaSota were included for comparison 
purposes. Brain samples were collected by sacrificing three birds from each group at 1, 2, 
3, 4 and 5 days post inoculation or as and when the birds died of infection. The virus 
titers in the tissue samples were determined by tissue culture infectivity dose 50 (TCID50) 
in DF1 cells (Reed and Muench, 1938). 
5.4.4 Pathogenesis assessment in chickens and turkeys 
 
One-day-old and 2-week-old SPF chickens (Charles River, USA) and 1-day-old 
and 2-week-old turkeys (Murry-McMurry hatchery, USA) were housed in positive 
pressure isolators in our BSL-2 facility. Birds confirmed to be negative for APMV-3 
specific antibody by HI assay were further isolated for pathogenesis experiments and 
housed in negative pressure isolators. 
The 1-day-old and 2-week-old chickens and turkeys, in groups of 12 for each 
species and age, were infected with 0.1 ml (103 PFU) per bird of APMV-3 strain 
Netherlands or Wisconsin through the occulonasal route. Infections with the different 
strains were performed at separate times to avoid cross infections. An additional six birds 
of each species/age group remained as uninfected controls. Birds were provided with 




daily. Three birds from each infected group were euthanized on 3, 5, 7 and 14 day post 
infection (DPI) by rapid asphyxiation in a CO2 chamber. The birds were swabbed orally 
and cloacally just before euthanasia. The following tissue samples were collected both for 
immunohistochemistry (IHC) and for virus isolation: brain, trachea, lung, spleen, kidney 
and pancreas. In addition serum samples were collected on day 14 when the three 
remaining birds in each group and the control birds were euthanized. Seroconversion was 
evaluated by HI assay (Alexander, 1996).   
5.4.5 Virus detection and quantification from tissue samples and swabs 
 
Half of the tissue samples containing brain, trachea, lung, spleen, kidney and 
pancreas were collected aseptically in Dulbecco's minimal essential medium (DMEM) in 
10X antibiotic solution containing Penicillin/Streptomycin/Amphotericin B to determine 
virus content. Briefly, a 10% homogenate of the tissue samples were prepared by using a 
homogenizer and centrifuged at 420 x g for 10min. The virus content in the supernatants 
of tissue homogenates was determined by plaque assay in DF-1 cells. Values for each 
tissue sample were based on average plaque count from two wells. The other half of the 
tissue samples were flash-frozen on dry ice using chilled 2-methyl butane, held for 
approximately 24 h, and processed for immunohistochemistry.  
The oral and cloacal swabs were collected in 1 ml of DMEM containing 
antibiotics. The swab containing tubes were centrifuged at 1000g for 20 min, and the 
supernatant was removed and flash frozen on dry ice for subsequent virus isolation. Virus 
isolation was performed by infecting the supernatant into 9-day-old SPF embryonated 
chicken eggs. Positive samples were identified by HA activity of the allantoic fluid 








Tissue samples collected in chilled 2-methyl butane were sectioned by using 
optimal cutting temperature compound under cryostat (Dolbey- Jamison, USA). The 
sections were immunostained to detect viral phosphoprotein (P) using the following 
protocol.  Briefly, the frozen sections were thawed and rehydrated in three changes of 
PBS (10 min each). The sections were fixed in ice cold acetone for 15 minutes at -80o C 
and then washed three times with 2% BSA in PBS and blocked with the same solution for 
1 h at room temperature. The sections were then incubated with a 1:500 dilution of the 
primary antibody (antipeptide polyclonal antisera raised against the P proteins of APMV-
3 strains Netherland and Wisconsin in rabbits) in PBS overnight in a humidified chamber. 
After three washes with 2% BSA in PBS, sections were incubated with the secondary 
antibody (FITC conjugated goat anti-rabbit antibody) for 30 min. After a further wash 
cycle, the sections were mounted with glycerol and viewed under a fluorescence 
microscope.  
 
5.4.7 Preparation of antipeptide polyclonal antisera against the APMV-3 P proteins 
in rabbits 
 
The antipeptide antisera to the P proteins of the two APMV-3 strains were 




to 60 to 73 amino acid (aa) of P protein of strain Netherlands), SPSQSSSPSPEPST, and 
FYIPKVNNYHSN    (corresponding to 39-52 and 99-110 aa, respectively, of P protein of 
strain Wisconsin) were custom synthesized (Invitrogen, USA). 0.2 mg of each protein 
was mixed in complete Freund's adjuvant and injected subcutaneously into a rabbit. After 
two weeks a booster immunization was given with the respective 0.2 mg of protein in 
incomplete Freund’s adjuvant and 2 weeks later the hyperimmune serum was collected. 
The antisera were tested by western blot analysis and were found to recognize 
specifically the P protein of their respective APMV-3 strain (data not shown). 
 
5.5 Results 
5.5.1 Pathogenicity index tests 
 
The pathogenicity of APMV-3 strains Netherlands and Wisconsin was evaluated 
by MDT in 9-day-old embryonated chicken eggs and ICPI in 1-day-old-chicks. The 
lentogenic NDV strain LaSota was included in the pathogenicity tests for comparison. 
The MDT for APMV-3 strain Netherland was 112 hr while that of APMV-3 strain 
Wisconsin was > 168 hr. The ICPI value for APMV-3 strain Netherlands was 0.39 while 
the ICPI for strain Wisconsin was zero. The MDT and ICPI values of NDV strain LaSota 
were 110 hr and zero, respectively, consistent with a lentogenic virus. Although, the ICPI 
and MDT values of strain Netherlands were higher than those of strain Wisconsin; their 
values indicate that both the APMV-3 strains are lentogenic viruses. These results 
indicate that APMV-3 strain Netherlands and Wisconsin are probably nonpathogenic to 
chickens, similar to lentogenic NDV strains.  




5.5.2 Virus growth in the chicken brain 
 
The ability of the APMV-3 strains Netherlands and Wisconsin to grow in the 
brains of 1-day-old chicks was evaluated in parallel with the mesogenic neurotropic NDV 
strain BC. This study was performed to determine whether the 0.39 and zero ICPI values 
of the APMV-3 strains Netherlands and Wisconsin, respectively, was due to the inability 
of the viruses to grow intracerebrally or if there was virus multiplication without a high 
degree of cell destruction.  
Virus replication was evaluated by inoculating 0.05 ml of 1:10 dilution of 28 HAU 
of each of the four viruses, strains Netherlands, Wisconsin, BC and LaSota, into the 
brains of fifteen 1-day-old SPF chicks per group. Three birds from each group were 
sacrificed on days 1, 2, 3, 4 and 5 post inoculation and virus titers in brain tissue were 
assayed and expressed as TCID50 per gram of the brain in DF-1 cells (Fig. 5.1). Neither 
of the two APMV-3 strains produced any clinical signs nor did they kill any chicks 
during the 5-day time course. Both of the strains of APMV-3 were isolated from the brain 
homogenates of all of the chicks on days 1 to 5 day post inoculation, grew with similar 
kinetics, and reached similar maximum titers of 2x7.9 log10 and 2x7.6 log10 TCID50/g on 
day 5 for strains Netherlands and Wisconsin, respectively (Fig. 5.1). In comparison, NDV 
strain BC replicated more rapidly, reached a titer of 2x8.25 log10 TCID50/g of brain tissue 
on day 3 post inoculation, and killed all of the chicks by day 3, while strain LaSota 
showed no replication.  The results showed that the efficiency of virus replication of the 
two APMV-3 strains in brain tissue was similar. Interestingly, while the two APMV-3 
strains replicated more slowly than NDV-BC, they achieved a similar final titer compared 
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Fig 5.1. Growth kinetics of APMV-3 strain Netherlands and Wisconsin in the brains of 1day-old chicks in 
comparison with neurotropic APMV-1 strain Beaudette C (BC) and lentogenic strain LaSota.  
 
Fifteen 1-day-old chicks were inoculated with 0.05 ml of 1:10 dilution of 28 HA units of 
APMV-1 strain BC or APMV-1 strain LaSota or APMV-3 strain Netherlands or 
Wisconsin via the intracerebral route. Brain tissue was collected by sacrificing three birds 
from each group on 1, 2, 3, 4 and 5 days post inoculation, except that in the case of NDV 
BC all remaining birds died of infection on day 3 and were assayed at that time point. 






5.5.3 Experimental infection of SPF chickens and turkeys: pathology 
 
1-day-old and 2-week-old chickens and turkeys were inoculated with either 
APMV-3 strain by the occulonasal route, and birds from each group were sacrificed on 
days 3, 5, 7, and 14 and evaluated for pathology, virus shedding, and virus replication in 
selected tissues. Infection of either APMV-3 strain in 1-day-old chickens and turkeys 
resulted in mild clinical symptoms that included altered gait, respiratory distress, 
dullness, ruffled-feathers, loss of appetite and weight loss. The birds of the 1-day-old 
groups of both species generally started showing symptoms at 3 DPI and recovered after 
7 DPI. The other visible signs included slight diarrhea that was evident in 1-day-old 
chickens and turkeys at 4 DPI. The neurological symptoms were more evident in 1-day-
old chicks and turkeys infected with APMV-3 strain Netherlands as compared to strain 
Wisconsin. In contrast, infection of 2-week-old chickens and turkeys with the APMV-3 
strains did not result in any clinical signs of disease. APMV-3 infection did not kill any 
of the 1-day-old or 2-week-old chickens and turkeys (Tables 5.1 and 5.2). The most 
remarkable finding upon postmortem examination of birds was enlargement of the 
pancreas with focal necrosis at 5 DPI in the 2-week-old chickens and turkeys (Fig. 5.2). 
The foci of necrosis were distributed along the entire length of pancreas and the extent of 
necrosis was similar in both chickens and turkeys. Gross examination of other organs 
including the brain, trachea, liver, kidney, spleen and lung showed normal tissue 







Virus shedding and mortality in 1-day-old and 2-week-old chickens infected with APMV-3. Virus shedding 
in oral secretions and cloacal swabs (C) were measured for 3 birds from each group on the indicated days. 
Mean body weight also was measured at sacrifice. Sera were collected from three birds in each group on 
day 14 and mean APMV-3-specific HI titers were determined. The pre-infection and control HI titers were 








Virus shedding and mortality in 1-day-old and 2-week-old turkeys infected with APMV-3. Virus shedding 
in oral secretions and cloacal swabs (C) were measured for 3 birds from each group on the indicated days. 
Mean body weight also was measured at sacrifice. Sera were collected from three birds in each group on 
day 14 and mean APMV-3-specific HI titers were determined. The pre-infection and control HI titers were 







Fig. 5.2  
Gross morphology of pancreas collected from 2-week-old turkeys infected with APMV-3 strain 
Netherlands (a) or Wisconsin (b): comparison with pancreas from uninfected controls (left panels) reveals 
necrotic foci along the length of the infected organ. 
 
5.5.4 Experimental infection of SPF chickens and turkeys: virus isolation and 
titration in oral and cloacal swabs 
 
From the experiment above, oral and cloacal swabs were taken when birds were 
sacrificed on days 3, 5, 7 and 14 DPI. These samples were inoculated into embryonated 
chicken eggs to detect the presence of infectious virus, which was determined by HA 
assay of egg allantoic fluid (Tables 5.1 and 5.2). Samples that were positive for virus 
were analyzed for virus quantitation by plaque assay in DF1 cells (not shown). Neither 
APMV-3 strain was isolated from cloacal swabs from any of the infected birds. Virus 
was isolated from oral swabs from 1-day-old chickens on days 3 and 5 for both strains, 
and from 2-week-old chickens on day 3 for strain Netherlands only (Table 5.1). This 
same pattern was observed for virus isolated from oral swabs from 1-day-old and 2-
week-old turkeys (Table 5.2). Thus, strain Wisconsin was not shed from any of the 2-
week-old chickens or turkeys. The highest titers in chickens (2.15 log10 TCID50/ml) were 
observed in oral swabs collected on 3 DPI from 1-day-old chicks infected with either 
strain of APMV-3 (not shown). Similarly, in turkeys, the highest titers (2.12 log10 
TCID50/ml) were observed in 1-day-old poults at 3 DPI with either strain of APMV-3 





5.5.5 Experimental infection of SPF chickens and turkeys: virus isolation and 
titration in tissue samples 
 
In the experiment described above, the following tissue samples were collected 
from three birds per group on 3, 5, 7 and 14 DPI: brain, trachea, lung, spleen, kidney and 
pancreas. Homogenates of these tissues were inoculated into embryonated chicken eggs 
to detect the presence of infectious virus, as described above, and positive samples were 
titrated by plaque assay in DF1 cells.  
Fig. 5.3 shows the distribution and titers of the two APMV-3 strains in various 
organs on different DPI of chickens. Infection with APMV-3 strains Netherlands and 
Wisconsin in 1-day-old chicks and 2-week-old chickens resulted in efficient replication 
of both viruses in the various organs tested. In general, both viruses replicated in most of 
the tested organs at early time periods of infection and were cleared at 7 DPI. The virus 
replication titers were higher in 1-day-old chicks than in 2-week-old chickens, and 
replication usually was the highest in the brain, trachea, and lung. Although APMV-3 
strain Wisconsin replicated less efficiently in 2-week-old chickens, the titer of virus in 
lungs on day 1 was somewhat higher than that of strain Netherlands, suggesting that it 
might be more respirotropic, whereas strain Netherlands appeared to be more neurotropic 









Virus titers from the indicated organs on the indicated days after infection of 1-day-old (upper panels) or 2-
week-old (lower panels) chickens with APMV-3 strain Netherlands (left panels) or Wisconsin (right 
panels). Titers are shown as mean PFU/gm.  
 
 In general, infected turkeys had virus replication in fewer organs and for shorter 
duration than chickens of same age groups (Fig. 5.4). Strain Netherlands was isolated 
from all of the tested organs on 3 DPI except for the pancreas in 1-day-old turkeys and 
the kidneys in 2-week-old turkeys. Strain Wisconsin was isolated from all of the tested 
organs on 3 DPI. Interestingly, APMV-3 strain Wisconsin was not detected at all on 3 
DPI in 2-week-old turkeys, but was detected in some of the organs on 5 DPI (Fig. 5.4). 




harvested from the infected turkeys, indicating virus clearance, whereas complete 
clearance in chickens did not occur until 14 DPI. These results suggest that turkeys are 




Virus titers from the indicated organs on the indicated days after infection of 1-day-old (upper panels) or 2-
week-old (lower panels) turkeys with APMV-3 strain Netherlands (left panels) or Wisconsin (right panels). 




An HI assay using chicken erythrocytes was performed with the sera collected 
from chickens and turkeys of both age groups on 14 DPI. The HI titers of the pre-




was considered positive. Each of the 1-day-old and 2-week-old chickens and turkeys 
infected with either strain seroconverted. The mean HI titers in 1-day-old chicks for both 
the strains were 1:128; while the mean HI titers in 2-week-old chickens for strain 
Netherlands and Wisconsin were 1:512 and 1:256 respectively (Table. 5.1). Similarly, the 
mean HI titers in 1-day-old-turkeys for the both the strains were 1:128, while the mean 
HI titers in 2-weeks-old turkeys for strain Netherlands and Wisconsin were 1:256 and 




The frozen sections of all the virus-positive tissue samples and some of the virus-
negative control samples were immunostained using antipeptide polyclonal antibodies 
against the P proteins of APMV-3 strains Netherlands and Wisconsin. Large amounts of 
viral P antigen was detected consistently in all the brain, trachea, lung, and pancreas 
samples that were positive by virus isolation, and no viral antigen was detected in tissue 
samples that were negative by virus isolation. Extensive immunofluorescence was 
observed in the brain, trachea, lung and pancreas, suggesting extensive virus replication 
in these organs (Fig. 5.5). The intensity of staining was greater for strain Netherlands 
(Fig. 5.3) than for strain Wisconsin (data not shown). The presence of fluorescence 
around the epithelial lining in the lungs and trachea showed the distribution of viral 
antigens on respiratory epithelium. The presence of generalized fluorescence in the 
pancreas and brain showed the uniform distribution of viral antigen. However, no viral P 
antigen was detected in kidney and spleens that were positive by virus isolation, 







Immunohistochemistry of different organs after three days post infection with APMV-3 strain Netherlands 
in turkeys. Viral antigen was visualized by indirect immunofluorescence using polyclonal anti-peptide 
rabbit antibody specific for the APMV-3 P protein as the primary antibody. The fluorescence was observed 
in brain (a), trachea (b), lung (c) and pancreas (d) while no fluorescence was observed in organs collected 




APMVs are frequently isolated from wild and domestic birds around the world 
and have been placed into nine serotypes based on antigenic relatedness. Of these nine 
serotypes, APMV-1 (NDV) is the best studied. APMV-2 to -9 are present in both free 
living and domestic birds, but their disease potential is not known in wild birds nor in 
domestic birds. It is probable that wild birds can transmit APMV-2 to -9 to domestic 
birds. APMV-2, -3, -4, -6, -7, -8, -9 have been isolated from domestic poultry birds and 
antibodies to these viruses have also been detected in domestic poultry. However, the 




Here, I investigated the clinical disease and pathogenicity of APMV-3 strains 
Netherlands and Wisconsin in embryonated chicken eggs, in 1-day-old chicks inoculated 
intracerebrally, 1-day-old chicks and turkeys inoculated oculonasally, and in 2-week-old 
chickens and turkeys inoculated oculonasally. The oculonasal route was intended to 
resemble a natural route of infection. In this study, 2-week-old chickens and turkeys were 
chosen over other possible age groups because at this age they are fully susceptible to 
viral infection. Furthermore, the pathogenicity in 1-day-old chicks and turkeys was 
studied to assess the impact of APMV-3 infection in young birds.  
APMV-3 strains Netherlands and Wisconsin were first characterized by standard 
pathogenicity tests (MDT and ICPI). The results of the MDT test showed that APMV-3 
strain Netherland was slightly pathogenic (112 hr) compared to strain Wisconsin (>168 
hr), which was completely apathogenic. Similar findings were also observed in ICPI test: 
APMV-3 strain Netherland showed an ICPI value of 0.39, while the ICPI value of strain 
Wisconsin was zero. Although results of pathogenicity index tests (MDT and ICPI) 
showed that APMV-3 strain Netherlands was slightly pathogenic to chickens, both strains 
belong to the lentogenic group of avian paramyxoviruses (Alexander, 1998). 
Since the APMV-3 strains did not kill 1-day-old chicks by the ICPI test, I 
investigated whether the absence of neurovirulence was due to lack of virus replication in 
brain or whether replication occurred without any notable cell destruction. The growth of 
APMV-3 strains in chicken brain showed that both the strains are equally competent to 
grow in brain tissue and the highest virus titer was observed 120 hr post inoculation. 
However, none of the APMV-3 inoculated chicks died 5DPI, while all chicks inoculated 




values of APMV-3 strains were due to nondestructive replication of the virus in brain 
tissue. 
It has been shown previously by experimental infection that APMV-3 strain 
Netherlands is more virulent than strain Wisconsin (Alexander, 1980). In another study, it 
was shown that the extent of disease and death in the birds after infection with APMV-3 
strain Netherlands depends on dose as well as route of infection (Alexander and Collins, 
1982). In this study, I evaluated the pathogenicity of APMV-3 strains Netherlands and 
Wisconsin in 1-day-old and 2-week-old chickens and turkeys by natural (oculonasal) 
route of infection. The clinical signs of illness were more evident in 1-day-old birds 
compared to 2-weeks-old birds. In chickens, both the strains of APMV-3 were isolated 
from tissues of respiratory, digestive and nervous systems. Similar findings were 
observed in turkeys that were infected with APMV-3 strains. However, the titers of 
APMV-3 strain Netherlands in different organs were higher than those of strain 
Wisconsin in all the infected bird groups. Although both the viruses were detected in oral 
swabs from both 1-day-old and 2-week-old chickens and turkeys, the shedding of viruses 
were less in 2-week-old birds. These results confirmed previous findings that chickens 
and turkeys are susceptible to APMV-3 infection and younger birds are more susceptible 
than older birds. In addition, my results are in agreement with the previous finding that 
strain Netherland replicates better than strain Wisconsin in chickens and turkeys 
(Alexander and Collins, 1982; Russell et al., 1989).  
Visceral gross lesions were evident in 2-week-old chickens and turkeys at 3 and 5 
DPI. Using IHC, viral P protein was detected in the same tissues that were positive by 




but negative by IHC. It is possible that the virus load in infected spleen and kidney was 
too low to be detected by IHC. An interesting finding was the presence of large amounts 
of viral antigens at the epithelial cell linings, suggesting that these cells are highly 
permissive to APMV-3 replication. Another finding of IHC study was the presence of 
viral antigen in both epithelial and sub-epithelial tissues except for trachea where the 
antigen was localized only in the epithelial surface. This suggests that this virus has a 
tropism towards both epithelial and sub-epithelial cells. In addition, the detection of viral 
antigens, and in most cases infectious virus, in multiple internal organs of the birds 
indicates that both the viruses are capable of replicating in multiple organs rather than 
being restricted only to respiratory and alimentary tracts. Presumably, the virus reached 
the various internal organs through the blood stream. Nonetheless, this extensive amount 
of virus replication was not accompanied by severe disease in birds. These results show 
that APMV-3 strains are capable of infecting young and adult chickens and turkeys using 
an oculonasal route of infection. Serologic assays demonstrated a humoral response in all 
the birds inoculated with either APMV-3 strain, a further indication of successful 
replication. However, results suggest that chickens are comparatively more susceptible 
than turkeys to APMV-3 infection. 
The F protein cleavage site of NDV is a well characterized determinant of NDV 
pathogenicity in chickens (Millar et al., 1988; de Leeuw and Peeters, 1999; Panda et al., 
2004). Virulent NDV strains typically contain a polybasic cleavage site that contains the 
preferred recognition site for furin (R-X-K/R-R↓), which is an intracellular protease that 
is present in most cells. This provides for efficient cleavage in a wide range of tissues, 




avirulent NDV strains typically have basic residues at the −1 and −4 positions relative to 
the cleavage site and depend on secretory protease (or, in cell culture, added trypsin) for 
cleavage. Also, the first amino acid of the newly-created F1 terminus is phenylalanine for 
virulent NDV strains and leucine for avirulent NDV strains, an assignment that also 
reduces the efficiency of cleavage (Morrison et al., 1993). The inability to be cleaved by 
furin limits the replication of avirulent strains to the respiratory and enteric tracts where 
secretory protease is available for cleavage. The putative F protein cleavage site of 
APMV-3 strain Netherlands (ARPRGR↓L) and strain Wisconsin (PRPSGR↓L) have 
three or two basic residues (underlined), which is similar but not identical to the pattern 
of virulent and avirulent NDV strains, respectively. Neither APMV-3 strain contains the 
preferred furin cleavage site. The F1 subunit of both APMV-3 strains begins with a 
leucine residue, as is characteristic of avirulent NDV strains, rather than a phenylalanine 
residue, as seen in most virulent NDV strains. The lack of a furin motif in the F protein 
cleavage site and the presence of leucine as the first residue at the terminus of the F1 
subunit predict that both APMV-3 strains should require added protease for replication in 
cell culture and should be limited to replication in the respiratory or enteric tracts in vivo. 
However, APMV-3 strains Netherlands and Wisconsin both replicate well in a wide 
range of cells in vitro in the absence of added protease, although each strain grows more 
efficiently (2 log2 higher) with the addition of protease (data not shown). Also, in the 
present study, both APMV-3 strains were detected abundantly in various internal organs, 
suggesting a systemic spread of the virus. These results indicate that the structure of the F 
protein cleavage site and F1 terminus are poor predictors of the growth properties of 




APMV-3 F protein is determined by factors in addition to the F cleavage site and F1 N-
terminus, and (ii) that systemic spread is a multifactorial phenomenon. Furthermore, 
systemic spread was a poor predictor of pathogenesis, since both APMV-3 strains spread 
systemically and replicated efficiently in the brain, lung, trachea, and pancreas with little 
or no disease.  
In conclusion, I have shown that adult SPF chickens and turkeys are susceptible to 
APMV-3 infection. However, in commercial chickens and turkeys the disease picture 
could be quite different depending on management practices, environmental conditions 
and other concomitant infections. This study has demonstrated that APMV-3 has an 
affinity for both epithelial as well as sub-epithelial cells of respiratory and alimentary 
tracts. Finally, dissociations were observed between F protein structure and systemic 
spread and between systemic spread and disease. Further studies are needed to 
























6.1 Title  
 
Evaluation of pathogenicity of avian paramyxovirus serotypes-3 strain 




Avian paramyxoviruses (APMVs) are frequently isolated from domestic and wild 
birds throughout the world. The APMVs are separated into nine serotypes (APMV -1 to -
9). Only in 
the case of APMV-1, also called Newcastle disease virus, has infection of non-avian 
species been investigated. The APMVs presently are being considered as human vaccine 
vectors. In this 
study, I evaluated the replication and pathogenicity of prototype strains of APMV-3 
strain Netherlands in hamsters and mice. The hamsters and mice were inoculated 
intranasally with APMV-3 and monitored for clinical disease, pathology, histopathology, 
virus replication, and seroconversion. On the basis of one or more of these criteria, 
APMV-3 was found to replicate in hamsters and mice. The APMVs produced mild or 
inapparent clinical signs in hamsters and mice. Gross lesions were observed over the 
pulmonary surface of both hamsters and mice infected with APMV -3, which showed 
petechial and ecchymotic hemorrhages. Replication of APMV-3 was confirmed in the 
nasal turbinates and lungs, indicating a tropism for the respiratory tract. Histologically, 
infection with the APMVs resulted in lung lesions consistent with broncho-interstitial 




epithelium lining the nasal septa. The majority of APMV-3 infected hamsters and mice 
exhibited transient histological lesions that self resolved by 14 days post infection. All of 
the infected hamsters and mice produced serotype-specific HI or neutralizing antibodies, 
confirming virus replication. Taken together, these results demonstrate that APMV-3 is 




APMV-1 (NDV) is known to replicate in non-avian species including humans 
(Hofstad, 1950; Nelson et al., 1952; Quinn et al., 1952; Yates et al., 1952), although its 
only natural hosts are birds. APMV-1 infections in non-avian species are usually 
asymptomatic or mild. Clinical signs in human infections commonly involve 
conjunctivitis, which usually is transient and self-limiting. Presently, APMV-1 is being 
evaluated as a vaccine vector against human pathogens (Bukreyev and Collins, 2008). 
When administered to the respiratory tract of non-human primates, NDV is highly 
restricted in replication, but foreign antigens expressed by recombinant NDV vectors are 
moderately to highly immunogenic. One of the major advantages of this approach is that 
most humans do not have pre-existing immunity to APMV-1. Pre-existing immunity is a 
potential drawback for using vectors derived from common human pathogens, and also 
can be a concern for any vector if two or more doses are necessary to elicit protective 
immunity. Therefore, I investigated APMV-3 which is antigenically distinct from 
APMV-1, as alternative human vaccine vectors. Also, APMV-3 will have differences in 
replication, attenuation, and immunogenicity compared to APMV-1 that may be 




species has not been studied. As a first step, I evaluated the replication and pathogenicity 
of APMV-3 in hamsters and mice. In this study, groups of hamsters and mice were 
infected with a prototype strain of APMV-3 strain Netherlands by the intranasal route and 
monitored for virus replication, clinical symptoms, histopathology, and seroconversion. 
The results showed that APMV-3 replicated in hamsters and mice without causing 
adverse clinical signs of illness, although histopathologic evidence of disease was 
observed in some cases, and also induced high neutralizing antibody titers. 
 
6.4 Materials and Methods 
6.4.1 Virus and cells 
 
APMV-3 strain parakeet/Netherlands/449/75 was obtained from the National 
Veterinary Services Laboratory, Ames, Iowa. Nine-day-old specific pathogen free (SPF) 
embryonated chicken eggs and chicken embryo fibroblast DF1 cells were used to 
propagate APMV-3 strain Netherlands. Hemagglutination (HA) titers of virus stocks 
were determined using 0.5% chicken RBC at room temperature. DF1 cells were grown in 
Dulbecco’s MEM containing 10% FCS. All the cells were grown in a 37°C incubator 
with 5% CO2. The virus titer in each cell type was quantified by plaque assay in DF 1 
cells as previously described (Krishnamurthy et al., 2000). The cells were overlaid with 
DMEM containing 2% FCS and 0.9% methylcellulose that were further supplemented 
with 10% allantoic fluid as a source of proteases. The plaques were visualized by staining 





6.4.2 Preparation of antipeptide polyclonal antisera against the APMV-3 P proteins 
in rabbits 
 
The antipeptide antisera to the P proteins of the APMV-3 strain Netherlands was 
generated using the protocol described in chapter 5.4.7.  
 
6.4.3 Experimental infection of hamsters and mice 
 
To study viral replication and pathogenicity, nine each of 4-week-old Syrian 
golden hamsters and BALB/c mice (Charles River Laboratories Inc, Wilmington, MA) 
were housed in negative-pressure isolators under Bio Safety Level (BSL)-2 conditions 
and provided feed and water ad libitum. The animals were cared for in accordance with 
the Animal Welfare Act and the Guide for Care and Use of Laboratory Animals and the 
protocols were approved by the institution’s IACUC. Six each of hamsters and mice were 
inoculated intranasally with 100 μl of infectious allantoic fluid containing 28HAU of 
APMV-3, which contained 3 X 103 PFU/ml, under isoflurane anesthesia. A group of 
three each of hamsters and mice served as uninfected controls and were mock infected 
with normal allantoic fluid. All the animals were observed three times daily for physical 
activity and for any clinical signs of illness, and were weighed on day 0, 5 and 14 days 
post inoculation (dpi). Three hamsters and mice from each group were euthanized at 3 
(dpi) and the other three (as well as the three animals in the control group) at 14 dpi by 
rapid asphyxiation in a CO2 chamber. Necropsies were performed immediately 
postmortem and the following tissue samples were collected for immunohistochemistry 




and small intestine. In addition serum samples were collected on 14 dpi immediately 
prior to euthanasia, and seroconversion was evaluated by HI assay (Alexander, 1998). 
 
6.4.4 Virus detection and quantification from tissue samples 
 
Half of each tissue sample was used for virus titration. These samples were 
collected aseptically in 1 ml of DMEM in 10X antibiotic solution containing 
2,000units/ml penicillin, 200ug/ml gentamicin sulfate, and 4ug/ml amphotericin B 
(Sigma chemical co., St.Louis, MO). They were processed immediately to avoid any 
reduction in virus titers. Briefly, a 10% homogenate of the tissue samples were prepared 
by using a homogenizer and clarified by centrifugation at 420 x g for 10min. The virus 
titers in the clarified supernatants were determined by end-point dilution on DF-1 cells. 
Ten-fold dilutions of tissue supernatant were inoculated onto DF-1 cells in 96-well plates 
and incubated for 3 days. The plates were fixed in 10% formalin for 30 minutes and the 
cells were permeabilized using 2% Triton X-100 for 2 min. The plates were washed five 
times with PBS to remove any residual formalin in the wells. The cells were blocked 
using 2% normal goat serum for 60 min and the plates were washed twice with PBS- 
Tween-20 (PBS-T). The cells were incubated with primary rabbit antiserum raised 
against the P protein of APMV-3 at room temperature for 1 h. The plates were washed 
with PBS twice, 5 min each. The cells were incubated with anti rabbit FITC antibody as 
secondary antibody for 45 minutes and washed finally with PBS twice, 5 min each. The 
slides were visualized and the virus titers were determined by end point titration method 
using the Reed and Muench formula, and were photomicrographed using a fluorescent 





6.4.5 Immunohistochemistry (IHC) and Histopathology 
 
The other half of each tissue sample was used for IHC and histopathology. The 
tissues were fixed in 10% neutral buffered formalin, held for approximately 7 days, and 
processed for IHC and histopathology. Paraffin embedded 5-micron sections of all the 
tissue samples were prepared at Histoserve, Inc. (Maryland, USA). The sections were 
stained with hematoxylin and eosin for histopathology. Sections were also 
immunostained to detect viral P protein using the following protocol. Briefly, the tissue 
sections were deparaffinized in two changes of xylene for 5 minutes each, hydrated in 
two changes of 100% ethanol for 3 minutes each, changes of 95% and 80% ethanol for 1 
minute each, and finally washed in distilled water. The sections were processed for 
antigen retrieval in a water bath containing sodium citrate buffer (10mM citric acid, 
0.05% Tween 20, pH 6.0), at 95-100°C for 40 minutes and then allowed to cool to room 
temperature for another 60 minutes. The sections were rinsed in PBS-Tween 20, twice for 
2 min each. The sections were blocked with 2% BSA in PBS for 1 h at room temperature. 
The sections were then incubated with a 1:500 dilution of the APMV-3 P-specific rabbit 
antiserum in PBS for 1 h in a humidified chamber. After three washes in PBS, the 
sections were incubated with the secondary antibody (FITC conjugated goat anti-rabbit 
antibody) for 30 min. After a further wash cycle, the sections were mounted with glycerol 






6.4.6 Serological analysis 
 
Sera were collected from all the hamsters and mice on 14 dpi and evaluated for 
seroconversion by HI assay (Alexander, 1988).  
 
6.5 Results 
6.5.1 Clinical disease and gross pathology 
 
Six four-week-old hamsters and mice were inoculated by the intranasal route with 
28 HA units of each of the APMV-3. Three animals from each group were sacrificed on 
day 3 and the remaining three animals were sacrificed on day 14; following sacrifice, the 
animals were processed for gross pathology, histopathology, IHC, quantitative virology, 
and seroconversion. Three uninfected animals served as controls and were sacrificed and 
processed on day 14. All of the animals were observed three times daily and weighed 
daily.  
None of the hamsters infected with APMV-3 showed any visible clinical signs of disease. 
The uninfected control hamsters appeared healthy and normal. Following sacrifice on 
days 3 and 14, the followings organs were removed and examined for gross pathology, 
histopathology, immunohistochemical analysis, and quantitative virology: brain, lungs, 
nasal turbinates, small intestine, kidney and spleen. Gross pathologic findings were 
limited to the lungs. There were several diffuse small round shaped red foci on the lungs 
(Fig. 6.1 marked arrow). There were no gross visceral pathologic lesions in any of the 






Fig.6.1 Lungs from a hamster infected with APMV-3, showing multifocal areas of consolidation and 
ecchymotic hemorrhage (arrow marked). 
None of the mice infected with APMV-3 displayed any overt clinical signs and loss of weight. Gross 
examination of lung, nasal turbinate, brain, spleen, kidney and small intestine of all the mice infected with 




Histopathological lesions at 3 dpi were observed in the nasal turbinates and lungs 
of all infected hamsters and mice. The most predominant histopathological lesions 
observed in the nasal turbinates were multifocal necrotic/apoptotic epithelial cells and 
nuclear pyknosis. Along the nasal septum were areas of epithelial necrosis, accumulation 
of nuclear debris in the mucosal epithelium, vacuolation of epithelial cells, and blunting 
or loss of cilia. Small numbers of mononuclear cells and neutrophils multifocally 




were small accumulations of inflammatory cells and necrotic cellular debris in the nasal 
cavity. All the lung samples from the infected hamsters and mice exhibited interstitial 
bronchopneumonia of varying severity at 3 dpi (Fig. 6.2). The inflammatory cell 
infiltrates were mixed populations of lymphocytes, macrophages, and neutrophils. 
Additionally, bronchiolar and type II pneumocyte hyperplasia in areas of inflammation 
with variable degrees of cellular atypia were noticed and the degree of cellular atypia was 
quite prominent. There were no histopathologic findings for any other organs (brain, 
small intestine, kidney, and spleen) from any infected hamsters and mice on day 3, or for 




Fig. 6.2 Representative histopathologic lesions in sections of lung from mice 3 dpi with control (A) and 




Deparaffinized sections of the virus-infected and uninfected control tissue (brain, 
lungs, nasal turbinates, small intestine, kidney, and spleen) were immunostained using 




antigens were detected on 3 dpi in the lungs and nasal turbinates (Fig. 6.3). In the nasal 
turbinates, virus-positive immunofluorescence was noticed throughout the nasal 
epithelium lining the turbinate bone. In the lungs, the viral antigens were mostly localized 
in the epithelium surrounding the medium and small bronchi. Viral P antigens were not 
detected in any additional organs of infected hamsters and mice at 3 dpi, and were not 
detected in any of the organs at 14 dpi. The organs of uninfected control hamsters and 
mice were also negative by immunohistochemistry assay. 
 
 
Fig 6.3. Immunofluorescence localization of viral P antigen in sections of lungs (A and C), and nasal 
turbinates (B and D) from hamster (C and D) and mice (A and B) at 3 dpi. Immunofluorescence was 
evident in the ciliated epithelium lining the turbinate bone. Moreover, immunofluorescence was also 
evident primarily at the apical surface of the ciliated epithelial cells and in the cytoplasm (B and D).  
Immunofluorescence was evident around the bronchial epithelium in the section of the lungs from mice 





6.5.4 Virus Isolation and titration in tissue samples 
 
To analyze sites of virus replication, several organs (brain, lungs, nasal turbinate, 
small intestine, kidney and spleen) were collected on 3 and 14 dpi, for virus isolation and 
titration. Virus was detected on 3 dpi; no virus was detected in any sample for any 
serotype on 14 dpi. APMV-3 was isolated from lungs and nasal turbinates of all three 
hamsters, with mean titers of 5.3 x 102 and 3.6 x 104, respectively. Also, no virus was 
isolated from the brain of any hamsters infected with APMV-3. Comparatively less titers 
were detected in mice where the mean titers of APMV-3 in lungs and nasal turbinates 




The virus replication in the hamsters infected with APMVs was further 
investigated by measuring seroconversion 14 dpi. Sera were analyzed by HI assay using 
chicken erythrocytes The HI titers of the pre-infection hamsters was 2 or less. HI titer 
greater than 8 was considered positive. The results showed that all of the infected 
hamsters seroconverted at 14 dpi, indicating replication of APMV-3. The mean HI titer in 
hamsters for APMV-3 was 1:512. The mean HI titer in serum of mice infected with 








APMVs are frequently isolated from a wide variety of avian species and are 
grouped into nine serotypes based on antigenic reactions (Alexander, 2000). APMV-1 
(NDV) is the most extensively characterized member of the APMV serotypes. APMV-3 
has been isolated from both wild and domestic birds, but their disease potential in wild or 
domestic birds is largely unknown. APMV-1 has also been shown to infect a number of 
non avian species (Hofstad, 1950) and presently is being evaluated as a potential human 
vaccine vector for human pathogens (Bukreyev and Collins, 2008). Therefore, there is a 
possibility that APMV -3 could also be used as human vaccine vectors for human 
pathogens. However, the ability of APMV-3 to replicate in mammalian hosts was 
unknown. Hence, I investigated the replication and pathogenicity of APMV-3 in 
Hamsters and mice inoculated intranasally. The intranasal route was intended to resemble 
the natural route of APMV infection as well as a likely route for vaccine vector 
administration.  APMV-3 produced gross pathological lesions in the lungs, while no 
gross pathology was evident for any other organs. Virus was recovered from all the 
animals infected with APMV-3. In all cases, virus was isolated 3 dpi: no virus was 
detected 14 dpi. The viral titers were moderate and were mostly restricted to the lungs 
and nasal turbinates.  
Using IHC, viral P antigen was detected in the same tissues that were positive by 
virus isolation. An interesting finding was the presence of large amounts of viral antigens 
at the epithelial cell linings, suggesting that these cells are highly permissive to APMV-3 




in nasal turbinates and lungs of the hamsters and mice indicate that APMV-3 replication 
is mostly restricted to the respiratory tract. These results show that APMV-3 are capable 
of infecting hamsters and mice using a nasal route of infection and the extensive amount 
of virus replication in the respiratory tract was not accompanied by severe disease in both 
the species. Serologic assays demonstrated a humoral response in all the animals infected 
with APMV-3, a further indication of successful virus replication. The results show that 
APMV-3 produced HI antibody titers that varied between1:64 to 1:512. The HI test is the 
most commonly used method to diagnose APMV infections and also is used to measure 
the antibody response. The replication of APMV-3 in hamsters produced mild rhinitis 
and mild pathology that was mainly restricted to the respiratory tract. There was a 
concern that APMV-3 may also replicate in the intestine and shed in feces, which might 
act as a source of infection for the other animals. But results indicated that none of the 
APMV-3 infected hamsters and mice showed any replication the intestinal epithelial 
cells. Importantly, results also suggest that APMV-3 do not cross the blood-brain barrier 
and do not induce neurological symptoms. Also, previous experimental studies of the 
APMV-3 in chickens and turkeys showed that they were avirulent. Taken together, these 
results showed that the APMV-3 replicate moderately in hamsters and mice and produce 
either mild or no clinical signs, and elicit substantial antibody responses. Therefore, it is 
possible that APMV-3 might replicate in other mammalian species including humans. In 
conclusion, this study is the first comparative report on the replication and pathogenicity 
of prototype strains of APMV-3 in hamsters and mice. My results lay the foundation for a 









Development of Avian Paramyxovirus serotype 3 (APMV-3) as a live viral 
vector: Establishment of reverse genetics system for APMV-3 and use of recombinant 




The full-length cDNA clone of APMV-3 strain Netherlands (pAPMV3fl) was 
constructed as six different subgenomic fragments in a transcription plasmid pBR322 
(pBR322/dr) between the T7 RNA polymerase promoter and autocatalytic hepatitis delta 
virus ribozyme. The plasmid pAPMV3fl was generated by cloning a 105-nucleotide (nt) 
long linker sequence containing unique restriction enzymes between AscI and RsrII 
enzyme sites of pBR322/dr plasmid.  The support plasmids expressing N and P proteins 
were constructed in pTM1 vector and the ORF of L gene was cloned into pcDNA3.1 
vector, all under the control of T7 promoter. Transfection of the full length cDNA 
plasmid into HEp-2 cells and infection with recombinant modified vaccinia strain Ankara 
expressing the T7 RNA polymerase (MVA-T7) resulted in the synthesis of antigenomic 
RNA of pAPMV3fl. The cotransfection of the support plasmids resulted in replication 
and transcription of the antigenomic RNA leading to generation of recombinant virus 
(rAPMV3). The recovered recombinant virus was amplified in 9-day-old embryonated 
specific pathogen free (SPF) chicken eggs and was confirmed for the presence of the 
artificially introduced restriction enzyme site markers using RT-PCR and sequencing. 




wild-type APMV-3. Furthermore, a recombinant virus, rAPMV3/EGFP expressing 
enhanced green fluorescent protein (EGFP) as a foreign protein was recovered and 
characterized. The growth pattern of GFP-expressing recombinant virus was similar to 
that of the recombinant parental virus. The recombinant viruses stably expressed EGFP 
for at least five serial passages in 9-day-old embryonated chicken eggs and in DF1 cells. 
This result shows that the established reverse genetics system can be used to engineer 




APMV-3 was first isolated from turkeys in Ontario in 1967 and Wisconsin in 
1968 (Tumova et al., 1979b). APMV-3 has been associated with encephalitis and high 
mortality in caged birds, and with respiratory disease in turkeys (Tumova et al., 1979b). 
The virus causes acute pancreatitis and CNS symptoms in psittacine and Passeriformes 
birds (Beck et al., 2003). Experimentally, APMV-3 can infects chickens at an early age 
with evidence of stunting growth that may be more marked in broiler chicken breeds 
(Alexander and Collins, 1982; Kumar et al., 2010a), but natural infection of chickens 
with APMV-3 has never been reported. APMV-3 is classified along with eight other 
APMV serotypes in the genus Avulavirus within the subfamily Paramyxovirinae in the 
family Paramyxoviridae. APMV-3 strain Neterlands has a 16,272-nt long, non-
segmented, negative-sense RNA genome, which contains six genes N, P, M, F, HN and L 
and encodes at least eight proteins N, P/V/W, M, F, HN and L (Kumar et al., 2008). 
The knowledge of the complete viral genome sequence is essential for genetic 




entirely from cloned cDNA (Conzelmann, 1998; Bukreyev et al., 2006). Most of the 
systems for recovery of NDV are based on co-transfection of cell with a plasmid 
expressing the full-length antigenomic RNA with three other support plasmids encoding 
viral N, P and L proteins, all under the control of bacteriophage T7 RNA polymerase 
promoter. The positive-sense antigenomic RNA instead of negative-sense genomic RNA 
was used to avoid hybridization with the positive-sense mRNAs transcribed from the 
support plasmids. The T7 RNA polymerase was provided by either a recombinant 
vaccinia virus expressing the T7 gene or a cell line constitutively expressing the T7 
polymerase. The reverse genetics system has been successfully used for the genetic 
manipulation of avian paramyxoviruses to study their molecular biology and 
pathogenesis and also, to develop a vaccine vectors against important and emerging 
pathogens by engineering viruses to express foreign immunogens (Huang et al., 2004a; 
Rout and Samal, 2008; Yan and Samal, 2008; Nayak et al., 2009; Yan et al., 2009; 
Khattar et al., 2010).  
This study describes the recovery of recombinant APMV-3 (rAPMV3) entirely 
from cloned cDNA using a reverse genetics system. The rescued recombinant virus was 
biologically similar to the wild-type APMV-3. Furthermore, I recovered recombinant 
viruses expressing enhanced green fluorescent protein (EGFP) to evaluate rAPMV3 as a 
vector to express foreign gene. The EGFP-expressing recombinant viruses were 
biologically similar to the parental recombinant and wild-type virus, and stably expressed 
GFP for at least five consecutive passages, suggesting its potential to be used as a vaccine 




7.4 Materials and Methods 
7.4.1 Cells and viruses 
 
HEp-2 and DF1 cells were grown and maintained in Dulbecco's modified Eagle's 
medium (DMEM) containing 10% fetal bovine serum (FBS) and maintained in DMEM 
with 5% FBS. APMV-3 strain parakeet/Netherlands/449/75 was obtained from the 
National Veterinary Services Laboratory, Ames, Iowa. The virus was grown in 9-day-old 
embryonated SPF chicken eggs by injecting the virus into the allantoic cavity. Four days 
later, the allantoic fluid was harvested and clarified. The virus was purified as described 
previously (Kingsbury, 1966). 
 
7.4.2 cDNA synthesis and construction of APMV-3 full-length plasmid 
 
Viral RNA was extracted from the purified virus by using TRIzol (Invitrogen, 
USA) according to manufacturer's protocol. A total of six cDNA fragments, spanning the 
entire APMV-3 genome, were generated by RT-PCR (Fig. 7.1). Specifically, each cDNA 
fragment was primed by a positive-sense oligonucleotide primer (Table 7.1), which 
carried a recognition sequence for a restriction enzyme that was unique to the APMV-3 
genome. The primer corresponding to the fragment I had a T7 promoter overhang 39 nt to 
the AscI restriction site, and the primer corresponding to fragment VI had a 24-nt 39-end 
sequence overhang of Hepatitis Delta Virus (HDV) ribozyme sequence. Also, the 
positive-sense oligonucleotide primer corresponding to fragment IV was modified at nt 
positions 8610 and 8616 to create an MluI site tag (at the HN/L intergenic region). The 
first-strand cDNA was synthesized using Superscript RT-PCR kit (Invitrogen, USA) 




fidelity Pfx DNA polymerase (Invitrogen, USA) in a reaction containing the primer used 
in the RT reaction and the corresponding negative-sense oligonucleotide primer (Table 
7.1). The RT-PCR product was then digested with the respective restriction enzymes and 
ligated to the plasmid pBR322/dr (Fig. 7.1). The fragments were ligated sequentially in 
the order shown in Table 7.1. Plasmid pBR322/dr was constructed by modification of 
plasmid pBR322. The modification included a backbone of 105-nt linker between the 
AscI and RsrII sites and an HDV 84-nt antigenome ribozyme sequence and T7 RNA 
polymerase transcription termination signal downstream of the polynucleotide linker. 
After ligation into the plasmid, each fragment was sequenced completely by using 
BigDye terminator v 3.1 matrix standard kit (Applied Biosystem) and 3130xl genetic 
analyzer data collection software v3.0 (Applied Biosystem). The resulting APMV-3 full-
length expression plasmid was termed pAPMV3fl. 
 
 
Fig.7.1 Generation of full length cDNA clone of pAPMV3fl.  
The full length cDNA clone was constructed by assembling  six subgenomic fragments  into pBR322/dr 
using a 105-nt long oligonucleotide linker sequence between T7 RNA polymerase promoter sequence and 
the hepatitis delta ribozyme sequence, which was followed by T7 terminator sequence (between the 




restriction enzyme site and A8616C, A8617G, and G8618T to generate unique MluI restriction enzyme 

















Table.7.1 The list of oligonucleotide primers used in the synthesis of full length cDNA of APMV-3. The restriction 
enzyme sites artificially created in the primers are underlined. 
 
7.4.3 Construction of expression plasmids 
 
cDNA fragments bearing the open reading frame (ORF) of N, P, and L genes 
were generated by RT-PCR. The N gene was cloned in the plasmid pTM-1 (pN) between 
NcoI and SpeI sites, while the P gene was cloned (pP) between NcoI and XhoI sites. The 
cloned gene was sequenced completely by the dideoxy chain termination method. The L 
gene was cloned in an expression plasmid pcDNA3.1 (pL) between XbaI and NheI site. 





7.4.4 Construction of full length plasmids expressing EGFP 
 
The plasmid pAPMV3fl was modified by the insertion of a transcription cassette 
containing the ORF for EGFP (Clontech, Inc.). The ORF of EGFP was flanked by the 
SacII enzyme site and 18-nt 5’ UTR upstream and by 161-nt P gene-end  (GE) sequence, 
62-nt intergenic sequences, a 10-nt putative M gene-start (GS) (AGGAGCGGAA), 51-nt 
3’UTR sequence and SacII enzyme site downstream. This fragment containing the ORF 
of EGFP was cloned between the P and M genes in the full length plasmid to generate the 
pAPMV3fl/EGFP plasmid (Fig. 7.2). The length of the encoded pAPMV3fl/EGFP was 
17,304 nt, which was an even multiple of six.  
The top panel (A) shows the construction of full length plasmid, pAPMV3fl and the 
bottom panel (B) shows the construction of pAPMV3fl/EGFP along with their respective 
EGFP cassettes. The EGFP ORF was inserted as a transcription cassette at the SacII site 
(at the putative M gene 5’ UTR).  
 
 
Fig. 7.2  Construction of full length plasmids expressing EGFP.  






7.4.5 Transfection and recovery of recombinant viruses 
 
The HEp-2 cells were chosen for transfection experiments because these cells are 
permissive for APMV-3, transfect efficiently, and are resistant to CPE of vaccinia virus 
strain MVA. Specifically, cells grown to 80% confluency in six-well plates were washed 
twice with Opti- MEM just before transfection. The cells were then transfected with 5 µg 
pAPMV3fl or pAPMV3fl/EGFP, 2.5 µg pN, 1.5 µg pP, and 0.5 µg of pL in a volume of 
0.2 ml of Opti-MEM/well. The transfection was carried out with Lipofectamine Plus 
(Invitrogen, USA), according to the manufacturer's instructions. Along with the 
transfection mixture, 1 focus-forming unit per cell of recombinant vaccinia virus 
(MVA/T7) expressing T7 RNA polymerase was added in a volume of 0.8 ml Opti-
MEM/well. Six hours later, the medium was replaced with 2 ml Opti-MEM containing 
2% FBS. Two days after transfection, the medium was harvested, the cell debris was 
pelleted by low-speed centrifugation, and the supernatant was used for infecting a fresh 
batch of HEp-2 cells in 25-cm2 flasks. Alternatively, 100 µl supernatant from 
transfection was directly used to inject 9-day-old embryonated chicken eggs. Two days 
later, the eggs were chilled for a period of 12 h, after which the allantoic fluid was 
harvested. The virus in the allantoic fluid was amplified by further passage in eggs. The 
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Fig. 7.3. A Plasmid based system for recovery of recombinant rAPMV3 from cDNA. 
 HEp-2 cells were first infected with recombinant vaccinia virus expressing T7 polymerase and 
cotransfected with antigenome full length cDNA plasmids pAPMV3fl or pAPMV3fl/EGFP and expression 
plasmids pN, pP, pL. This cartoon depicts the events that occur in the transfected HEp-2 cell leading to the 
recovery of recombinant viruses. 
 
7.4.6 Identification of genetic markers in recombinant viruses by RT-PCR and 
sequencing 
 
RT-PCR was performed on the RNA extracted from recombinant viruses using P 
gene-specific forward primer and M gene-specific reverse primer. The RT-PCR product 
was digested using SacII enzyme and sequenced to confirm the foreign gene. RNA 
isolated from rAPMV3 was included as a control. Furthermore, the GFP expression by 






7.4.7 Pathogenicity index tests  
 
The pathogenicity of all recombinant viruses was determined by two standard 
pathogenicity index tests.  These included the mean death time (MDT) in 9-day-old 
embryonated SPF chicken eggs and the intracerebral pathogenicity index (ICPI) in 1-day-
old SPF chicks (Alexander, 2009). 
MDT value was determined following the standard procedure. Briefly, a series of 
10-fold (10−6 to 10−12) dilutions of fresh infective allantoic fluid in sterile phosphate-
buffered saline (PBS) were made and 0.1 ml of each dilution was inoculated into the 
allantoic cavities of five 9-day-old embryonated SPF chicken eggs, which were then 
incubated at 37°C. Each egg was examined three times daily for 7 days, and the times of 
embryo deaths were recorded. The minimum lethal dose is the highest virus dilution that 
caused death of all the embryos. MDT is the mean time in hours for the minimum lethal 
dose to kill all inoculated embryos. The MDT has been used to characterize the NDV 
pathotypes as follows: velogenic (less than 60 h), mesogenic (60 to 90 h), and lentogenic 
(more than 90 h) (Alexander, 1998). 
For determining ICPI value, 0.05 ml of 1:10 dilution of fresh infective allantoic 
fluid (28 HA units) of each virus was inoculated into groups of ten 1-day-old SPF chicks 
via intracerebral route. The birds were observed for clinical symptoms and mortality 
every 8 h for a period of 8 days. At each observation, the birds were scored as follows: 0, 




8-day period. Highly virulent NDV (velogenic) viruses give values approaching 2 and 
avirulent NDV (lentogenic) viruses give values close to 0 (Alexander, 1998). 
 
7.4.8 Growth characteristics of the rAPMV3s in DF1 cells 
 
The multicycle growth kinetics of rAPMV3 and rAPMV3-EGFP were determined 
in DF1 cells. DF1 cells in duplicate wells of six-well plates were infected with viruses at 
an MOI of 0.01 PFU. After 1 h of adsorption, the cells were washed with DMEM and 
then covered with DMEM containing 2% FBS and 5% allantoic fluid. The cell culture 
supernatant samples were collected and replaced with an equal volume of fresh medium 
at 8-h intervals until 64 h post-infection. The titers of virus in the samples were quantified 
by 50% tissue culture infectious dose (TCID50) assay
 in DF1 cells.  
 
7.5 Results 
7.5.1 Construction of the full length cDNA and expression plasmids 
 
  In order to construct the full length cDNA of pAPMV3fl, the whole APMV-3 
genome was divided into six fragments and they were sequentially cloned. A 105-nt oligo 
linker was synthesized to contain unique restriction enzyme sites and was inserted 
between Asc I and Rsr II sites of the pBR322/dr vector to clone the full length cDNA. 
The DNA sequence results of the entire full length cDNA confirmed four nucleotide 
mutations, C6483G to delete an additional SacII restriction enzyme site and A8616C, 
A8617G, and G8618T to generate unique MluI restriction enzyme site and served as the 




by inserting the cDNA bearing the ORF of N, P into expression vector pTM-1, while pL 
was obtained by cloning the L ORF as two fragments into pcDNA3.1 (pL) between XbaI 
and NheI site. Furthermore, the support plasmids were confirmed by digesting with the 
corresponding restriction enzymes followed by sequencing the complete ORF, prior to 
using them in the recovery of the recombinant viruses. 
 
7.5.2 Construction of full length plasmids encoding EGFP 
 
The full length plasmid encoding the EGFP, pAPMV3fl/EGFP, was constructed 
by inserting the EGFP transcription cassette at SacII site between P and M genes. The 
EGFP ORF was inserted between the genes P and M since this position is known to 
support stable expression of foreign genes without affecting virus replication. The EGFP 
cassette contained appropriate viral GS and GE signals along with the EGFP ORF. The 
plasmids were sequenced to confirm the insertion of foreign cassette at the SacII site. 
 
7.5.3 Recovery of infectious recombinant viruses 
 
  The transfection of full length cDNA plasmids pAPMV3fl and pAPMV3fl/EGFP 
along with support plasmids pN, pP and pL in HEp-2 cells infected with MVA-T7, 
yielded infectious recombinant viruses two days post transfection. The recovered viruses 
were passaged in 9-day-old embryonated SPF chicken eggs to amplify the recombinant 
viruses (rAPMV3 and rAPMV3-EGFP). RT-PCR of the infective allantoic fluid and 




green fluorescence in the infected DF1 cells confirms the expression of GFP by the 
rAPMV3-EGFP which was absent in rAPMV3. 
 
 
Fig. 7.4. EGFP expression by the rAPMV3-EGFP. 
DF1 cells infected with rAPMV3-EGFP showed the GFP expression evident by the green fluorescent 
which was started 12 hr post-infection and completely saturated the cell culture monolayer 48 hr post-
infection. 
 
7.5.4 Biological characterization of recombinant viruses 
 
The cytopathic effects of recombinant viruses were similar to those of parental 
virus in DF1 cells. The GFP expression by the recovered virus was confirmed by 
infecting DF1 cells with rAPMV3-EGFP. The recovered viruses, rAPMV3 and rAPMV3-
EGFP were compared with the parental wild-type virus for their in vitro growth 




kinetics and the magnitude of replication of the recombinant virus were similar to those 
of the parental virus. The virus titers of the recombinant virus expressing GFP was 1.5 
log lower than those of the parental and recombinant viruses, suggesting that the insertion 
of foreign gene resulted in slight attenuation. 
The pathogenicity of these rAPMV3s was evaluated by the MDT assay in 
embryonated chicken eggs. The MDTs for these viruses were 120 h (rAPMV3) and 124 h 
(rAPMV3-EGFP). Furthermore, virulence of these rAPMV3s was evaluated by the ICPI 
assay in 1-day-old chicks. The ICPI values for these viruses were 0.33 for rAPMV3 and 
0.36 for rAPMV3-EGFP compared to 0.39 for parental APMV-3. According to OIE 
guidelines, an NDV strain with an MDT value of more than 90 h is considered lentogenic 
or avirulent while for ICPI, virulent NDV viruses give values approaching 2 and avirulent 
(lentogenic) viruses give values close to 0 (Alexander, 2009). Thus, the two rAPMV3s 
are avirulent viruses and expression of the EGFP proteins did not increase viral virulence. 




This study describes the recovery of infectious recombinant APMV-3 strain 
Netherlands from the cloned cDNA by reverse genetics system for the first time. The 
availability of the complete genome sequence of APMV-3 strain Netherlands assisted in 
generating the full length cDNA clone, required for recovery of infectious recombinant 
virus. In this system, recombinant vaccinia virus expressing T7 RNA polymerase (MVA-




proteins N, P, and L from the cotransfected support plasmids, pN, pP and pL. Similar 
systems have been used to recover other viruses (Schnell et al., 1994; Yunus et al., 1999; 
Krishnamurthy et al., 2000; Govindarajan et al., 2006).  The growth characteristics of the 
recombinant virus, rAPMV3 generated in this study was similar to that of the parental 
virus. These results indicate that it is possible to recover recombinant APMV-2 to -9 
entirely from cloned cDNAs.  
One of the important applications of reverse genetics system is the development 
of vaccine vectors by engineering viruses to express foreign immunogens. Paramyxovirus 
vectors have several advantages as follows; the ability to accommodate large foreign 
genes without drastic reduction in virus growth, stable expression of the inserted foreign 
genes even after many passages in vitro and finally, the absence of homologous RNA 
recombination makes them safe and stable vectors. 
Using the established reverse genetics system, a rAPMV3 expressing foreign 
protein, enhanced GFP, was recovered. Full length cDNA constructs were made with 
EGFP transcript cassette alone between the P and M genes. The enhanced GFP was 
preferred as the foreign gene mainly because of the small size and the ease of 
visualization of the expressed foreign protein. The region between P and M genes in the 
full-length cDNA clone was chosen for insertion of EGFP because paramyxoviruses 
show gradient transcription pattern wherein the genes located near the 3’ end of the 
genome are transcribed and expressed in higher quantities than those located further 
behind. This has also been shown in NDV that the expression of foreign genes are better 
when placed near the 3’ end (Huang et al., 2001). The recovered viruses were similar to 




viral titers were 1.5 log lower than the parental virus. The attenuation following the 
expression of foreign genes has also been reported in other paramyxoviruses 
(Krishnamurthy et al., 2000). The recombinant virus rAPMV3-EGFP stably expressed 
the GFP for at least five serial passages in 9-day-old embryonated SPF chicken eggs and 
in DF1 cells.  
In conclusion, a reverse genetics system was established for APMV-3 and the 
recovered recombinant virus showed similar morphological and in vitro growth 
characteristics and pathogenicity to the parental virus.  The reverse genetics system can 
be used as a tool to understand the APMV-3 molecular biology and pathogenesis. 
Furthermore, the ability to engineer recombinant rAPMV3 expressing a foreign gene has 
been demonstrated using enhanced GFP, which has implications in the development of 


























Evaluation of the Newcastle disease virus F and HN proteins in protective 




Newcastle disease virus (NDV) is an important pathogen of poultry worldwide. 
Current vaccination strategies are not completely satisfactory. The NDV surface 
glycoproteins, namely the fusion (F) and the hemagglutinin-neuraminidase (HN) 
proteins, are thought to be the major protective immunogens. However, the relative 
contributions of F and HN to protection in chickens are not well understood. I developed 
a recombinant version of avian paramyxovirus serotype-3 (APMV-3) by reverse genetics 
and used this recombinant virus as a vector to determine the individual contributions of 
the NDV F and HN proteins to protection and immunity against NDV in chickens. Three 
recombinant viruses, namely the parental (rAPMV3) and rAPMV3 expressing the NDV F 
(rAPMV3-F) or HN (rAPMV3-HN) protein were constructed. Protective efficacy was 
analyzed by vaccinating 2-week-old SPF chickens by the oculonasal route and 
challenging on day 21 post-vaccination with virulent NDV via three different routes of 
inoculation. Serum antibody responses were measured by hemagglutination inhibition 
and virus neutralization assays. All three recombinant viruses (rAPMV3, rAPMV3-F, and 
rAPMV3-HN) protected chickens against NDV challenge via the oculonasal and 
intramuscular routes, while all unvaccinated birds succumbed to death. This result 




challenge. However, immunization with rAMPV3 did not protect chickens against 
intravenous NDV challenge; whereas, birds vaccinated with rAPMV3-F alone or in 
combination with rAPMV3-HN were completely protected, and birds vaccinated with 
rAPMV3-HN alone were partially protected. NDV neutralizing antibody titers induced 
by rAPMV3-F were greater than those induced by rAPMV3-HN. The result shows NDV 
F and HN proteins are independent protective antigens, but the F protein contributes more 
to protection than does the HN protein.  Furthermore, rAPMV3, which is avirulent in 
chickens, can be used as a vaccine vector against NDV, since APMV3 itself provides 
protection against NDV due to its cross-reactivity, which is further enhanced due to 




Newcastle disease (ND) is a highly contagious disease of many avian species, 
which leads to substantial economic losses in the poultry industry worldwide. The 
severity of disease depends on the virus strain and the host species. Newcastle disease 
virus (NDV) is divided into three pathotypes based on the severity of the disease: 
Lentogenic (apathogenic), mesogenic (moderately pathogenic) and velogenic (highly 
pathogenic) (Alexander, 1998). Velogenic NDV strains cause acute infections with high 
mortality, preceded by respiratory and neurological signs with occasional haemorrhagic 
lesions in the gut, whereas mesogenic NDV strains cause respiratory disease in young 
birds and decreased egg production in laying flocks (Alexander, 2003a). In contrast, 




NDV belongs to the genus Avulavirus within the family Paramyxoviridae (Mayo, 
2002a; Mayo, 2002b). The genome of NDV is a nonsegmented, single-stranded, 
negative-sense RNA of 15,186 nucleotides (nt) (Krishnamurthy and Samal, 1998; de 
Leeuw and Peeters, 1999). The genome consists of six genes encoding at least six 
different proteins in the order of a nucleocapsid protein (N), a phosphoprotein (P), a 
matrix protein (M), a fusion protein (F), an attachment protein called the hemagglutinin-
neuraminidase (HN), and a large polymerase protein (L) (3’leader-N-P-M-F-HN-L-
5’trailer). Two additional proteins, V and W, may be produced by RNA editing during P 
gene transcription (Steward et al., 1993). 
The envelope of NDV virions contains two transmembrane glycoproteins, the 
virus attachment protein, HN, and the fusion protein, F, which form spike-like protrusions 
on the outer surface of the virion. The HN protein is responsible for the attachment of 
virus particles to sialic acid-containing receptors on the host cell. It is the largest 
glycoprotein molecule and carries both haemagglutinating and neuraminidase activities 
(Scheid and Choppin, 1973; Morrison, 2003). The F protein mediates fusion of the virion 
envelope with the cellular plasma membrane (Nagai et al., 1989). It has been shown that 
the polybasic basic amino acid residues at the F protein cleavage site found in virulent 
NDV strains is a prerequisite for the pathogenic phenotype (Nagai et al., 1976; Glickman 
et al., 1988; Romer-Oberdorfer et al., 2003). Both F and HN glycoproteins on the surface 
of NDV are important for virus infectivity and pathogenicity (Nagai et al., 1976; 
Meulemans et al., 1986; Ogawa et al., 1990; Nagy et al., 1991). Furthermore, F and HN 
proteins produce virus neutralizing antibody response and are protective antigens 




protein is known to play an important role in immunity to the disease and has been shown 
that this protein alone is sufficient to induce protective immunity to NDV in chickens 
(Meulemans et al., 1988). The HN protein has also been shown to protect birds from 
virulent NDV challenge, although the birds showed lower neutralizing antibody titers 
(Boursnell et al., 1990b; Nagy et al., 1991). It has also been shown that monoclonal 
antibodies to F protein neutralizes NDV better than monoclonal antibodies to HN protein 
(Russell, 1988). However, it is still not clear, which surface glycoprotein is the major 
protective antigen. Although, several vaccine studies have been done with F and HN 
glycoproteins (Boursnell et al., 1990a; Boursnell et al., 1990b; Romer-Oberdorfer et al., 
2003; Lee et al., 2008), their major role in protection against virulent NDV challenge is 
not well understood.  
Several vaccination strategies, including inactivated and live attenuated vaccines, 
have been evaluated to control NDV. Lentogenic strains are preferentially used for 
vaccine preparations due to their low pathogenicity for chickens. Although effective live 
or inactivated ND vaccines are currently available, the virus remains as a major threat to 
commercial flocks. Inactivated vaccines are used in breeder pullets but not practical 
because of the high cost and unsuitability for mass vaccination in the field. Although live 
attenuated vaccines are commonly used in field condition, it is always of the concern that 
the vaccine viruses may, through either mutation or genetic recombination with 
circulating strains, become virulent. Furthermore, both current live and inactivated 
vaccines cannot differentiate infected from vaccinated animals (DIVA). To overcome 
these difficulties, several strategies have been developed based on in vivo expression of 




adenovirus (Perozo et al., 2008),  fowl pox virus (Boursnell et al., 1990b; Ogawa et al., 
1990; Karaca et al., 1998), baculovirus (Nagy et al., 1991; Lee et al., 2010), pigeon pox 
(Letellier et al., 1991), herpes virus of turkeys (Morgan et al., 1993; Sakaguchi et al., 
1998), Marek’s disease virus, and retrovirus (Morrison et al., 1990; Sonoda et al., 2000), 
and infectious laryngotracheitis virus (ILTV) (Sun et al., 2008) or by transgenic crops 
(Yang et al., 2007). 
The avian paramyxoviruses that comprise genus Avulavirus have been divided 
into nine different serotypes (APMV-1 through -9) based on haemagglutination inhibition 
(HI) and neuraminidase inhibition (NI) assays. All strains of NDV belong to APMV-1. 
Although, there is a high degree of amino acid sequence variation between APMV-3 and 
APMV-1 (NDV), by the HI test there is cross reaction between APMV-3 and APMV-1 
serum samples, which often leads to misdiagnosis of APMV-3 as APMV-1. Recently, I 
sequenced the complete genome of APMV-3 (Kumar et al., 2008; Kumar et al., 2010b). I 
also studied its pathogenicity study in chickens and turkeys that showed  APMV-3 is 
nonpathogenic to chickens and turkeys (Kumar et al., 2010a).  
In the present study, I examined the relative contributions of each of the two NDV 
surface glycoproteins (F and HN) to induction of neutralizing antibodies and protective 
immunity in chickens. In order to address this, I generated recombinant avian 
paramyxovirus type-3 (rAPMV-3) vectors, which individually expressed each of the two 
surface glycoproteins F and HN of NDV. They were used to immunize chickens either 
individually or in combinations. Evaluation of the relative neutralization titers of serum 
antibody, shedding of challenge virus, and protection against lethal NDV challenge 




glycoprotein was the major contributor to induction of neutralizing antibodies and 
protective immunity, followed by HN protein, which conferred partial protection against 
intravenous challenge. 
 
8.4 Materials and Methods 
8.4.1 Cells and viruses 
 
HEp-2 and DF1 cells were grown and maintained in Dulbecco's modified Eagle's 
medium (DMEM) containing 10% fetal bovine serum (FBS) and maintained in DMEM 
with 5% FBS. APMV-3 strain Netherlands and NDV strain Texas GB (APMV-
1/chicken/U.S.(TX)/GB/1948) were obtained from National Veterinary Services 
Laboratory (Ames, IA). Recombinant NDV (rNDV) strain LaSota was generated as 
previously described (Huang et al., 2001). The virus was grown in 9-day-old 
embryonated SPF chicken eggs by injecting the virus into the allantoic cavity. Four days 
later, the allantoic fluid was harvested and clarified. Further the virus was purified as 
described previously (Kingsbury, 1966). 
  
8.4.2 Construction of full-length plasmid containing NDV F and HN gene 
 
Full length cDNA clone (pAPMV3fl) and expression plasmids of APMV-3 were 
generated as describe in chapter 7. 
The restriction enzyme site of SacII at position 3221 of pAPMV3fl was utilized to 
insert the F and HN genes of NDV between the P and M genes individually (Fig. 8.1). 




and gene end sequences. Specifically, the positive-sense oligonucleotide primers used to 
amplify the F and HN genes by PCR were modified to contain the SacII site overhang 
upstream and downstream of the F and HN-specific sequence. PCR was performed by 
using high-fidelity Pfx DNA polymerase. The PCR-amplified fragment of F and HN was 
inserted at the SacII site of pAPMV3fl and the resulting plasmid was designated as 
pAPMV3fl-F and pAPMV3fl-HN, respectively. The integrity of the entire foreign 
sequence was confirmed by sequencing whole F and HN sequences. The insertion of 
1662 nt (F orf) and 1734 nt (HN orf) of foreign sequences (a nt multiple of six) resulted 
in the plasmid encoding an antigenome of 18,252 nt and 18,324 nt, respectively, 
consistent with the “rule of six” (Calain and Roux, 1993). 
 
 
Fig. 8.1 Construction and characterization of rAPMV3s expressing NDV surface protein F and HN.  
Schematic diagram depicting the rAPMV3 genome with insertion of an added gene engineered to express 
the NDV surface protein F and HN. The NDV F and HN genes ORF was inserted as a transcription cassette 






8.4.3 Transfection and recovery of recombinant viruses 
 
The HEp-2 cells were chosen for transfection experiments because these cells are 
permissive for APMV-3, transfect efficiently, and are resistant to CPE of vaccinia virus 
strain MVA. Specifically, cells grown to 80% confluency in six-well plates were washed 
twice with Opti- MEM just before transfection. The cells were then transfected with 5 µg 
pAPMV3fl or pAPMV3fl-F or pAPMV3fl-HN, 2.5 µg pN, 1.5 µg pP, and 0.5 µg of pL 
in a volume of 0.2 ml of Opti-MEM/well. The transfection was carried out with 
Lipofectamine Plus (Invitrogen, USA), according to the manufacturer's instructions. 
Along with the transfection mixture, 1 focus-forming unit per cell of recombinant 
vaccinia virus (MVA/T7) expressing T7 RNA polymerase was added in a volume of 0.8 
ml Opti-MEM/well. Six hours later, the medium was replaced with 2 ml Opti-MEM 
containing 2% FBS. Two days after transfection, the medium was harvested, the cell 
debris was pelleted by low-speed centrifugation, and the supernatant was used for 
infecting a fresh batch of HEp-2 cells in 25-cm2 flasks. Alternatively, 100 µl supernatant 
from transfection was directly used to inject 9-day-old embryonated chicken eggs. Two 
days later, the eggs were chilled for a period of 12 h, after which the allantoic fluid was 
harvested. The virus in the allantoic fluid was amplified by further passage in eggs. 
  
8.4.4 Pathogenicity index tests  
The pathogenicity of all recombinant viruses was determined by two standard 




embryonated SPF chicken eggs and the intracerebral pathogenicity index (ICPI) in 1-day-
old SPF chicks (Alexander, 2009). 
MDT value was determined following the standard procedure. Briefly, a series of 
10-fold (10−6 to 10−12) dilutions of fresh infective allantoic fluid in sterile phosphate-
buffered saline (PBS) were made and 0.1 ml of each dilution was inoculated into the 
allantoic cavities of five 9-day-old embryonated SPF chicken eggs, which were then 
incubated at 37°C. Each egg was examined three times daily for 7 days, and the times of 
embryo deaths were recorded. The minimum lethal dose is the highest virus dilution that 
caused death of all the embryos. MDT is the mean time in hours for the minimum lethal 
dose to kill all inoculated embryos. The MDT has been used to characterize the NDV 
pathotypes as follows: velogenic (less than 60 h), mesogenic (60 to 90 h), and lentogenic 
(more than 90 h) (Alexander, 1998). 
For determining ICPI value, 0.05 ml of 1:10 dilution of fresh infective allantoic 
fluid (28 HA units) of each virus was inoculated into groups of ten 1-day-old SPF chicks 
via intracerebral route. The birds were observed for clinical signs and mortality every 8 h 
for a period of 8 days. At each observation, the birds were scored as follows: 0, healthy; 
1, sick; and 2, dead. The ICPI is the mean score per bird per observation over the 8-day 
period. Highly virulent NDV (velogenic) viruses give values approaching 2 and avirulent 
NDV (lentogenic) viruses give values close to 0 (Alexander, 1998). 
 
8.4.5 Expression of the NDV F and HN proteins in cells infected with rAPMV3s 
 
The expression of the F and HN proteins of NDV by the rAPMV3s was examined 




and rAPMV3-HN at a multiplicity of infection (MOI) of 0.01 PFU. The cells were 
harvested at 48 h post-infection, lysed, and analyzed by Western blotting using a 
monoclonal antibody against HN or a rabbit antiserum specific to a C-terminal peptide of 
the NDV F protein. To examine the incorporation of NDV surface proteins into rAPMV3 
particles, Western blot analysis was carried out using partially purified virus from 
allantoic fluid of rAPMV3s-infected eggs and the same two antisera. 
 
8.4.6 Growth characteristics of the rAPMV3s in DF1 cells 
 
The multicycle growth kinetics of rAPMV3, rAPMV3-F, and rAPMV3-HN were 
determined in DF1 cells. DF1 cells in duplicate wells of six-well plates were infected 
with viruses at an MOI of 0.01 PFU. After 1 h of adsorption, the cells were washed with 
DMEM and then covered with DMEM containing 2% FBS and 5% allantoic fluid. The 
cell culture supernatant samples were collected and replaced with an equal volume of 
fresh medium at 8-h intervals until 64 h post-infection. The titers of virus in the samples 
were quantified by 50% tissue culture infectious dose (TCID50) assay
 in DF1 cells.  
 
8.4.7 Virus titration 
 
Titration of rAPMV3s following in vitro or in vivo growth was performed by 
limiting dilution in DF1 cells, using the Reed and Muench method as described 
previously (Reed, 1938), and the titers were expressed as TCID50 units/ml. For both 
rAPMV3s and NDV, HA titers were determined using chicken red blood cells (RBC). 





by infecting five eggs per group for each 10-fold serial dilution. Following 24 h of 
infection, eggs were harvested for allantoic fluid, and the presence of virus was confirmed 
by HA test. For NDV challenge viruses, the chicken 50% lethal dose (CLD50)
 was 
determined by infecting three (5-week-old) chickens per group, and the 50% end point 
was determined by the Reed and Muench method (Reed, 1938). 
 
8.4.8 Immunization and challenge experiments in chickens 
 
The immunization and challenge experiments were performed in three phases. In 
first phase of the experiment, 5 groups (n = 13 per group) of 2-week-old SPF chickens 
were immunized by the oculonasal route with a dose of 106 EID50 of NDV strain LaSota, 
rAPMV3 (empty vector), rAPMV3-F, rAPMV3-HN, and a combination of rAPMV3-F 
and rAPMV3-HN. In addition, 13 birds were kept as an unvaccinated control. Three 
weeks post-immunization, pre-challenge serum samples were collected for serum 
antibody response, and the animals were challenged through the intranasal route with 100 
CLD50 of the highly virulent NDV strain GB Texas.
 Three chickens from each group 
were sacrificed on day 3 post-challenge for quantitation of challenge virus replication. 
Tissue samples were collected from the respiratory tract, including the trachea, nasal 
turbinates (upper respiratory tract), and lungs (lower respiratory tract), as well as from the 
lymphoid system (spleen), digestive system (gut), and nervous system (brain). The tissues 
were homogenized in cell culture medium (1 g/10 ml) and clarified by centrifugation. The 
challenge virus titers in organs were determined by limiting dilution. The remaining 10 
chickens in each group were observed daily for 10 days for disease symptoms and 




cloacal swabs were collected on day 3, 5 and 7 post-challenge from all chickens. The 
NDV challenge virus titers in the swab samples were determined by a limiting dilution 
assay in DF1 cell monolayers. Post-challenge sera were collected from the surviving birds 
before they were sacrificed on day 10 post-challenge.  
 In the second phase, 5 groups (n = 5 per group) of 2-week-old SPF chickens were 
immunized similarly as the first phase. In addition, 5 birds were kept unvaccinated 
controls. Three weeks post-immunization, the birds were challenged by intramuscular 
route with highly virulent NDV strain GB Texas. To monitor shedding of the challenge 
NDV, oral and cloacal swabs were collected on day 3, 5 and 7 post-challenge from all 
chickens. Post-challenge sera were collected from the surviving birds before they were 
sacrificed on day 15 post-challenge. 
 In the third phase, the birds were immunized similarly as the second phase. Three 
weeks post-immunization, the birds were challenged by intravenous route with highly 
virulent NDV strain GB Texas keeping all post challenge procedures the same as the 
second phase. 
All challenge experiments were carried out in an enhanced BSL3 containment 
facility certified by the USDA and CDC, with the investigators wearing appropriate 
protective equipment and compliant with all protocols approved by the Institutional 
Animal Care and Use Committee (IACUC) of the University of Maryland and under 






8.4.9 Serological analysis  
The antibody levels of serum samples collected from chickens vaccinated with 
rAPMV3s were evaluated by hemagglutination inhibition (HI) and virus neutralization 
(VN) assays as well as enzyme-linked immunosorbent assay (ELISA) and Western 
blotting using standard protocols. For the HI assay, twofold serial dilutions of immunized 
chicken sera (50 µl) were prepared, and each dilution was combined with 4 HA units of 
rNDV (NDV HI) or APMV-3 strain Netherlands (APMV3 HI). Following 1 h of 
incubation, 50 µl of 1% chicken RBC was added and incubated for 30 min at room 
temperature, and hemagglutination was scored.  
The virus neutralization test was carried out using post-immunization chicken sera 
in DF1 cells grown in 96-well tissue culture plates. Briefly, twofold serial dilutions of 50-
µl serum samples (complement inactivated) were carried out and incubated for 1 h with 
100 TCID50 of NDV or APMV-3 in DMEM.
 Following incubation, cells were infected 
with virus serum mixture. VN titer was obtained by confirmation of the presence of virus 
in wells with the highest dilution of serum. Commercial NDV ELISA kits (Synbiotics 
Corporation, San Diego, CA) were used to detect antibodies against the whole-NDV 
antigens of rAPMV3s. 
 
8.4.10 Statistical analysis 
 
 Statistically significant differences in serological analysis of different immunized 




patterns and median survival times were compared using the log-rank test and chi-square 
statistics. In the log-rank test, survival curves compare the cumulative probability of 
survival at any specific time and the assumption of proportional deaths per time is the 
same at all time points. Survival data and one-way ANOVA were analyzed with the use 




8.5.1 Generation of rAPMV3s expressing the NDV F and HN surface proteins 
 
The individual contributions of each of the NDV surface proteins (F, and HN) to 
immunogenicity and protection were evaluated by separately expressing each protein 
from an added gene inserted into the genome of APMV3 strain Netherlands by reverse 
genetics. The F and HN genes were derived from the NDV strain LaSota. Each ORF was 
placed under the control of a set of APMV3 transcriptional signals and inserted between 
the P and M genes in the APMV-3 antigenome cDNA. The recombinant viruses were 
recovered using a previously described reverse genetics method (Krishnamurthy et al., 
2000). The orientation of each NDV gene in the genome of the recombinant viruses was 
confirmed by reverse transcription-PCR (RT-PCR) and nucleotide sequence analysis. The 
recovered viruses were named rAPMV3 or rAPMV3-F or rAPMV3-HN, respectively. 
The expression of the NDV surface proteins by rAPMV3-F and rAPMV3-HN in infected 
DF1 cells was analyzed using a monoclonal antibody against HN and a rabbit antiserum 
specific to a C-terminal peptide of the F protein, respectively (Fig. 8.2). Analysis with the 




weight of 74 KDa in lysates of cells infected with rAPMV3-HN and F-related bands in 
lysates of cells infected with rAPMV3-F (Fig. 8.2), representing the N-terminally derived 
proteolytic cleavage product F1, with an apparent molecular weight of 55 KDa. To 
examine the incorporation of the NDV surface proteins into APMV3 particles, each of the 
rAPMV3s was partially purified from infected allantoic fluid by sucrose gradient 
centrifugation and analyzed by Western blotting. Analysis with the monoclonal antibody 
against HN detected the HN protein in virus preparations of rAPMV3-HN. In addition, a 
rabbit antiserum specific to a C-terminal peptide of the F protein detected the F1 protein 
in the virus preparation of rAPMV3-F (Fig. 8.2). These results indicated that both F and 
HN were packaged in the APMV3 vector particle. I could not detect the F0 fraction of the 
NDV F protein because of its processing by the presence of allantoic fluid (exogenous 
proteases) both in the cell culture and in purified virus preparations. 
 
 
Fig. 8.2 Expression of NDV surface proteins F and HN in DF1 cells and their incorporation into rAPMV3 




collected and processed to prepare cell lysates. In addition, allantoic fluid from embryonated eggs infected 
with the individual constructs was clarified and subjected to centrifugation on sucrose gradients to make 
partially purified preparations of virus particles. These samples were analyzed by Western blot analysis 
using a monoclonal antibody against the HN protein or a rabbit antiserum specific to a C-terminal peptide 
of the F protein (bottom). In addition, rabbit antisera specific to an N terminal peptide of the P protein of 
APMV-3 was also used. Partially purified virus particles of rAPMV3 empty vector (lane 1), rAPMV3-F 
(lane 2), rAPMV3-HN (lane 3), or rNDV (lane 4) [top 3]. Lysates of DF1 cells that had been infected with 
rAPMV3 empty vector (lane 1), rAPMV3-F (lane 2), rAPMV3-HN (lane 3), or rNDV (lane 4) [bottom 3].  
 
8.5.2 Biological characterization of rAPMV3 expressing NDV surface proteins 
 
The multicycle growth kinetics of rAPMV3-F and rAPMV3-HN were compared 
with those of the empty rAPMV3 vector in DF1 chicken fibroblast cells (Fig 8.3). Results 
demonstrated similar growth pattern between the rAPMV3 empty vector, rAPMV3-F and 
rAPMV3-HN. However, rAPMV3-F and rAPMV3-HN grew slightly slower than 
rAPMV3 but achieved maximum titers that were similar with the rAPMV3 empty vector 
64 h post-infection.  
The virulence of these rAPMV3s was evaluated by the MDT assay in embryonated 
chicken eggs. The MDTs for these viruses were 120 h (rAPMV3) and 124 h (rAPMV3-F 
and rAPMV3-HN). Furthermore, virulence of these rAPMV3s was evaluated by the ICPI 
assay in 1-day-old chicks. The ICPI values for these viruses were 0.33 for rAPMV3 and 
0.36 for rAPMV3-F and rAPMV3-HN. According to OIE guidelines, an NDV strain with 
an MDT value of more than 90 h is considered lentogenic or avirulent while for ICPI, 
virulent NDV viruses give values approaching 2 and avirulent (lentogenic) viruses give 




surface proteins are avirulent viruses and expression of the NDV proteins did not increase 




Fig. 8.3  Comparison of multicycle growth kinetics of rAPMV3s in DF1 cells. DF1 cells were infected with 
100 PFU (0.01 PFU per cell) of each virus, and the cell culture supernatant was harvested at 8-h intervals. 
The virus titer in allantoic fluid and cell culture supernatant samples was determined by TCID50 assay in 
DF1 cells. 
 
8.5.3 Evaluation of APMV3 and NDV-specific serum antibody responses following 
immunization with rAPMV3s expressing NDV surface proteins 
 
To evaluate the immunogenicity of the individual NDV surface proteins, groups 
of chickens were infected oculonasally with rAPMV3s individually or in combination. 
APMV3 and NDV-specific serum antibody responses were determined on day 21 post-
immunization using an NDV-specific ELISA and an APMV3 and NDV-specific HI 





detected by HI assays, indicating replication of the rAPMV3s in chickens (Fig. 8.4a). 
Interestingly, LaSota vaccinated birds also showed 2 log2 APMV3-specific serum 
antibodies by HI assay, indicating slight cross reactivity between APMV-3 and NDV.   
Moderate NDV-specific serum antibody responses were detected by the rAPMV3-
F and rAPMV3-HN measured by NDV-specific ELISA. Surprisingly, relatively high titer 
of NDV antibody response ( ̴ 4.5 log2 titer) was detected in rAPMV3-F and rAPMV3-HN 
vaccinated birds by HI assays (Fig 8.4b). In addition, the rAPMV3 empty vector 
vaccinated group also showed ̴ 1 log2 HI titer against NDV, again indicating cross 
reactivity between APMV3 and NDV.  The sera collected from rAPMV3-F and 
rAPMV3-HN vaccinated groups were treated with purified empty vector rAPMV3 to 
nullify any APMV3 specific background to further confirm the F and HN specific HI 
antibody response, respectively. The treated sera showed the specific F and HN antibody 
response in both ELISA and HI assays, indicating F can also induce HI specific antibody 
(Fig. 8.5). Alternatively, Western blot analysis showed the F and HN-specific antibody 
responses from rAPMVs groups (Data not shown). The chicken group immunized with 
rAPMV3-F+ rAPMV3-HN alone had the highest antibody titers, whereas the titer was 
one-fold less for chickens immunized with rAPMV3-HN and 1/2-fold less for chickens 
immunized with rAPMV3-F (Fig. 8.4c). Interestingly, the antibody response to the F 






Fig. 8.4 APMV-3 and NDV-specific serum antibody responses in chickens at 21 days following 
oculonasal immunization with the indicated rAPMV3s administered individually or in combination. 
APMV-3 specific serum antibody responses were determined by HI assay (a); whereas, NDV-specific 
serum antibody responses were determined by commercial NDV ELISA (C) and HI assay (B). Titers were 
expressed as mean reciprocal log2 titer and statistical differences were calculated by one-way ANOVA with 






Fig. 8.5 NDV- F and HN specific serum antibody responses in chickens at 21 days following 
oculonasal immunization. Serum antibody responses were determined by HI assay following treatment of 
sera with purified rAPMV3 virus. 
 
8.5.4 Evaluation of vaccine virus shedding in rAPMV3s vaccinated chickens 
 
Shedding of rAPMVs was monitored by taking oral and cloacal swab samples on 
day 3, 5 and 7 post vaccinations from all the birds. The frequency with which animals 
shed rAPMVs was determined by inoculation of embryonated chicken eggs and DF1 cell 
monolayers with swab samples, and HA assays were performed to confirm that the isolate 
was rAPMV. All of the birds immunized with LaSota were positive for both oral and 
cloacal shedding after 3 days post vaccinations. Two out of 13 in rAPMV3-F and 
rAPMV3-HN vaccinated chickens and 7 out of 13 in rAPMV3-F+ rAPMV3-HN 
vaccinated birds were positive for oral shedding after 3 days post-vaccination (Fig. 8.6a). 
Three out of 13 birds in LaSota vaccinated group were positive for oral shedding with a 
mean titer of 1.3 log10 even after 5 days post-vaccination, while only one bird showed the 
cloacal shedding (Fig. 8.6b). No rAPMVs shedding was observed from any bird after 5 







Fig. 8.6 rAPMV3s vaccine virus shedding titer as determined by TCID50 assay in oral and cloacal swabs 
collected from chicken groups immunized with rAPMV3s. No virus was detected in the rAPMV3s 
vaccinated groups 5DPI. 
 
8.5.5 Evaluation of NDV-neutralizing serum antibody responses in rAPMV3s 
expressing NDV surface proteins 
 
The ability of sera taken from chickens 21 days after immunization with 
rAPMV3s individually or in combination to neutralize NDV was assessed by a micro-
neutralization assay (Fig. 8.7). Sera from birds immunized with the rAPMV3 empty 
vector showed detectable neutralizing antibody titers, whereas sera from birds immunized 
with rAPMV3-F or rAPMV3-HN individually or together induced substantial titers of 
NDV-neutralizing antibodies, with the titer being one-fold greater for the rAPMV3-F 




similar to that of NDV LaSota group (positive control) (Fig. 8.7a). Moreover, all the 
vaccinated group showed high virus neutralizing antibody titers against APMV3 except 
the NDV LaSota vaccinated group (Fig 8.7b). 
 
 
Fig. 8.7 Induction of NDV and APMV3-neutralizing serum antibodies by rAPMV3s vaccine constructs. 
Chickens were immunized once by the oculonasal route with the indicated rAPMV3s constructs given 
individually or in combination, and sera were taken 21 days later and analyzed for the ability to neutralize 
the APMV3 or NDV strain LaSota. The serum-neutralizing antibody titers were expressed as mean 
reciprocal log2 titer (means ± SEM). Statistical differences were calculated by one-way ANOVA with P < 
0.001. 
 
8.5.6 Protective efficacy of rAPMVs against NDV virus and its replication after 
oculonasal challenge 
 
The chickens that had been immunized with the various rAPMV3s individually or 




lethal dose (100 CLD50) of NDV strain Texas GB. On day 3 post-challenge, three
 
chickens from each group were sacrificed and tissues were harvested from the respiratory 
tract (upper trachea, nasal turbinates, and lungs), lymphoid system (spleen), digestive 
system (gut) and nervous system (brain) of each chicken, and the NDV challenge virus 
titers were determined by limiting dilution (Fig. 8.8). All of the chickens in the 
unvaccinated group died by day 3 post-challenge while chickens in all other groups 
survived from mortality (Fig 8.11). NDV challenge virus replication was highest in 
chickens that had been unvaccinated and immunized with the rAPMV3 empty vector, 
whereas NDV replication in the tissues from chickens immunized with rAPMV3-F or 
rAPMV3-F+ rAPMV3-HN or LaSota was almost the same (Fig 8.8). There was a 
substantial reduction in challenge NDV titer compared to the rAPMV3 empty vector 
group in the lungs (a mean reduction of 5x2log10), trachea (a mean reduction of 13x2
 
log10), nostrils (a mean reduction of 3x2log10), and spleen
 (a mean reduction of 6x2log10), 
whereas replication in the brain was only a 10-fold reduction in mean titer. However, 
rAPMV3-HN group showed a mean increase of 3x2log10 NDV replication in upper 






Fig. 8.8 Replication of NDV challenge virus in different organs of chickens infected 21 days after 
immunization with rAPMV3s. Three chickens from each immunized group were sacrificed 3 days after 
challenge. Various organs from each chicken were collected and analyzed in DF cells. The NDV titers in 
different organs of each chicken are expressed in log10 TCID50 per gram of tissue. 
 
Shedding of NDV challenge virus was monitored by taking oral and cloacal swab 
samples on day 3, 5 and 7 post-challenge from the remaining 10 animals in each group. 
All of the birds immunized with rAPMV3, rAPMV3-HN, LaSota, and unvaccinated were 
positive for oral shedding when the samples were assayed using embryonated eggs. No 
NDV shedding was observed from any bird in the rAPMV3-F groups. For chickens 
immunized with rAPMV3-F+rAPMV3-HN, 6 out of 10 birds had NDV oral shedding 
(Fig. 8.9a). The magnitude of viral shedding was determined by a limiting dilution assay 
of swab samples (Fig. 8.9). The virus titers in oral shedding were high for unvaccinated 




rAPMV3 empty vector. In contrast, no oral shedding was detected in rAPMV3-F group. 
Low titers of oral shedding were detected in the rAPMV3-F+rAPMV3-HN and rAPMV3-
HN groups, indicating that the efficacy of rAPMV3-F was reduced when combined with 
rAPMV3-HN (Fig. 8.9a). All the challenged groups have no detectable cloacal shedding. 
Thus, the ability of rAPMV3-F to confer restriction of challenge virus replication against 
replication near the site of inoculation was substantially greater than rAPMV3-HN. 
 
 
Fig. 8.9 NDV challenge virus shedding titer as determined by TCID50 assay in oral and cloacal 
swabs 3, 5 and 7 DPC after oculonasal (a), intramuscular (b) and intravenous (c) challenge, collected from 




3DPC after oculonasal challenge. Furthermore, no virus shedding was observed 5 and 7 DPC after 
oculonasal challenge. Similarly, no virus shedding was observed 7 DPC after intravenous challenge. 
 
8.5.7 Protective efficacy of rAPMVs against NDV virus and its replication after 
intramuscular challenge 
The chickens that had been immunized with the various rAPMV3s individually or 
in combination were challenged intramuscularly on day 21 post-immunization with a 
highly lethal dose (100 CLD50) of NDV strain Texas GB. All of the chickens in the 
unvaccinated group died by day 4 post-challenge while chickens in all other groups 
survived from mortality. Shedding of NDV challenge virus was monitored by taking oral 
and cloacal swab samples on day 3, 5 and 7 post-challenge. All of the birds immunized 
with rAPMV3 were positive for both oral and cloacal shedding on day 3 post-challenge, 
while no shedding was observed in rAPMV3-F or APMV3-HN or rAPMV3-F+rAPMV3-
HN or LaSota vaccinated groups (Fig. 8.9b). Two out of 5 birds in rAPMV3 vaccinated 
group shed the NDV challenge virus from oral secretion till day 5 and 7 post-challenge 
(Fig. 8.9b), while no shedding was evident from cloacal secretion, suggesting inability of 
rAPMV3 to restrict challenge virus replication in upper respiratory tract. 
 
8.5.8 Protective efficacy of rAPMVs against NDV virus and its replication after 
intravenous challenge 
The chickens that had been immunized with the various rAPMV3s individually or 
in combination were challenged occulonasaly on day 21 post-immunization with a highly 




rAPMV3 vaccinated group died 3 days post-challenge, while 4 out of 5 birds died on day 
4 post-challenge in rAPMV3-HN vaccinated group. Although one of the birds in 
rAPMV3-HN survived, it showed all the typical neurological signs (head tilting and 
shaking) till day 8 post-challenge and gradually recovered. None of the birds died in 
rAPMV3-F, rAPMV3-F+ rAPMV3-HN, and LaSota vaccinated groups. Shedding of 
NDV challenge virus was monitored by taking oral and cloacal swab samples on day 3, 5 
and 7 post-challenge. All of the birds immunized with rAPMV3 and rAMPV3-HN were 
positive for both oral and cloacal shedding day 3 post-challenge. Although, the titers in 
rAMPV3-HN were 3 log10 and 1.5 log10 less than rAMPV3 in oral and cloacal shedding 
respectively, one of the surviving birds shed the virus from the cloaca till 5 days post-
challenge (Fig. 8.9c). 
The virus replication from birds that died after intravenous challenge showed high 
challenge virus titers in all the organs (lung, trachea, nasal turbinate, kidney, gut, and 
brain) tested, while birds that died in rAMPV3-HN group showed clearance of virus from 
the lower respiratory tract (lung), lymphatic system (spleen), and digestive tract (gut) 
(Fig. 8.10). High challenge virus replication was observed in the trachea (6.3x2log10), 
nasal turbinate (19x2log10), and brain (7x2log10) in the rAMPV3-HN group, suggesting 
that the death was caused by involvement of the upper respiratory tract and nervous 







Fig. 8.10 Replication of NDV challenge virus after intramuscular and intravenous challenge in different 
organs of chickens 21 days after immunization with rAPMV3s. Various organs from each chicken died 
post-challenge was collected and analyzed in DF1 cells. The NDV titers in different organs of each chicken 
are expressed in log10 TCID50 per gram of tissue. 
 
8.5.9 Protective efficacy of rNDVs against death from NDV challenge 
 
In the immunization and lethal challenge experiment described above, the 
chickens in each group were monitored following challenge to determine the total number 
of survivors and monitor the kinetics of death. All the chickens survived after intranasal 
(Fig. 8.11a) and intramuscular (Fig. 8.11b) virulent NDV challenge, while only 
rAMPV3-F, rAMPV3-F +rAMPV3-HN and LaSota groups survived after intravenous 
challenge, suggesting the role of rAMPV3+F in protection against intravenous challenge 





Fig. 8.11 Percent survival of rAPMV3-immunized chickens following NDV challenge by oculonasal (a), 
intramuscular (b) and intravenous (c) routes. Six chicken groups (10 chickens per group) were immunized 
with the indicated rAPMV3s either individually (rAPMV3 empty vector, rAPMV3-F, rAPMV3-HN, and 
LaSota) or in combination (rAPMV3-F+rAPMV3-HN). Twenty-one days after immunization, these groups 
were challenged with virulent NDV strain GBT. All of the chickens in the unvaccinated control died by day 
4 after oculonasal challenge while they died by day 5 after intramuscular challenge. All of the chickens in 
the rAPMV3 empty vector, rAPMV3-F, rAPMV3-HN, rAPMV3-F+rAPMV3-HN, and LaSota groups 
survived after both oculonasal (a) and intramuscular challenge (b). All the unvaccinated control, rAPMV3 
empty vector, and 4 out of 5 rAPMV3-HN died after intravenous challenge by day 3. All of the chickens in 
the rAPMV3-F, rAPMV3-F+rAPMV3-HN, and LaSota groups survived after intravenous challenge. 





8.5.10 Comparison of pre- and post-challenge NDV-specific serum antibody 
responses 
I compared the serum antibody responses to NDV proteins in sera collected 
immediately before challenge (day 21 post-immunization) versus sera collected from 
survivor chickens on day 10 post-challenge. Commercially available ELISA assay kit 
specific to NDV was used for determining the sera titers. Pre-challenge sera from 
rAPMV3-vaccinated birds were negative for NDV specific antibody by ELISA. There 
were post-challenge increases in mean HI antibody titers of eightfold, twofold, fourfold, 
fourfold and onefold in the rAPMV3, rAPMV3-F, rAPMV3-HN, rAPMV3-F + 
rAPMV3-HN and LaSota groups, respectively, consistent with replication of the NDV 
challenge virus (Fig. 8.12a). Similarly, the mean post-challenge antibody titer increased 
fourfold, fivefold, twofold, and onefold rAPMV3-F, rAPMV3-HN, rAPMV3-F + 
rAPMV3-HN and LaSota groups, respectively, consistent with challenge NDV 
replication (Fig. 8.12b). There were hundred fold increases in serum antibody titer in 
rAPMV3 empty vector group after intranasal challenge indicating very high replication 
of challenge virus. This provided further evidence of the high degree of restriction of 






Fig. 8.12 Comparison of pre-challenge (day 21) and post-challenge (day 31) NDV-specific serum antibody 
titers determined from surviving birds from the following immunization groups: rAPMV3 (n=10), 
rAPMV3-F (n=10), rAPMV3-HN (n=10), and rAPMV3-F + rAPMV3-HN (n=10). The NDV-specific 
serum antibody responses titers were measured by HI assay (a) and NDV ELISA (b). The statistical 
difference between the chicken groups were analyzed by one-way ANOVA, and the P values were <0.001 
for NDV ELISA. 
8.6 Discussion 
Newcastle disease is an economically important disease of poultry, and naturally 
occurring avirulent strains of NDV are widely used as live attenuated vaccines in many 
countries. Although, many avirulent strains of avian paramyxovirus have been recently 
sequenced and some of them are characterized for their pathogenicity in chickens, their 
use as a vector to express protective antigens would provide us a better vaccine against 
important poultry pathogens. APMV3 is a respiratory pathogen of chickens and has 




vector (Kumar et al., 2010a). Other advantages include an ease of administration, and the 
ability to distinguish between infected and vaccinated animals by assaying antibody 
responses to NDV proteins not present in the rAPMV3-vectored vaccine.  
The role of F or HN in immunogenicity and protection was not well understood in the 
context of either natural infection or a vectored vaccine. I prepared rAPMV3s 
individually expressing the NDV F or HN protein. The recombinant viruses grew 
efficiently in embryonated eggs and DF1 cells. Western blot analysis showed that both 
the NDV proteins were expressed in DF1 cells infected with the different recombinant 
viruses. In addition, both the F and HN proteins were found to be incorporated into the 
envelope of rAPMV3 virion. Importantly, incorporation of the NDV surface proteins into 
rAPMV3 particles did not increase the virulence of the vector in standard tests in 
embryonated eggs and one-day-old chicks, showing that the expression of NDV surface 
proteins by APMV3 does not pose a bio-safety hazard.  
I used rAPMV3 as a vector to compare the relative contributions of each of the two NDV 
surface proteins (F and HN) to immunogenicity and protection in chickens that were 
immunized and challenged naturally by the oculonasal route. Moreover, I also used other 
unnatural routes of challenge infection (intramuscular and intravenous) to cover the broad 
range of possibilities and to address the role of F and HN surface glycoproteins in 
protection against NDV.  In addition, I also evaluated the immunogenicity and protective 
efficacy of combinations of two rAPMV3s expressing NDV surface proteins to address 
whether both of the surface proteins act synergistically and have an added advantage than 




In this study, intranasal immunization with rAPMV3-F and rAPMV3-HN alone or 
in combination induced high levels of NDV-specific HI and neutralizing serum antibodies 
and completely protected chickens against a potent challenge with NDV. Furthermore, all 
animals were protected against death including rAPMV3 empty vector group, suggesting 
cross protection against NDV. This is consistent with the previous study where prior 
infection with APMV3 showed protection against NDV challenge. Although, APMV3 is 
serologically distinguishable from NDV, the subtle level of relatedness results in some 
degree of protection from challenge with virulent NDV (Smit and Rondhuis, 1976; 
Alexander et al., 1979). Both NDV F and HN proteins are independent neutralization and 
protective antigens, and a single immunization with a rAPMV3-vectored vaccine 
expressing F and HN alone induced a strong serum-neutralizing antibody response and 
complete protection against intranasal challenge with NDV.  
DNA vaccines encoding NDV F protein provided protection against NDV 
challenge in chickens (Sakaguchi et al., 1996). Furthermore, fowlpox virus expressing 
NDV F protein confers protection against the homologous NDV challenge, while their 
use in heterologous viral strain was not shown (Taylor et al., 1990). However, the 
individual contribution of F-specific antibodies to immunogenicity and protection against 
NDV remained unclear. Monoclonal antibody against both F and HN proteins has a 
protective effect upon virus infection (Umino et al., 1987). However, it has also been 
shown that anti-F serum with a marginal neutralizing activity had a comparable 
protective effect to that of anti-HN serum (Umino et al., 1990). I speculated that the 
protective effect of F antibody may result from a possible inhibitory effect of cell to cell 




the cell mediated immune response against NDV infection thereby protecting bird against 
the intravenous challenge that was not the case when HN is used as an antigen.  
Furthermore, it is thought that F-specific antibodies are not typically associated 
with HI. However, the titer of HI antibodies induced by rAPMV3-F was only onefold less 
than that induced by LaSota. Thus, the NDV F protein is a substantial, independent 
inducer of HI antibodies. It may be that HI by F-specific antibodies is achieved indirectly: 
specifically, antibodies bound to F on the surface of the NDV particle might cause steric 
hindrance of HN-mediated attachment and penetration. These findings corroborate our 
results of influenza NA protein where rNDV expressing the NA protein induced high 
levels of influenza virus-specific NI and neutralizing serum antibodies, although, NA-
specific antibodies are not typically associated with a classical neutralization of virus 
(Nayak et al., 2010)  In the present study, immunization with rAPMV3-F prevents the 
replication of NDV challenge virus comparable to LaSota. In addition, there was no oral 
and cloacal shedding of challenge virus, indicating biological containment in absence of 
potential spread. These results indicate that F-specific immunity reduce NDV replication 
and confer complete protection in a highly permissive host. 
Newcastle disease vaccinations generally protect birds from the more serious 
consequences of the disease but virus replication and shedding still occur in the infected 
birds after vaccination, although at reduced levels (Alexander DJ, 1999). A similar result 
was observed when chickens were immunized with the recombinant glycoprotein, which 
protected them against clinical signs and mortality but did not prevent virus shedding 




of chickens, with similar cellular and tissue tropisms, an APMV3 vector is probably the 
most relevant system to analyze the roles of NDV F and HN proteins in immunogenicity 
and protection. The NDV F and HN proteins are independent protective antigens, but the 
F protein contributes more to protection than does the HN protein.  My result showed that 
























Conclusion and Future prospects 
 
9.2 Conclusion and Future prospects  
 
Family Paramyxoviridae includes important human and animal pathogens. NDV 
or avian paramyxovirus (APMV) serotype 1 is an important poultry pathogen that causes 
severe economic loss to poultry industries around the world. There are nine different 
serotypes of APMV, among which NDV is the most characterized virus but very little is 
known about the other serotypes. APMV-3 causes mild clinical illness in chickens and 
turkeys, which gets exacerbated with secondary bacterial infections. APMV-3 also infects 
chickens at an early age, with evidence of stunted growth that may be more marked in 
broiler chicken breeds. APMV-3 has been associated with encephalitis and high mortality 
in caged birds. Moreover, APMV-3 causes acute pancreatitis and central nervous system 
(CNS) signs in Psittacine and Passerine birds. Prior to this study, only the pathogenic 
potential of APMV-3 infections was available. In this study, two strains of APMV-3 
(prototype strain Netherlands and Wisconsin) were characterized both in vitro and in 
vivo. A method was standardized for titrating APMV-3 strains since the viruses produced 
plaques in cell culture.  The APMV-3 strains were found to be lentogenic in chickens by 
internationally accepted standard pathogenicity tests- MDT in embryonated chicken eggs 
and ICPI in day-old chicks.  Mild respiratory disease signs were observed in 1-day-old 
chickens and turkeys when inoculated through oculonasal route with either strain. There 
were no overt signs of illness in 2-weeks-old chickens and turkeys by either strain, 




signs were also observed in hamsters and mice inoculated through oculonasal route with 
APMV-3, suggesting its broad host range. Moreover, both mice and hamsters showed 
significantly high HI titers against APMV-3, suggesting further the growth of the virus in 
these laboratory animals. 
As a first step towards molecular characterization, the complete genome 
sequences of the two APMV-3 strains were determined and compared with other 
paramyxoviruses. The genome lengths of strain Netherlands and Wisconsin was 16,272 
and 16,182 nt, respectively. The genome sequence and phylogenetic analyses justified the 
classification of APMV-3 under the genus Avulavirus within the family Paramyxoviridae 
and also indicated the existence of two subgroups within serotype 3. The concept of sub-
grouping was further supported by cross HI and cross neutralization tests in cell culture 
between homologous and heterologous sera. Hence I proposed that the strains represent a 
single serotype with two subgroups that differ substantially based on nt and aa sequences, 
but with only a modest antigenic difference.  
The availability of complete genome sequence enabled construction of a full 
length cDNA clone for APMV-3 strain Netherlands (APMV-3/Net) and subsequent 
recovery of infectious recombinant virus by reverse genetics system previously 
established in our laboratory using a recombinant vaccinia (expressing T7 polymerase)-
based approach. The development of reverse genetics system has several downstream 
applications such as engineering of vaccines, generation of vaccine vectors and to study 
molecular biology. In this study, infectious recombinant virus expressing enhanced GFP 




passages in DF1 cells suggesting that this system could be used to develop APMV-3 as a 
vaccine vector against emerging pathogens. 
NDV remains as a major problem for the poultry industry around the world. Previously, it 
has been shown that both the F and HN glycoproteins on the surface of NDV are 
important for virus infectivity and pathogenicity. Although several vaccine studies were 
done with F and HN glycoprotein (Boursnell et al., 1990a; Boursnell et al., 1990b; 
Romer-Oberdorfer et al., 2003; Lee et al., 2008), their major role in protection against 
virulent NDV challenge is not well understood. In order to address this, I generated 
recombinant avian paramyxovirus type-3 (rAPMV3) vectors, which individually 
expressed each of the two surface glycoproteins F and HN of NDV. Result showed that 
the NDV F and HN proteins are independent protective antigens, but the F protein 
contributes more to protection than does the HN protein.  Wild-type rAPMV3, which is 
avirulent in chickens, can be used as a vaccine vector against NDV, since APMV3 itself 
provides protection against NDV due to its cross-reactivity and in addition can express 
NDV protective antigens. 
This study has opened up new ways to develop vaccines, vaccine vectors and to study 
molecular biology of paramyxoviruses. It will be interesting to study the following in 
future: (i) antigenic and sequence analyses of additional APMV-3 strains (ii) The 
molecular mechanism of cleavage of APMV-3 fusion protein (iii) Application of APMV-
3 reverse genetics system to develop vectored vaccines against emerging diseases of 
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